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Abstract 
Background: Co-occurring substance use disorders (SUDs) occur in as many as half to three quarters of patients with 
severe mental disorders such as schizophrenia and bipolar disorder, a phenomenon also described as dual diagnosis. 
Past research from high income countries have shown that the presence of co-occurring SUDs are associated with a 
number of demographic and clinical factors, including worse clinical outcomes. Although the clinical profile and 
negative impact on prognosis has been well characterised in research on dual diagnosis samples from high income 
countries, little is known in the low- and middle-income country (LAMIC) context about the prevalence and factors 
associated with SUDs in patients with SMI, its clinical identification and diagnosis, as well as factors associated with 
its treatment.  
Objectives: In part-I of the thesis I investigate the clinical epidemiology of dual diagnosis by determining the 
prevalence of substance use disorders (SUDs) and its association with various clinical and demographic factors in two 
datasets, the first dataset containing data from a homogeneous sample of Xhosa South African patients with 
schizophrenia and the second dataset with data from a clinically more heterogeneous sample of patients with major 
affective and non-affective psychotic disorders. In part-II of the thesis I determine the psychometric properties of two 
Xhosa language versions of brief substance screening instruments, the Alcohol, Smoking and Substance Involvement 
Screening Test (WHO-ASSIST version 3) and the Severity of Dependence Scale (SDS), against a gold standard 
diagnostic instrument, the Structured Clinical Interview for DSM-IV-TR Axis I disorders (SCID-I for DSM-IV). In 
part-III of the thesis I examine aspects in the pharmacotherapy of dual diagnosis, firstly the association between 
methamphetamine use and extra-pyramidal medication side-effects (EPS) in patients treated with antipsychotics, and 
second in a systematic review, the efficacy of risperidone versus other antipsychotics for people with a dual diagnosis. 
Methods: This thesis consists of secondary analyses of two datasets (datasets#1 and dataset#2) and a Cochrane 
systematic review of existing randomised trials. Dataset#1 contains data from case-control study with the original aim 
of investigating the genomics of schizophrenia in the South African Xhosa population. Dataset#2 contains data 
collected in a cross-sectional manner from 3 studies; one study that investigating the presentation and psychobiology 
of psychosis, another which was a pilot randomised controlled trial of a text message treatment partner intervention 
and a third which was a neuroimaging and electrophysiological study of psychotic disorders. Across dataset #1 and #2, 
demographic information, clinical variables and psychotic and substance use disorder diagnoses were determined 
using the SCID-I for DSM-IV. In addition, for dataset #2 (conducted in a multi-cultural and ethnic population) we 
recorded self-identified ethnicity. For self-identified ethnic groups, the terms “Coloured” “Black” and “Caucasian” 
and “Other” (Asian), were not intended to reify sociocultural constructs but were instead used to study ongoing health 
disparities. Psychosocial Axis-IV problems were determined using a checklist from the SCID-I and legal involvement 
was determined using the legal section of the Addiction Severity Index (ASI). Functioning was determined with the 
global assessment of function, or GAF scale. The ASSIST and SDS instruments were used in a study based on data 
from dataset #1 investigating the psychometric properties of these screening tools. In turn, I investigated the 
relationship between methamphetamine use and medication related extra-pyramidal side effects (EPS) in a 
heterogeneous sample of patients with major affective and non-affective psychotic disorders (from dataset #2). For 
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this study the Simpson Angus Scale for Parkinsonism (SAS), the Barnes Akathisia Rating Scale (BARS) and the 
Abnormal Involuntary Movement Scale (AIMS) were used to measure EPS.  
For the first two objectives, logistic regression modelling was used to determine factors associated with having a co-
occurring SUD. For the validation study of the Xhosa language versions of the ASSIST and SDS, I determined the 
internal consistency, concurrent validity, and discriminant validity of these instruments and compared the sensitivity, 
specificity and the receiver operating characteristics (ROC) for the ASSIST and SDS. Logistic and ROC regression 
was used for the comparison of ROC area-under-the-curves for ASSIST versus SDS and for determining the impact of 
co-variates on ROC respectively. In part III, I determined the association between methamphetamine use and the 
presence of EPS using logistic regression. Finally, I conducted a Cochrane systematic review of randomised trials 
after a comprehensive literature search of several databases and duplicate study selection and data extraction. Where 
possible outcomes were pooled, and meta-analyses conducted using random effects models. Primary outcomes were 
changes in substance use and mental state. Secondary outcomes included substance craving, subjective-wellbeing, 
adherence, adverse effects, study retention, quality of life and mortality. Study selection, data extraction and quality 
appraisals were independently conducted. Random-effects meta-analysis was conducted, and the Cochrane risk of bias 
and GRADE approach used to assess evidence quality. 
Results: In both datasets#1 and #2, consisting of a total sample size of N=1420 (dataset#1) and N=248 (dataset#2) we 
found a high prevalence of lifetime SUDs (47.8% and 55.6%) in patients with schizophrenia and major affective or 
non-affective psychosis, respectively. In multivariable logistic models younger age, male gender, and legal 
involvement were significantly associated with co-occurring SUDs. Multiple substances were often used together, and 
SUDs were significantly correlated with one another. Methamphetamine use disorders were significantly more 
prevalent in the Western Cape province of South Africa and ethnic differences were also apparent with Coloured 
participants significantly more likely to use methamphetamine compared to Black participants. In addition, we found 
significant associations between post-traumatic stress symptoms, anxiety symptoms and suicidality and alcohol use 
disorders. Inpatient status and higher levels of prior admissions were associated with cannabis and methamphetamine 
use disorders.  
In a sample of 351 participants from dataset#1 who completed either the ASSIST (N=190), SDS (N=299), or both 
(n=138), good internal reliability was obtained for both the ASSIST-TSI (total substance involvement score) 
(Cronbach α= 0.77) and SDS (Cronbach α=0.80).  The ASSIST and SDS demonstrated good concurrent validity (rs= 
0.50, p<0.001).  ROC analysis demonstrated good discriminant validity with areas under the curve for the ASSIST 
(AUC=0.86) and SDS (AUC=0.76). After adjustment for covariates, participants who scored ≥6 on the ASSIST-TSI 
were 19 times more likely to have any SUD and participants with a score of ≥2 on the SDS were 7 times more likely 
to have any SUD. Conducting the lengthier ASSIST in addition to the shorter SDS did not yield any gain in predictive 
power. 
In sample of 102 patients from dataset#2 who completed assessments for EPS, methamphetamine use disorders were 
significantly associated with the presence of EPS in the unadjusted and adjusted analysis (ORadj = 4.01, 95% CI= 1.07-
14.98, p=0.039). In addition, patients with MA dependence and MA use > 3 years were significantly more likely to 
have EPS. We found a significant interaction effect between MA use disorders and standardised antipsychotic dose on 
7 
 
the occurrence of EPS (ORadj = 1.01, 95% CI= 1.00-1.01, p=0.042). There were no significant associations with EPS 
with comorbid alcohol, cannabis, or methaqualone use disorders.  
In the Cochrane systematic review of randomised controlled trials involving risperidone versus other antipsychotics 
for dual diagnosis, we identified eight trials containing a total of 1073 participants with SMI and co-occurring SUD. 
Seven trials contributed useable data to the review. Risperidone was compared to clozapine, olanzapine, perphenazine, 
quetiapine and ziprasidone. Only one study contained data comparing risperidone with a first-generation antipsychotic 
(perphenazine). Quality of the included studies varied from low to very low.  Outcome data were frequently missing 
and little, or no data was reported in most studies for craving, subjective-wellbeing, metabolic disturbances, global 
impression of illness severity, quality of life or mortality. For risperidone versus clozapine we found no clear 
differences between these two antipsychotics in the reduction of positive psychotic symptoms or reduction in cannabis 
use, improvement in subjective well-being, numbers discontinuing medication, extrapyramidal side-effects or leaving 
the study early. Clozapine was associated with lower levels of craving for cannabis. For risperidone versus olanzapine 
we found no clear differences in the reduction of positive psychotic symptoms, reduction in cannabis use, craving for 
cannabis, parkinsonism, or leaving the study early. For risperidone versus perphenazine, quetiapine and ziprasidone 
respectively, we found no clear differences in the number of participants leaving the study early.  
Conclusion: In the context of a dearth of research into dual diagnosis in LAMIC countries such as South Africa, this 
thesis contains a large-scale epidemiological investigation into substance use comorbidity in patients with 
schizophrenia and other psychotic disorders. In addition, for the first time we determine the psychometric properties 
and validity of the Xhosa language ASSIST and SDS and systematically investigate the relationship between 
methamphetamine use and extra-pyramidal side effects in people with psychotic disorders treated with antipsychotics. 
For the first time we also conduct a systematic review of the efficacy of risperidone compared to other antipsychotics 
for a number of primary and secondary outcomes. 
Our findings have a number of implications for clinicians and services planners. Firstly, SUDs occur in at least half of 
the people schizophrenia and other psychotic disorders. Accurate detection of SUDs is possible using brief screening 
tools such as the ASSIST and SDS. Some populations such a younger male population may need particular attention. 
Moreover, assessment of patients will need to include current and past legal involvement as well as careful assessment 
of associated comorbid anxiety, post-traumatic symptomology and suicide risk. In patients with co-occurring 
methamphetamine use disorders clinicians should regularly assess for the development of EPS and carefully titrate 
antipsychotic dosage from lower to higher doses to avoid EPS. Currently there is not sufficient high-quality evidence 
favouring the superiority of risperidone over any other antipsychotic in people with SMI and co-occurring SUDs. 
Results of ongoing trials are awaited, and future trials need to use consistent methodologies and adhere to CONSORT 
reporting guidelines. 
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Chapter 1 
Introduction 
1.1 Serious mental illness and dual diagnosis: Scope of the problem 
Serious mental illness (SMI), characterised by severe, persisting and functionally impairing psychiatric disorders such 
schizophrenia and bipolar disorder (Ruggeri et al., 2000)  frequently co-occurs with substance use disorders (SUDs) 
(Buckley, 2006). Findings from individual studies and systematic reviews have reported the lifetime prevalence of co-
occurring drug and alcohol use disorders and serious mental illness, also known as “dual diagnosis”, to vary widely 
from 25% to as high as 74% across different samples from the developed world  (Barnett et al., 2007, Fioritti et al., 
1997, Fowler et al., 1998a, Jablensky et al., 2000, Kessler, 2004, Koskinen et al., 2009, Koskinen et al., 2010, Lambert 
et al., 2005b, Menezes et al., 1996, Regier et al., 1990, Sara et al., 2015, Soyka et al., 1993, S. et al., 2004). In the 
developing world, including countries such as South Africa (SA), the phenomenon of dual diagnosis has a prevalence 
of 50% to 68% (Hauli et al., 2011, Weich and Pienaar, 2009a). 
Co-morbidity adversely affects the treatment and prognosis of both drug use disorders and mental illness. In 
comparison to people with SMI without substance use disorders, persons with a dual diagnosis have been reported to 
have shorter times to relapse, higher rates of readmission to hospital, lower remission rates (Lambert et al., 2005c, 
Swofford et al., 1996b, Wade et al., 2006b), higher levels of medication non-compliance (Lacro et al., 2002b, Owen et 
al., 1996b, Ascher-Svanum et al., 2006b), and worse clinical outcomes (Lambert et al., 2005c). There are virtually no 
data from South African clinical dual diagnosis populations addressing diagnosis or treatment. Sociodemographic and 
clinical correlates of dual diagnosis may include gender, service use profiles, comorbid anxiety disorders, 
complications such as medication adverse effects, legal involvement and associated risk behaviours. Such correlates 
may have an important impact on the integrated clinical management of dual disorders (Ziedonis et al., 2005). In this 
chapter I describe the background to the epidemiology, screening and diagnosis, and aspects important in the 
pharmacological treatment of people with a dual diagnosis. 
1.2 Epidemiology of dual diagnosis 
Studies have consistently demonstrated that persons with serious mental illness and co-occurring substance use 
disorders are significantly younger and more likely to be male, a finding confirmed in systematic reviews of 
prevalence studies (Duke et al., 2001, Farris et al., 2003, Kavanagh et al., 2004a, Mueser et al., 1990b, Weich and 
Pienaar, 2009a, Koskinen et al., 2009, Koskinen et al., 2010, Sara et al., 2015).  The association between younger age 
and substance is particularly strong for non-alcohol illicit drug use disorders as opposed to alcohol use disorders that 
occur more uniform across all age groups (Mueser et al., 2000b, Koskinen et al., 2009). Other demographic correlates 
with substance use disorders among inpatients with serious mental illness include lower educational levels, and for 
cannabis use disorders, single marital status (Mueser et al., 2000b). 
Systematic reviews and meta-analyses of prevalence studies of SUDs in schizophrenia and affective psychoses have 
demonstrated that cannabis use disorders are most prevalent, with a pooled lifetime prevalence of 27.1%, followed by 
alcohol (20.6%) and then stimulants such as amphetamines and cocaine (8.9%) (Koskinen et al., 2009, Koskinen et al., 
2010, Sara et al., 2015). There are currently few studies utilizing robust diagnostic instruments that examine the 
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prevalence and demographic as well as service utilization correlates in persons with serious mental illness in South 
African clinical populations. Furthermore, given the rise of admissions associated with methamphetamine use in 
certain inpatient populations in South Africa (Pluddemann et al., 2013) it is unclear what the impact of this 
phenomenon is on the relative prevalence of different types of substance use disorders and on the distribution of 
substance use disorders in serious mental illness in SA. 
In a recent secondary data analysis of the CATIE randomised trial data, latent class analysis revealed three distinct 
profiles of co-morbidity in patients with schizophrenia (Tsai and Rosenheck, 2013). Whereas co-morbid alcohol and 
drug use disorders were common in this sample, occurring in up to 30% of participants, the co-morbidity profiles 
revealed that patients cluster into a group with a high probability of having a co-occurring substance use disorder and 
two additional but separate groups, i.e. those with a high likelihood of having a co-morbid depressive and anxiety 
disorder and a third group with no co-morbidity (i.e. schizophrenia only group)(Tsai and Rosenheck, 2013). In 
addition, there is evidence from local and international research that certain anxiety disorder such as obsessive-
compulsive disorder may be less prevalent in dual diagnosis compared to single-diagnosis populations (Seedat et al., 
2007), whereas trauma and stress related disorders such post-traumatic stress disorder,  may be more prevalent in the 
dually diagnosed (Scheller-Gilkey et al., 2004a, Scheller-Gilkey et al., 2002). As interpersonal and community 
violence is highly prevalent in South Africa, it is important to determine the co-morbidity between dual diagnosis and 
anxiety disorders such as post-traumatic stress disorder in the South African context. In addition, alcohol use disorders 
in people with schizophrenia have been associated with elevated levels of for panic attacks in some studies (Goodwin 
et al., 2003). Further exploration is needed to determine the prevalence of anxiety disorders in patients with SMI with 
and without co-occurring SUD’s. 
Rates of police arrests have been reported to be significantly higher for persons with a dual diagnosis compared to 
persons without a dual diagnosis (McCabe et al., 2012). Whereas violent crime has been associated with substance use 
in persons with SMI, substance use is thought to elevate risk of violence and repeat offending in person with SMI by 
acting as an effect modifier or mediator in persons with schizophrenia bipolar disorder together with other static and 
historical risk factor profiles such as a history of criminal behaviour and violence (Elbogen and Johnson, 2009). 
Moreover, the majority of arrests that occur in persons with dual diagnoses are for minor crimes related to disturbance 
of public order or decency (i.e. possession of illegal substances (McCabe et al., 2012). Little is known about the 
patterns of legal involvement and police arrests in South African populations with serious mental illness. An improved 
knowledge of arrest types and legal complications can inform treatment and service planning. 
1.3 Screening and diagnosis 
Despite the high prevalence of substance use disorders in persons with serious mental illness, under-diagnosis in 
clinical settings remains a problem (Weich and Pienaar, 2009a, Woodward et al., 1991). Whereas a number of 
diagnostic instruments exist such as the Structured Clinical Interview for DSM (SCID-I)(First et al., 1994a) and the 
Psychiatric Research Interview for Substance Use and Mental Disorders (PRISM)(Hasin et al., 1998), these 
instruments require extensive clinical experience, training and take a significant amount of time to complete, 
precluding their use in routine clinical practice. A number of brief screening tools for substance use disorders have 
been validated against gold standard instruments within SMI populations. Among these are the Drug Abuse Screening 
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Tool (DAST)(Skinner, 1982) and Alcohol Use Disorder Identification Tool (AUDIT)(Saunders et al., 1993). Although 
instruments such as the DAST and AUDIT have been shown to yield good positive predictive values in person with 
schizophrenia and major affective disorder and major affective psychosis (Cassidy et al., 2008, Maisto et al., 2000), 
they have certain limitations. The DAST assesses drug use in general without specific reference to individual 
substances, whereas the AUDIT assesses alcohol use only. Recently, in an attempt to improve screening of substance 
use the WHO has developed the ASSIST (Alcohol Smoking and Substance Involvement Screening Test), a short 
instrument that assesses current and lifetime substance use including both alcohol and a variety of different drugs use 
disorders (Humeniuk et al., 2008a). This instrument has been validated in primary care populations as well as in a 
population of persons with first-episode psychosis and schizophrenia (Hides et al., 2009b, Newcombe et al., 2005b). 
Another brief instrument that assesses lifetime use of substances  is the Severity of Dependence Scale (SDS)(Gossop 
et al., 1995a). This instrument has been validated in a first-episode sample of patients with schizophrenia and co-
occurring cannabis use disorders (Hides et al., 2007). However there remains a paucity of data on the validity of these 
instruments in populations that include participants with all stages of illness beyond the first-episode of schizophrenia 
and participants from other cultural and language groups, in particular South African populations with schizophrenia.  
1.4 Treatment: Focus on pharmacotherapy 
Substances such as cocaine, cannabis and alcohol have been associated with neuroanatomical and molecular (D2 
receptor density) changes in striatal structures that mediate extrapyramidal motor side-effects in people treated with 
antipsychotics (Martinez et al., 2005, Martinez et al., 2009, Rodriguez de et al., 1998, Sullivan et al., 2005). In 
addition, clinical studies have demonstrated that dual diagnosis patients, in particular patients abusing stimulants such 
as cocaine, treated with antipsychotics are significantly more susceptible to extrapyramidal side-effects (EPS) such as 
akathisia, parkinsonism and tardive dyskinesia compared to persons without a dual diagnosis when treated with 
antipsychotics (Potvin et al., 2009b, Potvin et al., 2006, Salyers and Mueser, 2001b, Zhornitsky et al., 2010b). Motor 
side-effects can negatively impact on treatment compliance and potentially lead to self-medication with alcohol and 
drugs (Gregg et al., 2007, Mueser et al., 1998). It is therefore important to investigate whether there is an association 
between dual diagnosis and higher levels of extra-pyramidal symptoms as this has potential implications for treatment 
strategies and therapeutic monitoring for side-effects. The importance of investigating the association between 
substance use and EPS is underlined by rise of methamphetamine use among psychiatric patients (Pluddemann et al., 
2013). 
Although a variety of psychosocial interventions exist for the treatment of persons with a dual diagnosis, recent 
systematic reviews have pointed out that there is currently little evidence to suggest that any one psychological 
treatment is superior to other treatments or standard care (Hunt et al., 2013b, Hunt et al., 2014). Furthermore, 
antipsychotic medications remain the mainstay of treatment in schizophrenia and are indicated in both the acute and 
maintenance phases of persons with bipolar disorder type I (Geddes and Miklowitz, 2013, National Collaborating 
Centre for Mental Health, 2009, Yatham et al., 2005). It is been proposed that second-generation, atypical 
antipsychotics are potentially superior to first-generation antipsychotic in the treatment of persons with a dual 
diagnosis (Green, 2007, Smelson et al., 2008, Wobrock and Soyka, 2008). Several lines of evidence suggest that 
second-generation medication may be more efficacious in this patient population. Animal research has shown that 
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withdrawal from first, but not second-generation antipsychotics is associated with dopamine super-sensitivity and 
increased drug seeking behaviour in rats (Fukushiro et al., 2007, Fukushiro et al., 2008). This is potentially analogous 
to medication non-adherence and partial compliance situations that frequently occur in patients titrated with 
antipsychotic medication. 
In addition, compared to haloperidol a first-generation antipsychotic, clozapine, a prototypical second-generation 
antipsychotic has been shown to reduce alcohol craving in rodents (Green et al., 2004). In addition, atypical 
medication may result in lower levels of psychopathology via several potential pathways such as lower propensity 
toward negative affective states and dysphoria with improved subjective-wellbeing compared to first-generation 
antipsychotics (Vothknecht et al., 2011b); lower levels of extrapyramidal side effects leading to better treatment 
adherence and subsequently symptom control (Hunter et al., 2003b, Perkins et al., 2006, Sun et al., 2007); and lower 
levels of drug craving leading to reduced substance misuse (Rosenberg, 2009, Smelson et al., 2002a, Smelson et al., 
2004). However, second-generation antipsychotics are a heterogeneous group of medications, characterised by 
different pharmacological properties with differing dopamine type 2 receptor binding profiles (Kapur, 1996, Kapur 
and Seeman, 2001, Kapur and Remington, 2001, Seeman, 2002b, Tort et al., 2006). 
Risperidone is a second-generation antipsychotic characterised by serotonin and dopamine antagonism (Janssen et al., 
1988a, Moller, 2005). It is available both in long-acting injectable and oral formulations (Fleischhacker et al., 2003). 
Non-controlled trials have shown risperidone to be superior to in reducing drug craving in persons with schizophrenia 
(Smelson et al., 2002a, Smelson et al., 2004). The use of risperidone, previously restricted due to its cost, is also 
becoming widespread in the acute psychiatric services within Cape Town and South Africa. The first second-
generation antipsychotic to go off patent, there are currently no restrictions on its prescription and it is currently the 
most widely used and least expensive second-generation antipsychotic.  However, it remains unclear to what extent 
the pharmacological properties of risperidone offer advantages in terms of clinical outcomes and adverse effects in 
people with dual diagnosis compared to other first-generation and other second-generation antipsychotics. 
1.5 Rationale for dual diagnosis research in the South African context 
There is a paucity of research on the prevalence and clinical factors associated with dual diagnosis within the South 
African context. The recent surge in methamphetamine related presentations at psychiatric and substance treatment 
facilities in the Western Cape of South Africa (Pluddemann et al., 2013, Pluddemann et al., 2008) underlines the 
importance of studying the impact and consequences on clinical presentation and treatment in populations affected by 
both mental illness and substance use disorders. In addition, despite reported high rates of comorbidity, persons with 
dual diagnosis have low rates of treatment utilisation in the form of substance rehabilitation (Weich and Pienaar, 
2009a). Furthermore, comorbid substance use affects the clinical management of serious mental illness across several 
domains including clinical presentation, co-morbidity, treatment effects and medication related side-effects, related 
risk behaviour, legal consequences, diagnostic considerations and pharmacotherapeutic decision making. Consensus 
treatment guidelines advocate integrated treatment that emphasizes the addressing of multiple affected psychosocial 
and biological domains (Ziedonis et al., 2005). Therefore, the study of the occurrence and factors associated with dual 
diagnosis is essential in order to inform service development and future research priorities. 
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The next chapter contains a description of the general methodology of the thesis, followed by part I, consisting of two 
chapters, that investigate the clinical epidemiology of co-occurring SUDs in two separate databases containing data 
from different parent studies. This is followed by part II, in which the clinical utility, validity and psychometric 
properties of two brief substance use screening tools, the ASSIST and the SDS are investigated. Finally, in part III of 
the thesis, I investigate the impact of methamphetamine use disorder on antipsychotic induced extra-pyramidal side-
effects. In the next chapter of part III, risperidone is compared to other antipsychotics for dual diagnosis in a 
systematic review of randomised trials, investigating outcomes such as improvement of mental state, substance use, 
drug craving, subjective well-being, medication side-effects, adherence, treatment retention, and quality of life. This is 
followed by a discussion of the thesis findings and its impact on clinical care of patients with a dual diagnosis. 
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Chapter 2 
General methodology 
2.1. Overview of thesis methodology  
This chapter describes the general methodology and structure of the thesis. The results of the thesis are presented in 
three parts containing five different chapters, in total addressing five objectives. 
2.2 Study aims, objectives and hypotheses 
2.2.1 Study aims 
In this dissertation I aimed to investigate and characterise the clinical epidemiology, screening and diagnosis as well 
aspects in the pharmacological treatment of patients with psychotic disorders and co-occurring substance use 
disorders. 
Part I: Epidemiology and clinical characteristics 
Objective 1 
To determine the prevalence of substance use disorders (SUDs) and its association with sociodemographic factors, 
depression, anxiety, suicidality, psychosocial problems and treatment characteristics in a homogeneous sample of 
Xhosa South African patients with schizophrenia.  
Objective 2 
To determine the prevalence of substance use disorders and its association with sociodemographic factors, depression, 
anxiety, suicidality, legal involvement and treatment history in a heterogeneous sample of patients with various major 
affective and non-affective psychotic disorders.  
For objectives 1 and 2, I hypothesized there to be a high prevalence of SUDs, significant associations with male sex 
and younger age, elevated levels of depressive, anxiety and post-traumatic stress symptoms, more suicidal behaviours 
and increased legal and criminal justice involvement. I also aimed to explore the demographic, clinical and 
psychosocial factors associated with SUDs as well as associations between different types of SUDs. 
Part II: Screening and diagnosis 
Objective 3 
To determine the clinical utility, diagnostic accuracy, validity and related psychometric properties (sensitivity, 
specificity, positive predictive value, optimal cut-points) of two brief substance screening instruments, the Alcohol, 
Smoking and Substance Involvement Screening Test (WHO-ASSIST version 3) and the Severity of Dependence Scale 
(SDS) against a gold standard diagnostic instrument, the SCID-I for DSM-IV.  
I expected there to be a strong correlation between the SDS and ASSIST and hypothesized that participants with 
SUDs will have significantly higher scores on both the ASSIST and SDS compared to those who do not have SUDs.  
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Part III: Aspects of pharmacotherapy in dual diagnosis 
Objective 4 
To determine the association between methamphetamine use and the occurrence of extra-pyramidal motor side-effects 
(EPS) in patients with major affective and non-affective psychotic disorders receiving treatment with antipsychotics. 
I hypothesized that patients with a methamphetamine use disorder will have an increased likelihood of extra-
pyramidal side-effects (EPS). In addition, I aimed to explore the impact of the interaction between methamphetamine 
use and prescribed antipsychotic class (first-generation vs. second-generation) as well as antipsychotic dose on the 
occurrence of EPS. 
Objective 5  
To conduct a systematic review of randomised controlled trials in order to determine the efficacy of a prototypical 
second-generation antipsychotic, risperidone, compared to other first and second-generation antipsychotics in the 
treatment of dual diagnosis. 
2.3 Methods 
2.3.1 Study design 
Secondary analysis of two datasets 
Objectives 1 to 4 are secondary analyses of existing data from two datasets (dataset #1 and dataset #2) comprised of 
data gathered from four different primary studies. Table 9.4 in the Appendix contains a summary of the 
original/primary aims of the parent studies. These primary studies were not focused on the clinical profile, diagnostic 
and treatment implications of co-occurring SUDs. In order to address these limitations, I therefore conducted the 
secondary analyses described in this chapter. 
Systematic review of randomised trials 
Objective 5 is a Cochrane systematic review of randomised trials and includes all trials randomising participants with 
a dual diagnosis (major affective and non-affective psychotic disorder) either to risperidone versus any other 
antipsychotic. The details of the methodology of published systematic review are described in chapter 7, and the 
protocol has been published in 2014 (Temmingh et al., 2014).  In summary, this Cochrane systematic review of 
randomised trials included a comprehensive literature search of several databases and duplicate study selection and 
data extraction. The aim was to compare risperidone versus other antipsychotics in a people with serious mental 
illness and co-occurring SUDs on a number of primary and secondary outcomes. Primary outcomes were changes in 
substance use and mental state. Secondary outcomes, and possible effect modifiers, included substance craving, 
subjective-wellbeing, adherence, adverse effects, study retention, quality of life and mortality. 
2.3.2 Study populations, sampling and setting (secondary data analysis) 
For objectives 1 and 2, two different populations were used in order to contrast the distribution of various SUDs 
across the clinical and demographic features that define these separate populations. These features included diagnosis 
(schizophrenia in dataset #1 vs. various non-affective and affective psychotic disorders in dataset #2), demographic 
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differences such as geographic area of residence and self-defined ethnic group. In addition, the sample used in 
objective 1 (dataset #1) also explored psychosocial problems in more detail whereas in objective 2 (with the study 
samples combined in dataset #2), further explores and elaborates on the type of legal involvement and prior treatment 
for substances. 
Dataset #1 (SAX study) (Objectives 1 and 3) 
Dataset #1 contains data from a large case-control study, the SAX study (SAX-049/2013) that investigates the 
genomics of schizophrenia in the South African Xhosa population. The SAX study involved a collaboration between a 
number of Universities in the United States and South Africa and funded by the National Institutes of Mental Health 
(NIMH: Grant Number: 5U01MH096754) and was a member of the Human Heritability and Health in Africa 
consortium (www.h3africa.org). The SAX study recruited Xhosa speaking controls and cases with an established 
diagnosis (at least two years since illness onset) of schizophrenia or schizoaffective disorder, aged 21 to 55years, 
attending psychiatric hospitals and community clinics across two provinces (Western and Eastern Cape Provinces) in 
South Africa. This study began recruitment in 2013 and recruited 2800 participants over a 5-year period (Campbell et 
al., 2017a, Campbell et al., 2017b) . I used data from cases from dataset #1 in objectives 1 and 3. 
Dataset #2 (PRP, CIAM, SIP studies) (Objectives 2 and 4) 
Data contained in this dataset was collected in a cross-sectional manner as part of three different research projects. 
Data were combined from these three different original studies in order to maximize sample size. Study PRP-332-
2008, “The Presentation and Risk Factors in the Psychobiology of psychosis –PRP study” (Shelly et al., 2016); study 
CIAM-192-2010, “Cortical Inhibition and Attentional Modulation- a study of psychosis- CIAM study”(Howells et al., 
2018); and study SIP-511-2011, “Social Inclusion in Psychosis- SIP study” (Sibeko et al., 2017). We used data from 
dataset #2 for objectives 2 and 4 and included in the analyses data on adult male and female patients, aged 18-65, with 
a diagnosis of a major non-affective or affective psychotic disorder (i.e. schizophrenia, schizophreniform, 
schizoaffective disorder, brief psychotic disorder, psychotic disorder not otherwise specified, delusional disorder, 
bipolar mood disorder type I with psychotic features). To avoid duplicates being entered into the dataset, participant 
study numbers were recorded and linked across all three studies in order to ensure that each participant contributed 
data to the dataset only once. 
For the study entitled “The Presentation and Risk Factors in the Psychobiology of Psychosis” (UCT Ethics Rec. Ref 
332/2008) for which the PhD candidate is the principle investigator, data was collected between  in 2009 to 2014 
(Shelly et al., 2016). The aims of this original umbrella project were to determine the prevalence of co-morbid 
psychiatric disorders in persons with serious mental illness and to measure a variety of clinical correlates and their 
association with diagnosis. In addition, this study contained some biological measures such as facial morphometry and 
blood samples for genetic analysis.  Patients with a diagnosis of either schizophrenia or related psychotic disorders 
(schizophreniform, schizoaffective, delusional disorder, substance induced psychotic disorders and psychotic disorder 
not otherwise specified) and bipolar mood disorder type I were included in this study. Exclusion criteria for this study 
were participants with unipolar mood disorders such as major depressive disorder, bipolar mood disorder type II, non-
functional psychotic disorder such as psychosis due to a general medical condition or dementia with psychosis. 
Participants with moderate to severe mental retardation or a principle personality disorder diagnosis were also 
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excluded. Participants had to be conversational in the English language. This study used a random sampling strategy 
(using a random number table) and included inpatients with a diagnosis of a functional psychotic disorder enlisted as 
admitted in the pre-discharge wards of Valkenberg hospital, a large secondary-level referral hospital with 210 acute 
inpatients beds. This hospital serves a large catchment area of over 1.5 million people in the Cape Town metropole 
area as well as George Eden (South-east Coast and Karoo) area. The annual admission rate exceeds 1700 patients with 
the average length of stay of approximately 44 days. Outpatients who participated in the PRP study were first recruited 
via a sister study (the CIAM study-see below)(Howells et al., 2018) which used a different sampling strategy, i.e. 
recruitment through advertisements and screening of outpatients attending the OPD department (see selection methods 
of CIAM). These participants were then invited to undergo assessments unique to the PRP study (objective 4).   
In addition, dataset #2 contained data collected as part of two additional research projects (UCT rec. ref. 192/2010-
CIAM and rec. ref. 511/2011-SIP). The study “Cortical Inhibition and Attentional Modulation-a study of psychosis” 
(192/2010-CIAM) was a case-control study that investigated the neurobiological differences across three psychotic 
disorder groups (schizophrenia, methamphetamine psychosis and bipolar disorder type I disorder with psychosis) and 
a normal control group using MRI neuro-imaging and electroencephalography with transcranial magnetic stimulation 
(Howells et al., 2018). This study recruited only outpatients through advertisements and screening of outpatient clinics 
attached to Valkenberg hospital and related community psychiatric clinics in its catchment area. Exclusion criteria 
were the same as for the PRP-332/2008 study. Participants recruited for this study were also invited to participate in 
the PRP study. 
The third study that contributed data to dataset #2 entitled “Social Inclusion in Psychosis” (SIP study-511/2011), was 
a pilot randomised trial that investigated the efficacy and feasibility of mobile text messaging compared to standard 
care in improving treatment adherence (Sibeko et al., 2017). This study included inpatients in the pre-discharge wards 
after screening of clinical records. Patients diagnosed with schizophrenia spectrum disorders (schizophreniform, 
schizoaffective, delusional disorder, and psychotic disorder not otherwise specified), substance induced psychotic 
disorder, and bipolar mood disorder type I were included. Exclusion criteria were the same as for the PRP study-
332/2008.  
2.3.3 Measures and scales 
Instruments and scales are contained in the appendix.  
Structured Clinical Interview for DSM-IV-TR Axis I disorders (SCID-I)  
Translation and versions used: I used the SCID-I (First et al., 1994a), modules A, B, C, D, E, and F, to determine axis-
one psychiatric disorders across objectives 1-4. The English language version was used in objectives 2 and 4 and the 
Xhosa language version was used in objectives 1 and 3. The SCID-I was translated into Xhosa by bilingual research 
assistants and then back translated into English through an iterative process in accordance with World Health 
Organization (WHO) translation guidelines (Sartorius and Janca, 1996). Following forward and backward translation, 
a native English speaker compared the translated version with the original English language SCID. Discrepancies and 
problematic constructs were then discussed and debated by the research team in order to find the most suitable 
wording in Xhosa (Campbell et al., 2017b). 
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Overview section: Demographic details such as age, sex, marital status, level of education, employment status, 
treatments received, and past hospital admissions were recorded in the SCID overview section. For dataset #2 the 
overview section was supplemented with a detailed medication history including type and dosage of medication 
prescribed. In addition, for dataset #2 (conducted in a multi-cultural and ethnic population) we recorded self-identified 
ethnicity. For self-identified ethnic groups, the terms “Coloured” “Black” and “Caucasian” and “Other” (Asian), were 
not intended to reify sociocultural constructs but were instead used to study ongoing health disparities. 
Module A: 
In this module mood symptoms and episodes, i.e. depression, mania and hypomania, were assessed. The SCID-I 
allows for the assessment of symptoms that reach threshold level as well as falling short of threshold; i.e. 
“subthreshold” symptoms (for example depressed mood for 10 instead of 14 days, or anhedonia for some activities but 
not “almost all activities”). In addition, psychopathology at syndrome or episode level can also be rated as 
subthreshold if the full criteria set are not met, but clinically the symptoms are important (i.e. only depressed mood for 
2 weeks and two other symptoms but fails to meet full criteria). I coded as “1” the presence of any lifetime major 
depressive episode (MDE) meeting full DSM-IV-TR syndrome level criteria. In addition, I coded lifetime MDE 
symptoms as “1” in the presence of any lifetime threshold or subthreshold depressive symptoms defined as the 
presence of depressed mood or anhedonia, the minimum entry requirements for any mood episode in the SCID-I. 
Lifetime suicidality was coded as 0=absent, 1= suicidal ideation or recurrent thoughts of own death, 2= suicidal 
attempts. For objective 1, only past-month MDE symptoms/episodes and suicidality were available in dataset #1. 
Modules B, C and D: 
Psychotic symptoms (delusion, hallucinations, thought disorder and negative symptoms) are assessed in module B. 
Diagnosis of the principle axis I psychotic disorders are made in Module C and major mood (major depressive and 
bipolar disorders) are determined in Module D of the SCID-I.  
Module E: 
Alcohol and illicit drug use disorders were assessed in Module E of the SCID-I. The Module assesses substance abuse 
and dependence according to DSM-IV-TR criteria. I coded the presence of a substance use disorder as “1” if a 
participant fulfilled criteria for either abuse or dependence for any substance (any SUD) and separately for alcohol, 
cannabis, methaqualone (sedative-hypnotic), methamphetamine and an additional group of “other substance use 
disorders” if a participant had a cocaine, ecstasy, heroin or LSD use disorder. 
Module F: 
Anxiety symptoms and disorders were assessed as part of Module F. In addition to syndrome level disorders I entered 
the presence of any subthreshold or threshold symptoms that fell short of meeting criteria for a clinical disorder. I 
categorised anxiety, obsessive-compulsive and post-traumatic disorders or symptoms separately into different 
categories, with the presence of a disorder or symptoms coded=1 and absence=0. Panic, agoraphobia without a history 
of panic, social phobia, specific phobia and generalised anxiety were classified together as “lifetime anxiety disorders/ 
symptoms”. Obsessive-compulsive disorder and symptoms were classified separately and post-traumatic stress 
disorder and symptoms also into different categories. 
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DSM-IV Axis IV psychosocial and environmental problems 
For objective 1 in dataset #1 the presence or absences of psychosocial problems, forming part of DSM-IV axis IV, 
were systematically recorded in a checklist format. The presence or absence of any problem was coded as “1” or “0”. 
This checklist contains a number of nine headings with paired descriptors and assesses: problems with the primary 
support; problems related to the social environment; educational problems; occupational problems; housing problems; 
economic problems; problems with access to health care; problems related to interaction with the legal system/crime 
and other psychosocial and environmental problems. 
Global Assessment of Functioning (GAF score) 
This scale ranges from 0-100, with anchoring descriptors at each decile and assesses the worst functioning of the 
patients in the past month (DSM-IV Axis V level of functioning). Ratings are made based on either symptom severity 
or functioning, whichever is the worst, and interviewers are encouraged to rate precise scores within each decile (See 
appendix) (Endicott et al., 1976).  
Addiction Severity Index (ASI)  
I have used the section of the Addiction Severity Index (ASI) gathering legal information to record the presence and 
type of police arrests and legal problems (See appendix) (McLellan et al., 1992b). 
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST-WHO version 3)  
The WHO ASSIST, version 3 was used to screen for the presence of alcohol and drug use disorders (Humeniuk et al., 
2008a). Similar to the SCID-I, the English version of the ASSIST was translated into IsiXhosa through an iterative 
process of forward and backward translation by both English and IsiXhosa bilingual research fieldworkers. The 
ASSIST consists of 8 questions that assess the use of tobacco products, alcohol and illicit drugs (10 substances in 
total). Question 1 assesses lifetime use of these substances and acts as a screen whether or not to continue with 
additional questions. Questions 2, 3,4,5 assesses the frequency of various measures relating to substance use on a 5-
point scale (“never”, “once or twice”, “monthly”, “weekly” “daily or almost daily”) in the past 3 months. Question 2 
measures frequency of substance use, question 3 measures the frequency of desires or urges to use, questions 4 
measures health, social, legal or financial problems due to drug use, question 5 measures failure to fulfil role 
expectations. Questions 6 assesses whether a friend or relative has ever expressed concern over drug use, and question 
7 whether the participant has ever tried to control or cut down their substance use. Question 6 and 7 is rated on a 3-
point scale (“never”, “yes in the past 3 months” and “yes, but not in the past 3 months”). Question 8 enquires about 
lifetime intravenous drug use.  
Severity of Dependence Scale (SDS)  
Severity of Dependence Scale was used to screen for the presence of alcohol and drug use disorders (Gossop et al., 
1995a). The English version of the SDS was translated into IsiXhosa through an iterative process of forward and 
backward translation by both English and IsiXhosa bilingual research fieldworkers. The SDS is a 5-item scale with 
scores on each item/question ranging from 0-3, a minimum total score of 0 and maximum score of 15. The scale 
assesses perceived control over substance use (“do you think your use was out of control?”), anxiety about use (“did 
the prospect of missing a fix or dose make you anxious or worried?”), concerns over use (“did you worry about your 
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use of the drug?”), thinking about quitting (“did you wish you could stop?”), difficulties in stopping (“how difficult 
did you find it to stop or go without the drug?”). 
Extrapyramidal symptom rating scales 
Abnormal Involuntary Movement Scale (AIMS) was used to assess the presence of tardive dyskinesia (Guy, 1976b). 
This scale assesses choreiform or atetoid movements in 7 different body areas (orofacial, extremities and truncal 
areas) on a 5-point scale (scored from “none”, “minimal”, “mild” “moderate” through to “severe”). A score of 3 or 
more in one body area or a score of 2 or more in two separate body areas was scored as a positive test.  
The Barnes Akathisia Rating Scale (BARS) was used to assess the presence and severity of akathisia (Barnes, 1989). 
This scale rates both objective and subjective symptoms and the level of distress experienced by patients on a 4-point 
scale. A global score is derived ranging from 0 to 5 and a score of 2 or more is scored as positive.  
The Simpson Angus Scale (SAS) was used to assess the presence and severity of parkinsonism (Simpson and Angus, 
1970). This scale assesses bradykinesia, rigidity and tremor on 10 different items scored on a 5-point scale from 0 to 4. 
A score of ≥ 3 was scored as positive for the presence of parkinsonism. 
2.4 Statistical analyses, data management and quality appraisal 
In part I of the thesis, for the first two objectives derived from datasets#1 and #2, logistic regression modelling was 
used to determine factors associated with having a co-occurring SUD. In part II of the thesis, for the validation study 
of the Xhosa language versions of the ASSIST and SDS, I determined the internal consistency, concurrent validity, 
and discriminant validity of these instruments and compared the sensitivity, specificity and the receiver operating 
characteristics (ROC) for the ASSIST and SDS. Logistic and ROC-regression was used for the comparison of ROC-
area under the curves for ASSIST and SDS and for determining the impact of co-variates on ROCs. In part III, I 
determined the association between methamphetamine use and the presence of EPS using logistic regression. Finally, I 
conducted a Cochrane systematic review of randomised trials after a comprehensive literature search of several 
databases and duplicate study selection and data extraction. Study quality was assessed using the Cochrane Risk of 
Bias and GRADE tools. Where possible outcomes were pooled, and meta-analyses conducted using random effects 
models. All analyses were two-tailed and p<0.05 was considered as statistically significant. All data management, 
programming and statistical analyses were conducted using Stata version 13 for Windows (StataCorp, 2013). Meta-
analyses for the Cochrane review was conducted using Revman software (RevMan, 2014). 
2.5 Ethics 
For dataset #1, in addition to written informed consent, participants completed the University of California, San Diego 
Brief Assessment of Capacity to Consent Questionnaire (UBACC)(Jeste et al., 2007). This instrument was used to 
improve the understanding of study elements during the consent through an iterative learning process (Campbell et al., 
2017b).  The study was approved in 2013 by the University of Cape Town Human Research Ethics Committee, The 
Walter Sisulu University Research Ethics and Biosafety Committee, The Rhodes University Ethical Standards 
Committee, The Columbia University Internal Review Board and the University of Washington Institutional Review 
Board (SAX study, Rec. Ref. 049/2013; NIH: R01MH096754 - 01A1). Data in dataset #1 was kept in a password 
protected database at the Columbia University, Mailman School of Public Health, and access was controlled via study 
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requests to the SAX study team steering committee. Research clinical folders are kept in a locked office to which only 
research staffs have access to. 
All studies forming part of datasets #2 was approved by the Human Research Ethics Committee of the University of 
Cape Town. The PRP study was approved in 2008 (Rec. Ref 332/2008). The other two studies were approved in 2010 
(CIAM study, rec ref 192/2010) in 2011 (SIP study, Rec. Ref. 511/2011) Data from the PRP, CIAM and SIP studies 
were merged into dataset#2 and stored in a password protected database. All participants received a unique 
identification number. Access to database #2 is limited to the principle investigator and study staff (data capture and 
co-investigators). Research clinical folders are kept in a locked office to which only research staffs have access to. All 
participants gave written informed consent. 
Participants were informed that the study is carried out independently of their clinical care, and that it will not 
influence their clinical care. Participants were informed that they could withdraw their participation at any time during 
the study and that this would not influence their clinical care and treatment.  Research conducted has adhered to the 
principles of research on human subjects according to the Declaration of Helsinki.  
2.6 Role of the PhD candidate: 
I am the principal investigator on the PRP-332/2008 study and co-investigator on the CIAM-192/2010 and SIP 
511/2011 studies. I designed the PRP-332/2008 study and consulted on the design of the CIAM and SIP studies. I 
acted as a consultant to the SAX-049/2013 study. Data from the PRP-332/2008 study formed the basis for the SAX 
NIMH research proposal. I designed the systematic review (objective 5).  
For objectives 1-4, I participated in the data collection for the PRP, SIP and CIAM studies and trained researchers and 
research assistants on the PRP, SIP, CIAM and SAX studies. I was in charge of data management, which included 
managing the data entry process, auditing the data, merging datasets from different studies, and managing data 
cleaning and coding. I conducted all statistical analyses and programming, designed the output tables and reporting of 
results. All data management and programming were conducted using Stata version 13 for Windows (StataCorp, 
2013). The Appendix contains a table (table 9.4) outlining the characteristics of the different studies contributing to 
datasets #1 and #2, the role of the PhD candidate and the aims of the original parent studies. 
For objective 5, with the support of the South Africa Cochrane collaboration and the Nottingham Cochrane 
Schizophrenia Group, I wrote the protocol for the systematic review, independently selected the studies for inclusion 
and compared my selection with 2 co-authors. I also managed the data extraction, which also occurred in duplicate 
with two co-authors. I conducted all meta-analyses (using Revman software)(RevMan, 2014) and wrote the initial and 
subsequent manuscripts, managed the editorial and peer review process of the protocol and review and conducted all 
revisions prior to publication of the systematic review in the Cochrane library. 
2.7 Appendix 
Contains additional tables and figures and study measures. 
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Part I: Chapter 3 
Prevalence and clinical correlates of substance use disorders in South African Xhosa patients 
with schizophrenia  
3.1 Introduction 
As noted in the introduction of the thesis, substance use disorder (SUDs) frequently co-occur with schizophrenia (SZ), 
leading to worse treatment outcomes and prognosis (Lambert et al., 2005b, Wade et al., 2007).  Depending on the 
study, lifetime prevalence rates of SUDs have been reported to be as low as 10% and as high as high as 74% (Cantor-
Graae et al., 2001b, Lambert et al., 2005b).  Systematic reviews and meta-analyses of SUD prevalence rates in SZ and 
affective psychoses have shown that cannabis use disorders occur the most frequently with a pooled median lifetime 
prevalence of 27.1% (Koskinen et al., 2010), followed by alcohol use disorders (median lifetime prevalent of 20.6%) 
and finally stimulants (amphetamine, cocaine, ecstasy and other stimulants) which occur at a pooled lifetime and 
recent rate of 10.4% (Koskinen et al., 2009, Koskinen et al., 2010, Sara et al., 2015). Variations in prevalence of 
different substance use disorders across studies may depend on various aspects including the diagnostic methods used, 
clinical setting (inpatient vs. outpatient), stage of illness (first episode vs. multi and chronic), country and region, 
sample age and sex distribution. Meta-regression analyses from systematic reviews have pointed to variables that 
significantly affect variation in prevalence (Sara et al., 2015). These variables include diagnostic method used, male 
sex, younger age, first episode vs. more established illness, inpatient vs. outpatient status; higher rates of cannabis use 
in younger samples with alcohol use disorders occurring more frequently in older age groups; cannabis use and 
geographic region as a significant predictor of amphetamine use (Koskinen et al., 2009, Koskinen et al., 2010, Sara et 
al., 2015).  
Whereas some studies show no association between depressive symptoms and SUD in SZ (Gut-Fayand et al., 2001, 
Kamali et al., 2000), others have shown elevated depressive symptoms (Cuffel et al., 1993, Jimenez-Castro et al., 
2010, Kerfoot et al., 2011b, Margolese et al., 2004), and corresponding risky behaviours such as suicidality (Gut-
Fayand et al., 2001, Rush and Koegl, 2008). In turn, anxiety symptoms such as panic attacks and post-traumatic stress 
symptoms have been found to be elevated in patients with SZ and SUDs in some studies (Goodwin et al., 2003, 
Scheller-Gilkey et al., 2004b), whereas other studies have found no such an association (Seedat et al., 2007, Shoval et 
al., 2007). Similarly, risky and impulse behaviours such as criminal involvement and consequent legal problems have 
been found to be elevated in people with SZ and co-occurring disorders (Cantor-Graae et al., 2001b, Carra et al., 2015, 
Rush and Koegl, 2008). Studies examining DSM-IV axis IV psychosocial problems in people with psychotic disorders 
found elevated rates of problems with primary support groups, housing, educational and legal problems, although 
studies examining SZ spectrum disorder in particular only found significantly elevated rates of housing and access to 
healthcare problems (Compton et al., 2011, Compton et al., 2005). 
Within the South-African context there are few studies examining the prevalence and correlates of substance use 
disorder in adults with psychotic disorders and none examining SZ in particular (Davis et al., 2016, Paruk et al., 2013, 
Taukoor et al., 2017, Vos et al., 2010, Weich and Pienaar, 2009b). In turn, these studies have not used structured 
diagnostic instruments. Diagnosis of SUDs and other psychiatric comorbidities are improved by using semi-structured 
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interviews that make use of multiple sources of information and faced-to-face clinical interviewing to validate clinical 
diagnoses. The SCID-I is such an instrument and has demonstrated good reliability in the diagnosis of substance use 
disorders (First et al., 1994a). In order to improve cross-cultural validity this instrument has been translated into 
several languages worldwide (http://www.scid4.org). In this secondary data analysis of an existing larger study 
investigating the genomics of SZ in Xhosa people from South Africa, I aimed to determine the prevalence and 
distribution of SUDs as well as associated clinical and demographic features. The study utilised the Xhosa language 
version of the SCID-I in a homogeneous sample of Xhosa speaking patients with a well-established diagnosis of SZ 
spectrum disorders (SZ or schizoaffective disorder) and measured correlates of SUDs, including depressive and 
anxiety symptoms and disorders, risky behaviours such as suicidality and criminal involvement as well as other 
psychosocial problems. 
3.2 Methods 
3.2.1 Design, sample and setting 
This study is a secondary data analysis of an existing case-control study. Participants included cases from an existing 
larger case-control study investigating the Genomics of SZ in the South African Xhosa Population (SAX 
study)(Campbell et al., 2017b). The SAX study involved a collaboration between a number of Universities in the 
United States and South Africa and funded by the National Institutes of Mental Health (NIMH: Grant Number: 
5U01MH096754) and was a member of the Human Heritability and Health in Africa consortium (www.h3africa.org). 
This study aimed to recruit over 2800 participants over 5 years and started recruitment in 2013 across various 
psychiatric treatment settings, including community mental health clinics and psychiatric hospitals in two South 
African provinces (Western and Eastern Cape Provinces). Eligible participants were IsiXhosa speaking, aged 21-60 
years; had a suspected diagnosis of SZ or schizoaffective disorder with duration of illness of at least 2 years and the 
ability to give informed consent to the genomics study.  Controls were participants without a psychotic disorder but 
were excluded in this analysis which focuses on SZ spectrum cases with and without co-occurring SUDs. Participants 
were volunteers who were approached by study staff attending community psychiatry clinics and admitted to inpatient 
psychiatric treatment units. In addition, mental health practitioners (psychiatric nurses and psychiatrists) referred 
suitable cases. 
3.2.2 Measures and procedures 
Demographic and clinical characteristics were collected using the overview section of the SCID-I. The diagnoses of 
lifetime substance use disorders (abuse or dependence) were determined using Module E of the Structured Clinical 
Interview for DSM-IV (SCID-I). In addition, the diagnoses of SZ or schizoaffective disorder were confirmed using the 
SCID-I modules A, B, C, and D.  Module F of the SCID was used to determine comorbid anxiety disorders (panic 
disorder, agoraphobia without a history of panic, social phobia, specific phobia, obsessive compulsive disorder, post-
traumatic stress disorder and generalized anxiety disorder). 
In addition, psychosocial and environmental problems which form part of Axis IV of the DSM-IV-TR were also 
systematically recorded in this study. Axis IV psychosocial problems were recorded under a number of headings with 
paired descriptors, and included: “problems with primary support group”  (including death of family member,  health 
problems in family, disruption of family by separation, divorce, or estrangement, removal from the home,  remarriage 
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of parent,  sexual or physical abuse, parental overprotection, neglect of child,  inadequate discipline, discord with 
siblings, birth of a sibling); “problems related to the social environment” (including death or loss of a friend; 
inadequate social support; living alone; difficulty with acculturation; discrimination; adjustment to life-cycle transition 
such as retirement);  “educational problems “ ( illiteracy, academic problems, discord with teachers or classmates, 
inadequate school environment),  “occupational problems” (unemployment, threat of job loss,  stressful work 
schedule,  difficult work conditions,  job dissatisfaction,  job change,  discord with boss or co-workers); “housing 
problems” (homelessness,  inadequate housing, unsafe neighbourhood, discord with neighbours or landlord); 
“economic problems”  (extreme poverty, inadequate finances, insufficient welfare support); “problems with access to 
health care”  (inadequate health care services, transportation to health care facilities unavailable,  inadequate health 
insurance); “problems related to interaction with the legal system/crime”  (arrest,  incarceration,  litigation,  victim of 
crime) and  “other psychosocial and environmental problems” (exposure to disasters, war, other hostilities, discord 
with non-family caregivers such as counsellor, social worker, or physician; unavailability of social service agencies). 
Global functioning was ascertained by means of the Global Assessment of Functioning Scale (GAF scale), which 
assesses functioning on a 100-point scale (Endicott et al., 1976). Participants were interviewed by bilingual (isiXhosa 
and English speaking) psychiatric research assistants (a psychiatrist, a research fellow in psychiatry and psychiatric 
nurses) with extensive experience in working with patients with serious mental illness. In addition, research staff 
underwent extensive training in structured clinical interviewing and participated in weekly supervision and interrater 
reliability meetings to discuss diagnostic issues. The SCID-I was translated into isiXhosa in accordance with 
guidelines recommended by the World Health Organization (Sartorius and Janca, 1996). The translation design 
included a forward and back-translation approach where materials were first translated into isiXhosa by a group of 5 
first language isiXhosa speaking, experienced mental health practitioners, and then back-translated by an independent 
isiXhosa speaking psychiatrist. Initial translations were piloted and compared to the SCID by a native English-
speaking researcher and then improved through an iterative process. Where there were discrepancies in the translation, 
these were discussed in group meetings and consensus was reached on the final translation.  Interrater reliability 
obtained on a smaller sample of participants (N=22) was substantial for the principle psychotic disorder diagnosis 
(kappa=0.74, p<0.001). Similarly, for the SCID-I DSM-IV substance use disorder (abuse or dependence) diagnoses, 
interrater reliability ranged from substantial to near perfect (any SUD, kappa=0.82; alcohol use disorder, kappa=0.84, 
p<0.001; cannabis use disorder, kappa=0.85, p<0.001, methamphetamine use disorder, kappa=0.71, p<0.001). 
Typical SCID-I interviews lasted 2.5-3.5 hours. In addition to the patient interview, additional information was 
considered in the diagnostic process from referral notes, including urine drug tests conducted on hospital admissions 
where available, past and current clinical records, interviews with other members of the multidisciplinary teams and 
information from family members or other associates of the patients. 
3.2.3 Ethics 
All participants gave written informed consent to participate in the study. The consent procedure included the 
administration of the University of California, San Diego Brief Assessment of Capacity to Consent Questionnaire 
(UBACC)(Jeste et al., 2007). This instrument was used to screen for decisional capacity and improve the understating 
of study elements during the consent process (Campbell et al., 2017b).  The study was approved by the University of 
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Cape Town Human Research Ethics Committee, The Walter Sisulu University Research Ethics and Biosafety 
Committee, The Rhodes University Ethical Standards Committee, The Columbia University Internal Review Board 
and the University of Washington Institutional Review Board. 
3.2.4 Statistical analysis 
Demographic variables included age, sex, marital status, education level, employment, recruitment area, i.e. Western 
Cape or Eastern Cape provinces, inpatient or outpatient status. From module A of the SCID-I, I coded as “1” the 
presence of any current (past month) major depressive episode (MDE) as well as (separately coded) the presence of 
any current (past month) threshold or subthreshold depressive symptoms defined as the presence of depressed mood or 
anhedonia, the minimum entry requirements for any mood episode in the SCID-I. Suicidality (current) was entered as 
a separate variable in models. 
For anxiety, from Module F of the SCID-I, in addition to syndrome level disorders, the presence of any subthreshold 
or threshold symptoms that fell short of meeting criteria for a clinical disorder were also entered into models. I 
categorised anxiety, obsessive-compulsive and post-traumatic disorders or symptoms separately into different 
categories, with the presence of a disorder or symptoms coded=1 and absence=0. Panic, agoraphobia without a history 
of panic, social phobia, specific phobia and generalised anxiety were classified together as “lifetime anxiety disorders” 
and “lifetime anxiety symptoms”. Obsessive-compulsive disorder (OCD) and symptoms as well as post-traumatic 
stress disorder (PTSD) and symptoms were classified separately and into different categories. Axis-IV psychosocial 
and environmental problems were entered as eight separate variables (problems with primary support group, problems 
related to the social environment, educational problems, occupational problems, housing problems, economic 
problems, and problems with access to health care, problems related to interaction with the legal system/crime, other 
psychosocial and environmental problems). In addition, based on the number of axis IV problems present participants 
were categorised into those with no axis IV problems, those with at least 1 to 2 problems and those with three or more 
problems. Numbers of lifetime hospitalisations were also categorized into 3 categories, none, ≤2, ≥3 hospitalisations. 
The 95% confidence intervals of the various SUD prevalence’s were calculated using the normal approximation of the 
binomial distribution. Six separate dichotomous dependent variables were constructed denoting the presence or 
absence of any lifetime, alcohol, cannabis, methaqualone, methamphetamine and other drug (cocaine and 
hallucinogens) SUDs (abuse or dependence). For the association between SUDs and demographic and clinical 
variables, I firstly conducted bivariate logistic regression analyses for each dependent variable separately onto each of 
the different independent demographic and clinical predictor variables. I then constructed multivariable logistic 
regression models with the dependent variables and the various SUDs (any SUDS, alcohol, cannabis, 
methamphetamine, methaqualone, and other drug use disorders) and entered independent variables that were 
significant in the bivariate analyses at a p ≤ 0.10 level into the final models.  I inspected models for multicollinearity 
using variance inflation and tolerance measures and removed redundant and collinear variables in order to obtain 
parsimonious models. To handle missing at random (MAR) data (see tables 1 and 2 for variables with missing data), 
multiple imputation models with chained equations (MICE) were constructed utilising variables selected for final 
models including auxiliary variables, to derive 20 imputed datasets with estimation models from which parameter 
estimates were then pooled using Rubin’s rules (Rubin, 1987). I report the associations between independent variables 
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and dependent (SUD) variables as adjusted odds ratios (aORs) with their 95% confidence intervals. All analyses were 
two-tailed and considered significant at the 5% level.  I used Stata version 13 for Windows for all analyses (StataCorp, 
2013).  
3.3 Results 
3.3.1 Sample characteristics 
The total sample consisted of 1420 participants. The mean age was 36.2 years (SD=9.2), and the majority of the 
sample were male (87.7%). Tables 3.1 and 3.2 contain a description of the sample demographics and clinical 
characteristics.  The majority of the sample were never married, had less than 12 years of education and were 
unemployed. Over half resided in the Eastern Cape Province, and two thirds were inpatients. The majority had SZ, and 
only a small group were diagnosed with schizoaffective disorder. The occurrence of past month depressive symptoms 
and MDE was very low as were the presence of suicidal ideation, plans or attempts. Lifetime anxiety, OCD and PTSD 
occurred infrequently, with the most common disorder being PTSD and PTSD symptoms. Problems with education 
and economic problems occurred in almost half the sample, followed by problems with housing. Other psychosocial 
problems occurred at lower levels. More than half the sample had a history of at least one axis IV psychosocial 
problem and almost all participants have had at least one hospital admission.  The average GAF score (Global 
Assessment of Functioning) was in the moderate symptom level and functional impairment range. 
3.3.2 Prevalence, patterns and distribution of substance use disorders 
Of the 1420 participants the prevalence of any SUD was 47.8% (95% CI= 45.1% - 50.4%). The most prevalent SUD 
was cannabis use disorders (39.6%, 95% CI= 37.1% - 42.2%), followed by alcohol use disorders (20.5%, 95% CI= 
18.4% - 22.7%), and methaqualone use disorders (sedative-hypnotic) (6.2%, 95% CI= 5.0% - 7.6%).  
Methamphetamine use disorders occurred much less frequently in this sample (4.8%, 95%CI= 3.8% - 6.1%) as did 
other SUDs (hallucinogens, cocaine and opioids) (0.6%, 95% CI= 0.2 %– 1.1%). Of all participants with SUDs, 
40.1% used two or more substances, 13.5% had a diagnosis of substance abuse and 39.1% a diagnosis of substance 
dependence. Participants who used cannabis had several fold increased odds of also using alcohol, methaqualone and 
methamphetamine. In turn cannabis, methamphetamine and methaqualone often occurred together and using one of 
these substances often increased the odds of using another several fold (Table 3.3). 
3.3.3 Demographic and clinical correlates of substance use disorders 
After adjustment for demographic and clinical covariates in multivariable logistic regression models, some variables 
remained significantly associated with SUDs (Tables 3.4 and 3.5). For any SUD, there was a significant association 
with younger age, male sex, inpatient status, lifetime PTSD symptoms, economic problems and legal or criminal 
involvement. For alcohol use disorders male sex and PTSD symptoms were significant in the final models. In turn, 
younger age, male sex, inpatient status, legal/criminal involvement and having had three or more prior hospitalisations 
had significant positive associations with having a cannabis use disorder in the adjusted analyses. Younger age and 
male sex had a significant positive association with methaqualone use disorder, whereas having a methaqualone use 
disorder was significantly less likely if living in the Eastern Cape compared to the Western Cape. Similarly, having a 
methamphetamine use disorder was also significantly less likely for those residing in the Eastern Cape than the 
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Western Cape, but significantly more likely with younger age and having inpatient status. Having a diagnosis of 
schizoaffective disorder, a lifetime anxiety disorder diagnosis and at least 1-2 prior hospitalisations had significantly 
increased odds of having a “other SUDs” diagnosis (i.e. cocaine, hallucinogens, and opioids). 
 
Table 3.1 Sample sociodemographic characteristics (N=1420) 
Age (years) N (%) 
 21-30 454 (31.9) 
 31-40 474 (33.4) 
 41-55 492 (34.7) 
Sex   
 Female 174 (12.3) 
 Male 1246 (87.7) 
Marital status†   
 Never married 1087 (85.1) 
 Married or cohabiting 107 (8.4) 
 Previously married 84 (6.5) 
Education (years)†   
 ≤7 453 (32.4) 
 8-11 697 (49.6) 
 12 142 (10.1) 
 >12 112 (7.9) 
Employment†   
 No 1028 (93.9) 
 Yes 67 (6.1) 
Recruitment locality   
 Western Cape province 601 (42.3) 
 Eastern Cape province 819 (57.7) 
Treatment setting†   
 Outpatients 449 (31.7) 
 Inpatients 969 (68.3) 
†Missing data for marital status:  n=142, education:  n=16, employment 
status: n=325, Treatment setting: n=2 
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Table 3.2 Sample clinical characteristics (N=1420) 
Diagnosis N (%) 
 Schizophrenia 1385 (97.5) 
 Schizoaffective disorder 35 (2.5) 
Lifetime MDEa 23 (1.6) 
Current MDE symptoms 24 (1.7) 
Suicidality (past month/current)   
 No suicidality 1409 (99.2) 
 Ideation or plans 9 (0.6) 
 Attempt 2 (0.1) 
Lifetime anxiety disordersb 14 (0.9) 
Lifetime anxiety symptoms 17 (1.2) 
Lifetime OCDc 1 (0.1) 
Lifetime PTSDd 18 (1.2) 
Lifetime PTSD symptoms 23 (1.6) 
Axis IV Psychosocial problems   
 Primary social support group 81 (5.7) 
 Social environment 59 (4.1) 
 Education 732 (51.5) 
 Housing 260 (18.3) 
 Economic 595 (41.9) 
 Access to healthcare 22 (1.5) 
 Legal/ criminal involvement 108 (7.6) 
 Other 58 (4.0) 
Number of axis IV problems   
 None 587 (41.3) 
 ≤ 2 208 (14.7) 
 ≥ 3 625 (44.0) 
Number of hospitalisations†   
 None 65 (5.2) 
 ≤ 2 427 (33.8) 
 ≥ 3 770 (61.0) 
GAF scoree †   
 mean (sd) 56.7 (15.3) 
a. MDE: Major depressive disorder 
b. Anxiety symptoms or disorders to include: Panic disorder, Agoraphobia 
without a history of panic, specific phobia, social phobia, generalised 
anxiety disorder 
c. OCD=Obsessive compulsive disorder. 
d. PTSD=Posttraumatic stress disorder. 
e. GAF: Global Assessment of Functioning scale 
† Missing data: Number of hospitalisations: n=158, GAF score: n=230 
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Table 3.3 Patterns and relationship between substance use disorders (N=1420) 
SUD Alcohol (R2= 0.06) Cannabis (R2= 0.09) Methaqualone (R2= 0.22) Methamphetamine (R2= 0.17)  Other (R2= 0.13) 
 Adjusted OR 95% CI Adjusted OR 95% CI Adjusted OR 95% CI Adjusted OR 95% CI Adjusted OR 95% CI 
Alcohol  - - 3.1*** (2.3 - 4.1) 1.7* (1.0 - 2.7) 1.8* (1.1 - 3.1) 1.8 (0.5 - 7.2) 
Cannabis 3.1*** (2.4 - 4.2) - - 8.8*** (4.6 - 17.0) 3.4*** (1.8 - 6.3) 2.5 (0.4 - 14.0) 
Methaqualone 1.5 (0.9 - 2.5) 8.5*** (4.4 - 16.5) - - 7.3*** (4.1 - 13.0) 5.0* (1.0 - 24.4) 
Methamphetamine 1.7 (1.0 - 2.9) 3.1*** (1.6 - 5.8) 7.3*** (4.1 - 13.2) - - 3.2 (0.6 - 16.4) 
Other 1.6 (0.4 - 6.4) 2.3 (0.4 - 14.3) 5.0 (1.0 - 26.1) 3.1 (0.6 - 16.4) - - 
*** p<0.001, ** p<0.01, * p<0.05 
a. SUD= substance use disorders 
Each substance in columns adjusted for the effects of all other substances  
R2=general coefficient of determination, (McFadden’s R2) 
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Table 3.4 Adjusted demographic and clinical association with any, alcohol and cannabis use disorders. (N=1420) 
  Any SUD Alcohol Cannabis 
  Adjusted OR 95% CI Adjusted OR 95% CI Adjusted OR 95% CI 
Age       
 21-30 1 (ref) - - 1 (ref) 
 31-40 0.8 (0.6 - 1.0) - - 0.8 (0.6 - 1.0) 
 41-55 0.7** (0.5 - 0.9) - - 0.5*** (0.4 - 0.7) 
Sex: male:female 8.6*** (5.1 - 14.6) 4.3*** (2.2 - 8.1) 12.7*** (6.1 - 26.3) 
Marital status       
 Never married 1 (ref) 1 (ref) 1 (ref) 
 Married or cohabiting 0.7 (0.5 - 1.2) 1.2 (0.7 - 2.0) 0.7 (0.4 - 1.2) 
 Previously married 0.9 (0.5 - 1.5) 0.6 (0.3 - 1.2) 0.9 (0.5 - 1.6) 
Setting: Inpatient vs. outpatient 1.7*** (1.3 - 2.1) 1.3 (0.9 - 1.7) 1.6*** (1.3 - 2.1) 
Diagnosis       
 Schizophrenia - - 1 (ref) - - 
 Schizoaffective - - 2.0 (0.9 - 4.3) - - 
Lifetime PTSD symptoms 4.6** (1.6 - 13.4) 6.7*** (2.7 - 16.3) - - 
Axis IV Psychosocial 
problems 
      
 Primary social support group 1.5 (0.8 - 2.7) 1.5 (0.9 - 2.6) - - 
 Social environment 0.9 (0.5 - 1.8) - - 1.0 (0.6 - 1.9) 
 Education 1.1 (0.7 - 1.6) - - 1.0 (0.6 - 1.5) 
 Occupation 0.8 (0.5 - 1.3) - - 1.1 (0.7 - 1.8) 
 Economic 1.4* (1.0 - 2.0) 1.1 (0.8 - 1.4) 1.3 (0.9 - 1.8) 
 Legal/criminal involvement 3.4*** (2.1 - 5.5) 1.3 (0.8 - 2.1) 2.4*** (1.5 - 3.7) 
Number of hospitalisations       
 None - - - - 1 (ref) 
 ≤ 2 - - - - 1.3 (0.7 - 2.3) 
 ≥ 3 - - - - 2.1* (1.1 - 3.9) 
*** p<0.001, ** p<0.01, * p<0.05 
Multiple imputation models, utilisation all cases observed (n=1420) 
Omitted variables did not reach significance at p<0.10 in bivariate analysis, and were not entered into models 
 
 
 
 
 
 
 
 
 
 
 
39 
 
 
Table 3.5 Adjusted demographic and clinical associations with methaqualone, methamphetamine, and other 
substance use disorders. (N=1420) 
  Methaqualone Methamphetamine Other 
  Adjusted OR 95% CI Adjusted OR 95% CI Adjusted OR 95% CI 
Age       
 21-30 1 (ref) 1 (ref) - - 
 31-40 0.6* (0.3 - 0.9) 0.3*** (0.1 - 0.6) - - 
 41-55 0.2*** (0.1 - 0.5) 0.1*** (0.0 - 0.4) - - 
Sex: male:female 9.5* (1.3 - 69.6) 16.8 (1.0 - 283.2) - - 
Marital status       
 Never married 1 (ref) 1 (ref) - - 
 Married or cohabiting 0.4 (0.1 - 1.8) 0.8 (0.2 - 3.3) - - 
 Previously married 0.7 (0.2 - 2.9) 0.6 (0.1 - 3.5) - - 
Education (years)       
 ≤7 - - 1 (ref) - - 
 8-11 - - 1.5 (0.8 - 2.9) - - 
 12 - - 0.9 (0.3 - 2.8) - - 
 >12 - - 0.9 (0.3 - 2.9) - - 
Employed - - 2.2 (0.9 – 5.5) 3.1 (0.7 - 14.4) 
Eastern vs. Western Cape 0.4*** (0.3 - 0.7) 0.1*** (0.1 - 0.3) 0.4 (0.1 - 1.9) 
Setting: In vs. Outpatient - - 3.7*** (1.8 – 7.5) - - 
Diagnosis       
 Schizophrenia - - - - 1 (ref) 
 Schizoaffective - - - - 11.8** (2.3 - 61.0) 
Suicidality (current)       
 No suicidality - - - - 1 (ref) 
 Ideation or plans - - - - 1.2 (0.0 - 39.9) 
 Attempt - - - - 0.1 (0.0 - 5.0) 
Lifetime anxiety disordersb - - - - 9.9* (1.3 - 76.7) 
Lifetime OCDc - - - - 21.8 (0.6 - 836.8) 
Lifetime PTSDd - - 2.2 (0.5 - 9.2) - - 
Axis IV Psychosocial 
problems 
      
 Social environment - - 1.1 (0.4 - 2.9) - - 
 Education 1.3 (0.6 - 3.1) - - - - 
 Housing - - 1.0 (0.5 - 2.1) - - 
 Economic 1.1 (0.6 - 2.1) 1.2 (0.7 - 2.3) - - 
 Occupation 1.4 (0.6 - 3.6) - - - - 
 Legal/criminal involvement 1.9 (1.0 - 3.6) - - - - 
Number of axis IV problems       
 None - - - - 1 (ref) 
 ≤ 2 - - - - 4.9* (1.1 - 22.8) 
 ≥ 3 - - - - 1.0 (0.2 - 5.6) 
*** p<0.001, ** p<0.01, * p<0.05 
Multiple imputation models, utilisation all cases observed (n=1420) 
Omitted variables did not reach significance at p<0.10 in bivariate analysis, and were not entered into models 
 
3.4 Discussion 
3.4.1 Main findings and comparison with other studies 
In a sample of Xhosa speaking patients with an established diagnosis of SZ, a high lifetime prevalence (47.8 %) of 
substance use disorders was found. This corresponds well with findings from other local and international studies that 
typically find about half of patients with SZ have a SUD (Cantor-Graae et al., 2001b, Weich and Pienaar, 2009b). In 
turn, findings are also in agreement with meta-analyses of prevalence studies of SUDs in SZ, that have found that the 
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most prevalent SUD to be cannabis use disorders, although the prevalence of  39.6% found in this study is somewhat 
higher than the pooled prevalence of 27% from one meta-analysis (Koskinen et al., 2010). Alcohol use disorders had a 
prevalence of 20% in this sample, a rate very similar to pooled prevalence rates from one meta-analysis (20%) 
(Koskinen et al., 2009). Methamphetamine use disorders occurred in a somewhat lower rate of 4.7% in this sample, 
less than half of that found in meta-analyses of prevalence studies of amphetamines (Sara et al., 2015). These findings 
of a lifetime prevalence of any SUD contrast to that from nationally representative South African general population 
sample that found any substance use disorder  in only 13.3%, with alcohol use disorders to be the most prevalent 
substance used (abuse 4.5% and dependence 1.2 % ), followed drug abuse (3.9%) and drug dependence (0.6%), that 
occurred at much lower rates (Herman et al., 2009). In turn, consistent with findings of meta-analyses of SZ patients, 
in this study sample a diagnosis of dependence was more common compared to a diagnosis of abuse, while the 
opposite is found in the general community sample from a South African sample and other studies in the international 
literature (Herman et al., 2009, Koskinen et al., 2010). Polydrug use (2 or more substances) occurred in 40% of those 
who had a SUD, and “other substance use disorders” occurred in less than 1% of patients. There were significant 
associations between having a methamphetamine use disorder and cannabis use disorder, similar to findings from 
extant literature (Sara et al., 2014). There was an even stronger significant association between having cannabis or 
methamphetamine use disorder and a methaqualone (sedative hypnotic) use disorder. 
Consistent with meta-analyses of  SUD and gender, there was a strong association between male sex and any SUD in 
this study sample (Cantor-Graae et al., 2001b, Koskinen et al., 2009, Koskinen et al., 2010, Sara et al., 2015, Swartz et 
al., 2006, Weich and Pienaar, 2009b). This association held across most multivariable models for different substances. 
In turn, consistent with other studies in this sample there were significant associations with younger age and SUDs, 
with the exception of alcohol use disorders which, similar to findings from meta-analyses, typically occur more 
equally spread across age groups, with high prevalence in older groups (Koskinen et al., 2009, Koskinen et al., 2010, 
Rush and Koegl, 2008, Sara et al., 2015). Patients from the Eastern Cape Province were significantly less likely to use 
methamphetamines or methaqualone, perhaps since methamphetamine use is currently particularly prevalent to the 
Western Cape (Pluddemann et al., 2013). This is echoed in the international literature with meta-analyses showing 
significant differences between geographic regions (i.e. USA and Australia vs. Europe and UK) in stimulant use 
among patients with psychotic disorders (Sara et al., 2015). Moreover, there was a significant association with being 
an inpatient as opposed to an outpatient and a having any SUD, cannabis use disorder and methamphetamine use 
disorders, which perhaps reflects the illness severity of those people with a dual diagnosis. Of note, participants with 
cannabis use disorders had significant higher odds of having three of more compared to no prior hospitalisations. In 
one meta-analysis cannabis use disorders were more prevalent among inpatients (31.3% vs. 25.2%), but this difference 
did not reach statistical significance (Koskinen et al., 2010). Similarly, in studies with hospitalised patients there was a 
significantly higher prevalence of stimulant use disorders (cocaine and amphetamines) compared to studies with 
community samples (Sara et al., 2015). For diagnosis, there was a positive association with having a schizoaffective 
disorder and a diagnosis of other SUDs (cocaine, ecstasy and heroin). Interestingly, in one meta-analysis of prevalence 
studies (that included a high number of studies with cocaine, ecstasy and mixed stimulant use) there was a significant 
association between stimulant disorders and an affective psychosis diagnosis in univariate meta-regression which was 
no longer significant after adjusting for geographic and treatment setting in meta-regression models. Axis IV 
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economic problems were significantly more prevalent in those with any SUD and only legal problems remained 
significantly associated with cannabis use disorders in multivariable models. These findings are somewhat different 
from one other study that found significant economic and legal problems in unadjusted models, with only economic 
problems remaining significant in adjusted models (Compton et al., 2011). Despite the low prevalence of anxiety 
disorders, PTSD and OCD, there was a significant association between having PTSD symptoms and a SUD, alcohol 
use disorders in particular. Anxiety disorders were significantly associated with having an “other SUD”. This finding 
resonates with that of the South African Stress and health study that found a strong association with anxiety disorders 
and PTSD in particular and substance use disorders notably alcohol use disorders (Saban et al., 2014). 
3.4.2 Clinical Implications 
These findings have several potential implications for clinicians treating patients with SZ. Within this population of 
Xhosa speaking patients from a variety of treatment settings varying from inpatient settings and community health 
clinics across two provinces in South Africa, almost half the participants had a SUD.  Screening for theses disorder 
would be of importance, and significant clinical predictors were younger age and male sex. The fact that both cannabis 
and methamphetamine use disorders were associated with inpatient status may underline concerns that these 
substances may be related to increasing admissions due to their potential for triggering underlying psychotic states 
(Andrade, 2016, Hermens et al., 2009), and an association with higher hospitalisation rates (Ouellet-Plamondon et al., 
2017). Another important finding was the significant association of PTSD symptoms with any substance use disorder, 
alcohol use disorders in particular. Screening for trauma and related PTSD symptoms would be important in this 
population, specifically patients with alcohol use disorders. Economic problems (extreme poverty, inadequate 
finances, insufficient welfare support) and legal problems (i.e. involvement with the law police arrests are also 
significantly elevated, underlying the importance of an assessment of problems with finances (and its relationship with 
drug use) and liaison with the criminal justice system when patients have problems in this area.  
3.4.3 Study strengths and limitations 
This study is the first large clinical survey investigating the prevalence of substances in the Xhosa speaking SZ 
population in the South African setting using a semi-structured clinical interview. To improve validity this study 
utilised an isiXhosa language version of the SCID-I to determine clinical and substance related diagnoses.  
Nevertheless, there are some limitations to the findings of this study. Firstly, the sample was selected from volunteers 
with a clinical diagnosis of SZ who attended treatment centres. The exclusion of some patients who were not treatment 
seeking or in treatment cannot be ruled out and this may have had an impact on the estimation of the prevalence of 
SUDs. This sample is also heavily skewed towards male participants, possibly as a result of the study recruitment 
procedures that focused on participants admitted to psychiatric hospitals, where male sex predominated.  This makes 
the findings less generalizable to females with schizophrenia.  In addition, the lack of biological validation of 
substance use is an important shortcoming of this study. Nevertheless, validation of drug use in diverse samples such 
this one that contains inpatients in hospitals as well as community patients, are less than ideal, with several issues such 
as short detection windows of drug tests and limited practical methods for assessment of alcohol use disorders. 
Furthermore, multiple sources of information (clinical interview, case notes, family collateral) were used to assess 
substance use, and studies have demonstrated that clinical methods can be accurate in diagnosing substance use 
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disorders. The use of the SCID-I to determine comorbid anxiety, post traumatic and obsessive disorders could have led 
to lower frequencies of anxiety disorders due to the use of diagnostic hierarchy rules. This, however, could have been 
offset to a degree by including in the analyses subthreshold anxiety symptoms. Furthermore, there was no data on 
lifetime depressive symptoms and the analysis in this study was limited to current (past month) MDE and depressive 
symptoms.  
3.4.4 Conclusions 
This study demonstrated a high occurrence of comorbid SUD in people with SZ and underlines the importance of 
conducting an assessment for SUDs in patients with SZ. Having a dual diagnosis was also associated with certain 
characteristics such as younger age, male sex, higher inpatients status, more prior admissions, economic and legal 
problems as well as high levels of post-traumatic stress disorder symptomology. This underscores the importance of 
also assessing the presence of these factors in patients who have both SZ and a SUD.  
In the next chapter, I investigate the demographic and clinical correlates of dual diagnosis using a similar 
methodology but in a clinically more heterogeneous sample of patients with a variety of different major affective and 
non-affective psychotic disorders. 
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Part I: Chapter 4 
The prevalence and clinical correlates of substance use disorders in patients with major 
affective and non-affective psychosis from an Upper-Middle-Income-Country 
4.1 Introduction 
As mentioned in previous chapters, depending on the sample characteristics and setting, the prevalence of substance 
use disorders (SUDs) in patients with serious mental disorders varies from as low as 10% to as high as 74% (Cantor-
Graae et al., 2001b, Lambert et al., 2005b, Weich and Pienaar, 2009b). Whereas the variation in prevalence is affected 
by a variety of factors, meta-analyses of prevalence studies report cannabis use disorders to occur in 27.1% , alcohol 
use disorders in 20.6% and amphetamine use disorders in 10.4% of patients with major affective and non-affective 
psychoses (Koskinen et al., 2009, Koskinen et al., 2010, Sara et al., 2015). SUDs have a negative impact on the 
clinical course and outcome of patients with SMI, and higher rates of re-hospitalisation and poor clinical outcomes are 
reported in patients with SUDs (Lambert et al., 2005b, Swofford et al., 1996b, Wade et al., 2007). 
Variation in the prevalence of difference substance use disorders is influenced by factors such as geographical region, 
setting, phase of illness (first vs. chronic), diagnostic method and other demographic and clinical characteristics. Some 
of these characteristics include variations in clinical diagnosis and ethnic grouping, and in some studies stimulant use 
disorders were more prevalent in patients with affective psychosis (Sara et al., 2015), and some but not all studies 
have shown higher prevalence in patients from some ethnic groups (Mazzoncini et al., 2010, Montross et al., 2005, 
Weaver et al., 2001).  In turn, whereas meta-analyses and studies with predominantly schizophrenia spectrum patients 
report the most prevalent substance used to be cannabis or alcohol, followed by stimulants such as cocaine and 
amphetamines (Cantor-Graae et al., 2001b, Dixon et al., 1991, Fowler et al., 1998b, Goodwin et al., 2003, Jimenez-
Castro et al., 2010, Koskinen et al., 2009, Koskinen et al., 2010, Margolese et al., 2006, Mueser et al., 1990a, Sara et 
al., 2014, Sara et al., 2015, Sevy et al., 2001, Shoval et al., 2007), some studies of predominantly bipolar patients 
report alcohol use disorders to be most prevalent (Escamilla et al., 2002). 
In patients with SMI and SUDs, substance rehabilitation treatment is typically reported as to be low (Kerfoot et al., 
2011b, Mowbray et al., 1997). In the South African setting, where community mental health teams are severely 
overburdened and under-resourced, most patients with co-occurring SMI and SUDs are treated in the public mental 
health sector, mostly as inpatients where clinical presentations are characterised by severe  relapses of mental disorder, 
and treatment tends to be sequential with mental health treatments occurring first, and only a small proportion of 
patients then getting referred on to traditional drug and alcohol rehabilitation centres in the community. In one SA 
sample less than 5% of SMI/SUD patients had attended some form of substance rehabilitation program (Weich and 
Pienaar, 2009b). Pressured mental health services may be forced to discharge such patients as soon as the mental 
illness has been stabilised, often leaving patients in a pre-contemplative phase regarding change in terms of substance 
use. 
Whereas most studies report that male gender, younger age, ethnic minority status, low educational attainment, 
unemployment, single marital status are significantly associated with SUDs (Bersani et al., 2002, Cantor-Graae et al., 
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2001b, Compton et al., 2000, Hapangama et al., 2013, Kamali et al., 2000, Kavanagh et al., 2004b, Latt et al., 2011, 
Montross et al., 2005, Mueser et al., 1990a, Rush and Koegl, 2008, Sara et al., 2014, Swartz et al., 2006, Talamo et al., 
2006, Van Mastrigt et al., 2004, Weich and Pienaar, 2009b), a few studies have shown a lack of these associations 
(Sevy et al., 2001, Jimenez-Castro et al., 2010). Some studies have also found that patients with co-occurring SUDs 
are more likely to have contact with law enforcement with subsequent arrests, in particular for minor and drug related 
crimes (Cantor-Graae et al., 2001b, Carra et al., 2015, McCabe et al., 2012, Mowbray et al., 1997, Mueser et al., 
2000a, Robertson et al., 2014, Rush and Koegl, 2008). The association between dual diagnosis and mood or anxiety 
symptoms vary, with some studies reporting lower mood, anxiety or obsessive compulsive symptoms (Seedat et al., 
2007, Shoval et al., 2007) and some studies finding elevated depressive, anxiety (i.e. panic attacks) and post-traumatic 
stress disorder symptoms in particular (Cuffel et al., 1993, Goodwin et al., 2003, Jimenez-Castro et al., 2010, Kerfoot 
et al., 2011b, Margolese et al., 2004, O'Hare and Sherrer, 2013, Scheller-Gilkey et al., 2004b), whereas other studies 
report no association between depressive or anxiety symptoms and SUDs (Gut-Fayand et al., 2001, Kamali et al., 
2000). Further, suicidality has been found to be elevated in SMI/SUD patients in several studies (Gut-Fayand et al., 
2001, Kamali et al., 2000, Rush and Koegl, 2008, Shoval et al., 2007), but not all (Fowler et al., 1998b).   
In the South African context there are only a few studies examining the prevalence and correlates of SUDs in adults 
with major affective and non-affective psychotic disorders (Weich and Pienaar, 2009b, Davis et al., 2016).  These 
studies have used screening tests such as the ASSIST (Alcohol Smoking and Substance Involvement Screening Test) 
and self-reported use, and none employed structured clinical interviews to validate diagnoses. 
In contrast to the study in chapter 3, which was conducted in a clinical and ethnically homogenous population, in this 
study I aimed to determine the prevalence, patterns, demographic and clinical correlates of co-occurring SUDs in a 
clinically heterogeneous sample of patients with major affective and non-affective psychotic disorders from an 
ethnically diverse background, using a structured diagnostic clinical interview. An additional aim was to determine in 
SMI the association of co-occurring SUDs with anxiety, and lifetime depressive symptoms including suicidality, and 
prior treatment for SUDs. Furthermore, I also aimed to determine the specific nature and type of legal involvement in 
terms of police arrests for various offences. 
4.2 Methods 
4.2.1 Sample and Setting 
This study is a secondary analysis of a database (N=248) derived from three separate studies that ran concurrently at 
Valkenberg hospital, a large psychiatric academic hospital attached to the University of Cape Town’s Department of 
Psychiatry and Mental Health. The hospital is a secondary and tertiary level service that receives referrals from 5 
community-based regional psychiatric short-stay units and several psychiatry outpatient clinics situated in a number of 
community mental health centres within the Western and Southern Cape regions of South Africa. Participants attended 
inpatient or outpatient services or community psychiatric clinics in the hospitals’ Western metropolitan region 
catchment area. Participants from the first cross-sectional study; “Presentation and risk factor in the psychobiology of 
psychosis” (N=86) were selected randomly from inpatients listed as attending pre-discharge inpatients wards (Shelly 
et al., 2016). Inclusion criteria included a diagnosis of a major non-affective psychotic disorder (schizophrenia, 
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schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, substance induced psychotic disorder, 
psychotic disorder not-otherwise specified) or major affective psychotic disorder (bipolar I disorder with psychotic 
features). All participants had to be conversational in the English language. Exclusion criteria included psychotic 
disorders due to a general medical condition, dementia, intellectual disability, a primary diagnosis of a personality 
disorder and neurological disorders. The second study was a pilot randomised controlled trial (“Social inclusion 
Project-SIP”, N=59)  investigating the effect of a treatment partner text messaging and psychoeducational intervention 
on treatment adherence in patients with serious mental illness, and participants included inpatients attending the pre-
discharge wards at Valkenberg hospital (Sibeko et al., 2017). The third study recruited outpatients via referral from 
clinicians and advertisements in the media and investigated the cortical inhibition and attentional modulation using 
MRI neuroimaging and electroencephalography across patients with schizophrenia, methamphetamine psychosis, and 
bipolar mood disorder with psychosis and normal controls (CIAM study, N=103) (Howells et al., 2018). Exclusion 
criteria for the last two studies were the same as the first study. 
4.2.2 Measures and procedures 
A socio-demographic schedule was used across the parent studies to record participants’ demographic details such as 
age, gender, self-identified ethnicity, level of education, marital status, employment and past drug or alcohol 
treatment. For self-identified ethnic groups, the terms “Coloured” “Black” and “Caucasian” and “Other” (Asian), were 
not intended to reify sociocultural constructs but were instead used to study ongoing health disparities. Across all three 
parent studies all participants had to complete the English language version of the Structured Clinical Interview for 
DSM-IV (SCID-I) (First et al., 1994a), resulting in complete data across studies for this instrument. The SCID-I 
assesses mood episodes (depression and suicidality) in modules A, psychotic symptoms in module B and derives 
diagnoses for principal psychotic mood and psychotic disorders in modules C and D. Furthermore, lifetime SUDs 
were assessed using module E of the SCID-I which assesses abuse and dependence according to DSM-IV criteria. To 
optimize the accuracy of assessments for substance use disorders, interviewers were trained in non-judgemental 
interviewing styles, clear phrasing of initial open-ended questions and the use of normalising statements about drug 
use. In addition, longitudinal data on substance use were considered from multiple sources including case files, 
members of the multidisciplinary team and family reports.  Anxiety including panic, specific and social anxiety, 
generalised anxiety, agoraphobia, obsessive compulsive and post-traumatic stress symptoms and disorders were 
assessed in module F of the SCID-I. The SCID-I assesses symptoms as either present or absent at threshold level and 
allows clinicians to rate symptoms as subthreshold based on clinical judgement in cases where a symptom appears to 
be present but falls short of the full criterion. From module A of the SCID-I, the presence of any lifetime major 
depressive episode (MDE) as well as the presence of any lifetime threshold or subthreshold depressive symptoms 
(defined as the presence of depressed mood or anhedonia, the minimum entry requirements for any mood episode in 
the SCID-I), were coded. Suicidality was entered as a separate variable in models. For anxiety, in addition to 
syndrome level disorders the presence of any subthreshold or threshold symptoms that fell short of meeting criteria for 
a clinical disorder were entered as variables. Depressive, anxiety, obsessive-compulsive and post-traumatic disorders 
or symptoms were categorised separately, with the presence of a disorder or symptoms coded=1 and absence=0. 
Panic, agoraphobia without a history of panic, social phobia, specific phobia and generalised anxiety were classified 
together as “lifetime anxiety disorders/ symptoms”. Obsessive-compulsive disorder and symptoms were classified 
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separately and post-traumatic stress disorder and symptoms also into different categories Lifetime police contact and 
histories of criminal arrests were assessed based on the section of the Addiction Severity Index (ASI) gathering 
information on legal involvement (McLellan et al., 1992b). Legal involvement and police arrests were classified as 
“serious violent crime” (including assault, rape, murder or armed robbery), “major crime” (shoplifting, vandalism, 
parole violation, forgery, weapons offense, burglary, arson, contempt of court, domestic violence not involving 
assault), “other crimes” (possession of illegal substances, weapons offense, prostitution, disorderly conduct in public, 
major driving violation, driving under the influence of substances). Typical SCID-I interviews lasted 2.5-3.5 hours and 
in addition to the patient interview, additional information was considered in the diagnostic process from referral 
notes, including urine drug tests conducted on hospital admissions where available, past and current clinical records, 
interviews with other members of the multidisciplinary teams and information from family members or other 
associates of the patients.  Participants were assessed by psychiatric nurses, research and senior consultant 
psychiatrists with extensive training and experience in SCID-I interviewing. Inter-rater reliability was obtained on a 
smaller sample (n=8) of participants with good agreement for the principle psychiatric diagnosis (kappa=0.70, 
p<0.001) and comorbid SUDs (kappa=0.80, p<0.001). 
4.2.3 Ethics and consent 
All participants in the original studies provided written informed consent to participate in the studies and the 
secondary data analysis was also approved by the Human Research Ethics Committee of the University of Cape 
Town. 
4.2.4 Statistical analysis 
The 95% confidence intervals of prevalence estimates were calculated using the normal approximation of the binomial 
distribution. Six separate dichotomous dependent variables were constructed denoting the presence or absence of any 
lifetime, alcohol, cannabis, methamphetamine, methaqualone and other drug (cocaine and hallucinogens) SUDs 
(abuse or dependence). The distribution and relationship between the different SUDs were then explored using logistic 
regression analyses. For the association between SUDs and demographic and clinical variables, bivariate logistic 
regression analyses were firstly conducted for each dependent variable separately onto each of the different 
independent demographic and clinical predictor variables. Following this, multivariable logistic regression models 
were constructed with the dependent variables the various SUDs (any SUDS, alcohol, cannabis, methamphetamine, 
methaqualone, and other drug use disorders) and as independent variables, those variables that were significant in the 
bivariate analyses at a p ≤ 0.10 level.  The associations between independent variables and dependent variables are 
reported as adjusted odds ratios (ORs) with their 95% confidence intervals. All analyses were two-tailed and 
considered significant at the 5% level.  Stata version 13 for Windows was used for all analyses (StataCorp, 2013). 
4.3 Results 
4.3.1 Sample characteristics 
In the total of sample of 248 participants the mean age was 31.5 years (SD=9.2), with the majority of participants 
being male (64.5%). Table 4.1 and 4.2 contain the sample demographic and clinical characteristics, respectively. Most 
participants were of mixed ethnic (“Coloured”) background, single, had less than 12 years of education, were 
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unemployed and had a diagnosis of a schizophrenia spectrum disorder. Lifetime major depressive episodes or anxiety 
disorders occurred only in 20.6% and 13% of participants, but both depressive and anxiety symptoms were more 
prevalent and occurred in as many as half the sample (depressive symptoms, 55.7%) with anxiety symptoms occurring 
in a quarter (25%). Self-reported arrests were common and among participants with a SUD the most prevalent was 
arrest for “other crimes” (26.1%) whereas arrests for major and serious violent crimes were less common (occurring in 
10.1% and 11.6% with SUDs respectively). Of those patients with SUDs, less than a quarter (23.9%) indicated that 
they had attended any form of substance rehabilitation programme, of which 14.5% had attended inpatient and 13.0% 
outpatient rehabilitation programmes (Table 4.2). 
Table 4.1 Sample sociodemographic characteristics (N=248) 
Age (years) N (%) 
 18-29 122 (49.2) 
 30-44 97 (39.1) 
 45-65 29 (11.7) 
Sex   
 Female 88 (35.5) 
 Male 160 (64.5) 
Ethnicity   
 Coloured 141 (56.9) 
 African 72 (29.0) 
 Caucasian 28 (11.3) 
 Other
a 7 (2.8) 
Marital status   
 Never married 198 (79.8) 
 Married or cohabiting 33 (13.3) 
 Previously married 17 (6.9) 
Education (years)   
 ≤7 39 (15.7) 
 8-11 119 (48.0) 
 12 64 (25.8) 
 >12 26 (10.5) 
Employment   
 No 168 (67.7) 
 Yes 80 (32.3) 
Study and setting   
 CIAM study (outpatients) 103 (41.5) 
 PRP study (inpatients) 86 (34.7) 
 SIP study (inpatients) 59 (23.8) 
a. Other: Asian 
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Table 4.2 Sample clinical characteristics (N=248) 
Diagnosis N (%) 
 Schizophrenia spectrum disorder 132 (53.2) 
 Bipolar type I disorder 51 (20.6) 
 Schizoaffective disorder 33 (13.3) 
 Substance induced psychotic disorder 32 (12.9) 
Lifetime MDE 51 (20.6) 
Lifetime MDE symptoms 138 (55.7) 
Suicidality   
 No suicidality 171 (69.0) 
 Ideation or plans 54 (21.8) 
 Attempt 23 (9.3) 
Lifetime anxiety disorders 31 (13) 
Lifetime anxiety symptoms 62 (25) 
Lifetime OCD 2 (0.8) 
Lifetime OCS 13 (5.2) 
Lifetime PTSD 10 (4.0) 
Lifetime PTSD symptoms 23 (9.3) 
Legal involvement   
 No arrests 167 (67.3) 
 Serious/violent crime 22 (8.9) 
 Major crime 20 (8.1) 
  Other crime 39 (15.7) 
History of substance rehabilitation   
 Any rehabilitation 33 (13.3) 
 Inpatient 23 (9.3) 
 Outpatient 18 (7.3) 
a. Schizophrenia, schizophreniform disorder, brief psychotic 
disorder, psychotic disorder NOS 
b. MDE=Major depressive disorder 
c. Symptoms or disorders: Panic disorder, Agoraphobia 
 without a history of panic, 
specific phobia, social phobia, generalised anxiety disorder 
d. OCD=Obsessive compulsive disorder. 
 OCS=obsessive compulsive symptoms 
e. PTSD=Posttraumatic stress disorder. 
f. Legal involvement: Serious violent crime 
 (assault, rape, murder, armed robbery), 
 Major crime (shoplifting, vandalism, parole violation, 
 forgery, weapons offense, burglary, arson, 
 contempt of court, domestic violence), Other crime  
(possession of illegal substances, 
weapons offense, prostitution, disorderly conduct in public, 
major driving violation, driving under the influence of 
substances) 
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4.3.2 Prevalence and patterns of substance use disorders 
In the total sample of 248 participants, the prevalence of any substance use disorder (abuse or dependence) was 55.6% 
(95% CI= 49.2% - 62.0%). For the individual SUDs in the total sample, the most common SUD was cannabis use 
disorders with a prevalence of 34.3% (95% CI: 28.3% - 40.5%), followed by alcohol use disorders (30.6%; 95% CI= 
25.0% - 36.7%), methamphetamine use disorder (27.4%; 95% CI= 22.0% - 33.4%) and methaqualone (sedative-
hypnotic) use disorders (10.4%; 95% CI= 6.9% - 14.9%). Other drug use disorders occurred at a much lower 
frequency with cocaine use disorder occurring in only 4.4% (95%CI= 2.2% - 7.7%) and hallucinogens (MDMA and 
LSD) only in 1.6% (95% CI= 0.4%- 4.0%). All participants with SUDs fulfilled criteria for more than one SUD, with 
4% abusing more than one substance and 22.9% fulfilling criteria for more than one substance dependence syndrome. 
There was a significant association between having a cannabis and alcohol use disorder (OR=2.0, p=0.031, 95%CI= 
1.1 – 3.7) (Table 4.3). In turn, cannabis, methamphetamine or methaqualone use disorders often occurred together 
with the odds of having any one of these disorders significantly increasing the odds of having another with as many as 
4-5-fold (Table 4.3).  
4.3.3 Demographic and clinical correlates of substance use disorders 
After adjustment for demographic and clinical covariates in multivariable models some variables remained 
significantly associated with the presence of the various SUDs (Tables 4.4 and 4.5). For the presence of any SUD 
there were significant positive associations in the adjusted multivariable model with male gender, substance induced 
psychosis, serious violent and “other crimes” categories. For alcohol use disorders there were significant positive 
associations with male sex, lifetime anxiety symptoms, suicide attempts and other crime categories. For cannabis use 
disorder significant positive associations were found with male gender, lower educational attainment, substance 
induced psychosis, major and other crimes. For methamphetamine use disorder significant associations was found 
with younger age, significant negative associations with African ethnicity as compared to mixed (“Coloured”) 
ethnicity, a strong positive association with having a substance induce psychosis and a significant positive association 
with other crimes. For methaqualone there was a significant association between past marriage (divorced or widowed), 
and serious and violent crime, whereas for the category of “Other SUDs” (of which cocaine 92%, LSD or MDMA 
8%) there were significant associations between Asian ethnicity and serious violent crime. 
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Table 4.3 Patterns and relationship between substance use disorders (N=248) 
SUDa Alcohol (R2= 0.05) Cannabis (R2= 0.17) Methamphetamine (R2= 0.17) Methaqualone (R2= 0.27) Other (R2= 0.13) 
 Adjusted OR 95% CI Adjusted OR 95% CI Adjusted OR 95% CI Adjusted OR 95% CI Adjusted OR 95% CI 
                      
Alcohol - - 2.0* (1.0 - 3.7) 1.2 (0.6 - 2.5) 2.4 (1.0 - 6.2) 2.1 (0.6 - 7.5) 
Cannabis 2.0* (1.1 - 3.7) - - 4.4*** (2.3 - 8.5) 5.1** (1.7 - 15.0) 1.9 (0.5 - 7.6) 
Methamphetamine 1.3 (0.6 - 2.5) 4.4*** (2.3 - 8.4) - - 5.2** (1.9 - 14.1) 2.0 (0.5 - 7.5) 
Methaqualone 2.1 (0.8 - 5.2) 4.7** (1.6 - 14.1) 4.7** (1.7 - 12.8) - - 3.3 (0.8 - 13.7) 
Other 2.1 (0.6 - 7.3) 1.8 (0.4 - 7.7) 1.7 (0.5 - 6.5) 3.7 (0.9 - 14.7) - - 
*** p<0.001, ** p<0.01, * p<0.05 
a. SUD= substance use disorders 
Each substance in columns adjusted for the effects of all other substances  
R2=general coefficient of determination, (McFadden’s R2) 
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Table 4.4 Adjusted demographic and clinical association with any, alcohol and cannabis use disorders. (N=248) 
    Any SUD (R2= 0.26) Alcohol (R2= 0.16) Cannabis (R2= 0.24) 
  
Adjusted 
OR 95% CI 
Adjusted 
OR 95% CI 
Adjusted 
OR 95% CI 
Age (years)       
 18-29(ref) 1 (ref) 1 (ref) 1 (ref) 
 30-44 0.9 (0.4 - 1.8) 0.8 (0.4 - 1.5) 0.6 (0.3 - 1.1) 
 45-65 0.6 (0.2 - 1.9) 1.0 (0.3 - 3.5) 1.0 (0.3 - 3.1) 
Sex: male: female 3.9*** (1.9 – 8.3) 2.8** (1.3 – 6.0) 4.7*** (2.0 - 11.1) 
Ethnicity       
 Coloured (ref) - - - - 1 (ref) 
 African - - - - 0.5 (0.2 - 1.1) 
 Caucasian - - - - 0.7 (0.2 - 2.2) 
 Other - - - - 1.2 (0.2 - 6.8) 
Education       
 ≤7 1 (ref) - - 1 (ref) 
 8-11 0.6 (0.2 - 1.5) - - 0.5 (0.2 - 1.3) 
 12 0.6 (0.2 - 1.8) - - 0.4 (0.1 - 1.0) 
 >12 0.6 (0.2 - 2.3) - - 0.1* (0.0 - 0.8) 
Employed - - - - 0.8 (0.4 - 1.7) 
Marital status       
 Never married 1 (ref) 1 (ref) - - 
 Married or cohabiting 0.7 (0.3 - 1.9) 0.7 (0.2 - 2.0) - - 
 Previously married 1.0 (0.3 - 3.8) 0.3 (0.1 - 1.7) - - 
Diagnosis       
 Schizophrenia spectrum disorder 1 (ref) - - 1 (ref) 
 Bipolar type I disorder 1.1 (0.5 - 2.5) - - 1.7 (0.7 - 4.0) 
 Schizoaffective disorder 0.9 (0.3 - 2.4) - - 0.9 (0.3 - 2.9) 
 
Substance induced psychotic 
disorder 12.0*** (3.3 - 43.6) - - 
3.3* (1.1 - 9.4) 
Lifetime MDE 0.5 (0.2 - 1.2) - - 0.9 (0.4 - 2.4) 
Lifetime MDE symptoms - - 1.6 (0.7 - 3.3) - - 
Lifetime anxiety symptoms - - 2.5* (1.2 - 5.1) 0.5 (0.2 - 1.1) 
Suicidality       
 No ideation - - 1 (ref) - - 
 Ideation or plan - - 1.0 (0.4 - 2.5) - - 
 Attempt - - 3.3* (1.1 - 9.8) - - 
Legal involvement       
 No arrests 1 (ref) 1 (ref) 1 (ref) 
 Serious violent crime 3.2* (1.0 - 9.8) 1.6 (0.6 - 4.5) 2.0 (0.7 - 5.7) 
 Major crime 2.7 (0.9 - 8.4) 2.3 (0.8 - 7.0) 3.5* (1.2 - 10.2) 
  Other crime 11.9*** (3.4 - 42.2) 2.8* (1.2 - 6.5) 3.4** (1.5 - 8.0) 
Study and setting       
 CIAM study (outpatients)   1 (ref)   
 PRP study (inpatients)   1.6 (0.8 - 3.2)   
 SIP study (inpatients)   0.3* (0.1 - 0.9)   
*** p<0.001, ** p<0.01, * p<0.05 
R2=general coefficient of determination, (McFadden’s R2) 
Omitted variables did not reach significance at p<0.10, and were not entered into models 
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Table 4.5 Adjusted demographic and clinical association with methamphetamine, methaqualone and other 
substance use disorders. (N=248) 
   
Methamphetamine 
(R2=0.38) 
Methaqualone  
(R2=0.17) 
Other 
 (R2=0.29) 
  
Adjusted 
OR 95% CI 
Adjusted 
OR 95% CI 
Adjusted 
OR 95% CI 
Age (years)       
 18-29(ref) 1 (ref) - - - - 
 30-44 0.7 (0.3 - 1.6) - - - - 
 45-65 0.1* (0.0 - 0.7) - - - - 
Sex: male: female 1.9 (0.7 - 5.3) 2.6 (0.8 - 8.4) 2.7 (0.4 - 16.0) 
Ethnicity       
 Mixed 1 (ref) - - 1 (ref) 
 African 0.3** (0.1 - 0.7) - - 0.5 (0.1 - 3.3) 
 Caucasian 0.6 (0.2 - 2.4) - - 2.0 (0.4 - 9.5) 
 Asian 0.5 (0.1 - 4.5) - - 20.9** (2.7 - 162.6) 
Education       
 ≤7 1 (ref) - - - - 
 8-11 0.7 (0.2 - 2.0) - - - - 
 12 0.5 (0.1 - 1.5) - - - - 
 >12 0.2 (0.0 - 1.8) - - - - 
Employed 0.7 (0.3 - 1.7) - - - - 
Marital status       
 Never married - - 1 (ref) - - 
 Married or cohabiting - - 0.4 (0.1 - 2.5) - - 
 Previously married - - 4.4* (1.1 - 16.6) - - 
Diagnosis       
 Schizophrenia spectrum disorder 1 (ref) - - - - 
 Bipolar type I disorder 0.5 (0.2 - 1.6) - - - - 
 Schizoaffective disorder 0.4 (0.1 - 1.6) - - - - 
 
Substance induced psychotic 
disorder 
26.5*** (7.1 - 98.6) - - - - 
Lifetime MDE 0.6 (0.3 - 1.2) 0.4 (0.2 - 1.0) - - 
Lifetime anxiety symptoms - - - - 2.7 (0.8 - 9.3) 
Legal involvement       
 No arrests 1 (ref) 1 (ref) 1 (ref) 
 Serious violent crime 2.9 (0.9 - 9.7) 4.4* (1.3 - 15.1) 6.7* (1.4 - 32.0) 
 Major crime 1.0 (0.2 - 4.1) 2.4 (0.7 - 8.8) 0.2 (0.0 - 10.1) 
  Other crime 4.8** (1.8 - 12.8) 1.3 (0.4 - 4.1) 3.4 (0.8 - 14.5) 
Study and setting       
 CIAM study (outpatients)   1 (ref)   
 PRP study (inpatients)   3.3* (1.1 - 10.0)   
 SIP study (inpatients)   2.5 (0.7 - 8.6)   
*** p<0.001, ** p<0.01, * p<0.05 
R2=general coefficient of determination, (McFadden’s R2) 
Omitted variables did not reach significance at p<0.10, and were not entered into models 
  
53 
 
4.4 Discussion 
4.4.1 Main findings and comparison with other studies 
This study, one of the few from a LMIC context such as South Africa, confirmed the high prevalence of SUDs in 
patients with major affective and non-affective psychotic disorders. The prevalence for any SUD was 55.6%, a finding 
similar to other studies in similar populations across the world, and very close to the previously found prevalence of 
51% in a similar sample from Cape Town (Weich and Pienaar, 2009b). Similar to other studies, including meta-
analyses, the predominant substances in this sample were cannabis then alcohol, followed by methamphetamines 
(Cantor-Graae et al., 2001b, Koskinen et al., 2009, Koskinen et al., 2010, Sara et al., 2015, Weich and Pienaar, 
2009b). In contrast to other studies a lower prevalence of cocaine use disorders was found, and no participants had 
opioid use disorders (Carra et al., 2015, Mueser et al., 2000a). One reason for the lower prevalence of cocaine use (and 
higher methamphetamine use) in this sample may be the lower socioeconomic status of this sample, with most patients 
being unemployed (and perhaps unable to afford cocaine). Another reason for the low occurrence of SUDs such as 
cocaine and heroin may be the fact as the sample in this study consisted exclusively of patients with psychotic 
disorders, the majority with a diagnosis of schizophrenia spectrum disorders, which is consistent with other samples 
for other settings that also included mainly this patient group and excluded patients with a diagnosis of mood disorders 
without psychotic features and  patients with a principle diagnosis of personality disorders (who may be more likely to 
use opioids). The finding of 23.7% of participants reporting having attended substance rehabilitation programmes is 
higher than the previously found in another study from a Cape Town with serious mental illness, where less than 5% 
reported such interventions (Weich and Pienaar, 2009b). Nevertheless, this is still less than a quarter of the total 
sample, emphasising the need for more treatment services for this population. 
Consistent with other studies, the association between methamphetamine and younger age remained significant in the 
multivariable models (Sara et al., 2014). Like most studies in adults (Cantor-Graae et al., 2001b, Escamilla et al., 
2002, Hapangama et al., 2013, Jimenez-Castro et al., 2010, Kamali et al., 2000, Kavanagh et al., 2004b, Latt et al., 
2011, Margolese et al., 2004, Mueser et al., 2000a, Rush and Koegl, 2008, Swartz et al., 2006, Van Mastrigt et al., 
2004, Weich and Pienaar, 2009b), with the exception of one study in older adolescents (Shoval et al., 2007), a 
significant association between male sex and SUDs was found across most substances in the adjusted analyses. A 
significant association was found between having been previously married (i.e. separated or divorced, widowed) and 
methaqualone use. Similar to other studies, none of the other SUDs in this sample were associated with marital status 
(Sevy et al., 2001). African participants were significantly less likely to use methamphetamine compared to 
participants from a mixed (“Coloured”) ethnic background. Some studies from the United States of America have 
found a  significant positive relationship between ethnic minorities (i.e. African Americans), and  substance use; 
amphetamine and cocaine use in particular (Compton et al., 2000, Montross et al., 2005, Swartz et al., 2006). 
Comparatively high use of methamphetamines in mixed ethnic groups versus other ethnic groups has also been found 
in other studies in non-psychotic populations in the South African context (Myers et al., 2013), and may reflect a 
neighbourhood effect as population groups still correlate with geographical areas a result of the legacy of Apartheid 
segregation in South Africa. Similar to other studies (Hapangama et al., 2013, Kavanagh et al., 2004b, Mueser et al., 
2000a, Swartz et al., 2006), a significant association between lower educational attainment and any SUD in unadjusted 
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analyses, which remained significant for only cannabis use disorders in the adjusted analyses, were found. One reason 
for this finding in populations with predominantly schizophrenia patients has been postulated to be school drop-out 
associated with cannabis use (Kavanagh et al., 2004b). 
Similarly, to other studies a significant association was found with SUDs and a diagnosis of substance induced 
psychosis (Helseth et al., 2009, Weich and Pienaar, 2009b). Depressive and anxiety symptoms were significantly more 
prevalent in participants with alcohol use disorders, and anxiety symptoms remained significant in the adjusted 
analysis for alcohol use disorders. These findings are consistent with other studies that have found higher anxiety 
symptoms (i.e. panic)  in patients with alcohol use disorders and SZ but not in those with cannabis use disorders 
(Goodwin et al., 2003). There is however some inconsistency in the literature; several studies have found depressive 
and anxiety symptoms to occur more often in both cannabis and alcohol or any SUDs categories (Cuffel et al., 1993, 
Jimenez-Castro et al., 2010, Kerfoot et al., 2011b, Margolese et al., 2006), but some studies have shown no 
association with depressive or anxiety symptoms (Sevy et al., 2001) or even lower depressive and anxiety symptoms 
especially in predominately cannabis using populations (Shoval et al., 2007). Similar to other studies we found a 
significant adjusted association with suicide attempts (Gut-Fayand et al., 2001, Rush and Koegl, 2008), particularly 
for participants with alcohol use disorders. 
With the exception of alcohol use disorder, all categories of SUDs including any SUDs had significantly elevated 
occurrence of legal involvement, including serious and violent crime with an even stronger association with the “other 
crime” category denoting police arrests for crimes relating to illegal drug possession, prostitution, driving violations 
and disorderly conduct in public. In addition, cannabis users also were significantly more likely to get arrested for 
major crimes  (shoplifting, vandalism, parole violation, forgery, weapons offense, burglary, arson, domestic violence 
not involving assault) and methaqualone and “other drug users” (predominantly cocaine users) were significantly 
more likely to be involved with serious violent offenses (assault, rape, murder, armed robbery). These findings are 
consistent with those from high income countries (Cantor-Graae et al., 2001b, Carra et al., 2015, Fowler et al., 1998b, 
Mueser et al., 2000a, Rush and Koegl, 2008) and among the first from a middle income context. Interestingly, 
although risky and impulsive behaviour manifested as suicide attempts in alcohol users, other drug users were more 
likely to engage in externalising risk-taking behaviours involving criminal activity in the adjusted analyses. 
4.4.2 Clinical Implications 
Results from this study confirm the clinical profile of participants with SUDs as being more likely to be male, have a 
younger age (in particular methamphetamine users) and having a diagnosis of a substance induced psychosis. In 
particular, those with alcohol use disorders were more likely to experience anxiety symptoms (i.e. panic, generalised 
and social anxiety) and significantly more likely to have attempted suicide. This underscores the importance of 
screening for anxiety and suicide risk assessments in patients with co-occurring alcohol use disorders. For most 
substances, involvement in crimes relating to drug possession, prostitution, disorderly conduct and driving violations 
(other crimes” category) were significantly more likely; and involvement in major crimes, serious violent crimes was 
also significantly elevated for cannabis, methaqualone and other (predominantly cocaine) users. Practitioners who 
manage patients with co-occurring disorder are likely to need to liaise with criminal justice institutions, state 
prosecutors and police.  
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4.4.3 Study limitations 
Several limitations should be acknowledged.  First, is the absence of biological verification of substance use. Although 
urine tests for substances such as cannabis and methamphetamine were conducted on some patients who were 
admitted to short-stay psychiatric units (from where referrals emanated) were taken into consideration during patient 
assessment and interviews, tests for alcohol and other drugs are not routinely conducted, neither were such tests 
recorded consistently to allow for use in this study. Short detection windows of most biological tests are also likely to 
result in false negative tests in participants who used recently but were tested only days after last use. As participants 
are more likely to underreport substances this would have led to an underestimation of substance use in this study. In 
addition, self-report of substances has in fact been shown to yield accurate results, with other techniques like hair 
samples often being problematic in multi-ethnic samples (Selten et al., 2002). Self-report is also characteristic of 
epidemiological studies in this area (Sara et al., 2014).  Second is the reliance on self-report, family collateral and past 
records to record criminal involvement.  Police data on formal charges and conviction rates were lacking and data was 
limited to reasons for police arrests. As the design of the some of the parent studies were cross-sectional, recall bias 
could have affected reports of substance use and police arrest rates. Third, the use of DSM hierarchical rules 
(characteristic of the SCID-I) can often lead to lower prevalence estimates for anxiety, obsessive-compulsive and post-
traumatic stress disorders. Nevertheless, subthreshold anxiety, obsessive and post-traumatic stress symptoms, were 
also recorded which led to higher yields of these symptoms. It is also not possible to determine the direction of the 
association between alcohol use and anxiety symptoms as alcohol withdrawal can be associated with anxiety but is 
also possible that people with more anxiety are more likely to use alcohol. Finally, there were no continuous severity 
rating measures in this sample of psychotic, anxiety or depressive symptoms (i.e. PANSS scales).  
4.4.4 Conclusion 
This study found high prevalence of substance use disorders and multiple substance use in patients with major 
affective and non-affective psychosis in a middle-income country context. This study also confirmed some of the 
findings of the first analysis in chapter 3 and went beyond these findings to explore differences between ethnic groups, 
psychotic disorder diagnosis, and explored associations between lifetime depressive symptoms and suicidality (as 
opposed to only current/past 1-month symptoms) as well as the specific type of legal involvement in terms of arrest 
types. These findings underscore the importance of a thorough clinical assessment for various substance use disorders, 
particularly in the presence of anxiety, suicidality and risky behaviours involving clashes with the law. 
In part II of the thesis, I explore the use of two brief, practical screening instruments, the ASSIST (Alcohol, Smoking 
and Substance Involvement Screening Test) and SDS (Severity of Dependence Scale) in the identification and 
diagnosis of SUDs. In particular, I explore the validity and psychometric properties of these screening instruments 
against the SCID-I as the diagnostic gold standard. 
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Part II: Chapter 5  
The validity of the Xhosa version of the Alcohol Smoking and Substance Involvement Screen 
Test (ASSIST) and the Severity of Dependence Scale (SDS) in South African patients with 
schizophrenia 
5.1 Introduction 
Depending on the sample, the prevalence of substance use disorders (SUD) in patients with schizophrenia (SZ) has 
been reported to vary from 25% to 74% (Cantor-Graae et al., 2001a, Lambert et al., 2005b). SUD in people with SZ is 
associated with worse clinical outcomes, higher symptom levels, risk taking behaviour, more medication side-effects, 
and greater relapse rates (Ascher-Svanum et al., 2006b, Lambert et al., 2005c, Owen et al., 1996b, Swofford et al., 
1996b, Meade and Sikkema, 2007). Consequently, the identification of SUDs has important implications for prognosis 
and treatment planning. However, gold standard diagnostic instruments for SUDs like the structured clinical interview 
for DSM-IV (SCID-I) are lengthy to complete, require expertise and training that are not practical in routine clinical 
settings. Therefore, there is a need for reliable, valid, brief, easy to administer and practical screening instruments in 
clinical settings. This need is even more pronounced in low and middle income countries (LMIC) such as South 
Africa, where there are few trained mental health professionals and even fewer psychiatrists (Saxena et al., 2006).  
The Alcohol Smoking and Substance Involvement Screening Test (ASSIST) and the Severity of Dependence Scale 
(SDS) are two such brief instruments (Newcombe et al., 2005a, Gossop et al., 1995b).  The ASSIST has been 
validated in the general population, primary care, addiction treatment settings, adult and adolescent populations across 
a number of developed countries such as Australia, the United Kingdom, the United States of America and LMICs 
such as India, Brazil, Zimbabwe and Zambia (Gryczynski et al., 2015, Humeniuk et al., 2008b, Johnson et al., 2015, 
Newcombe et al., 2005a). The ASSIST has also been validated in an English and Afrikaans speaking sample of 
patients attending emergency rooms in the South African setting (van der Westhuizen et al., 2016). The ASSIST has 
been translated and validated in Spanish and Portuguese for primary care populations as well as French for the elderly 
population (Henrique et al., 2004, Khan et al., 2011, Khan et al., 2012, Rubio Valldolid et al., 2014).  However, there 
has been only one study that examined the reliability and validity of the ASSIST in a clinically heterogeneous 
population with both major affective and non-affective first episode psychosis (Hides et al., 2009a). There has not 
been a study assessing the validity of the ASSIST in a clinically homogenous sample of patients with SZ. 
The Severity of Dependence Scale (SDS) has been validated in heroin, cocaine, cannabis, ketamine, khat users in a 
variety of primary care settings (Chen et al., 2008, Cuenca-Royo et al., 2012, Gonzalez-Saiz et al., 2009, Gossop et al., 
1995b, Kassim et al., 2010, Kaye and Darke, 2002, Tung et al., 2014). In addition, The SDS has been translated into 
Chinese for heroin users (Chen et al., 2008). Similarly to the ASSIST, there is a paucity of research on the reliability 
and validity of the SDS in people with psychotic disorders, with only one study investigating the validity of the SDS 
in cannabis users with SZ spectrum disorders (Hides et al., 2007). Moreover, there are no studies investigating the 
SDS in people from LMIC settings including African populations.  
In this chapter, I aimed to determine and compare the reliability and validity of the Xhosa language version of the 
ASSIST and SDS in a homogenous clinical sample of people of Xhosa speaking African people with an established 
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diagnosis of SZ. In addition, I aimed to compare the psychometric properties of the ASSIST with the SDS, in order to 
determine if there is any diagnostic benefit of adding both instruments instead of using only one. 
5.2 Methods 
5.2.1 Sample and participants 
Participants were administered the ASSIST and SDS scales as part of an add-on study to an existing larger case-
control study investigating the Genomics of SZ in the South African Xhosa Population (SAX study). This study was a 
collaboration between a number of Universities in the United States and South Africa, funded by the National 
Institutes of Mental Health. This study aimed to recruit over  1400 cases and 1400 controls over 5 years, and started 
recruitment in 2013 across various psychiatric treatment settings including community mental health clinics and 
psychiatric hospitals across two South African provinces (Western and Eastern Cape) (Campbell et al., 2017a). 
Eligible participants were aged 21-55 years; had a suspected diagnosis of SZ or schizoaffective disorder with duration 
of illness of at least 2 years and the ability to give informed consent to the genetics study. Participants were volunteers 
who were approached by study staff attending community psychiatry clinics and admitted to inpatient psychiatric 
treatment units. In addition, mental health practitioners (psychiatric nurses and psychiatrists) referred suitable cases. 
5.2.2 Measures 
Gold standard diagnoses and functional assessment 
Demographic and clinical characteristics were collected using the overview section of the Structured Clinical 
Interview for DSM-IV (SCID-I). The reference standard diagnoses of substance use disorders (abuse or dependence) 
were determined using Module E of the SCID-I (First et al., 1994a). All participants received the SCID-I gold 
standard. In addition, the primary psychiatric diagnosis was determined using the SCID-I modules A, B, C, and D.  
Global functioning was ascertained by means of the Global Assessment of Functioning Scale (GAF scale), which 
assesses functioning on a 100 point scale(Endicott et al., 1976).  Participants were interviewed by bilingual (isiXhosa 
and English speaking) psychiatric research assistants (a psychiatrist, a research fellow in psychiatry and psychiatric 
nurses) with extensive experience in working with patients with serious mental illness. In addition, research staff 
underwent extensive training in Structured Clinical Interviewing and participated in weekly supervision and interrater 
reliability meetings to discuss diagnostic issues. The SCID-I was translated into isiXhosa in accordance with 
guidelines recommended by the World Health Organization (Sartorius and Janca, 1996). The translation design 
included a forward and back-translation approach where materials were first translated into isiXhosa by a group of 
five first language isiXhosa speaking, experienced mental health practitioners, and then back-translated by an 
independent isiXhosa speaking psychiatrist. Initial translations were piloted and then improved through an iterative 
process. Where there were discrepancies in the translation, these were discussed in group meetings and consensus was 
reached on the final translation.  Interrater reliability obtained on a smaller sample of participants (N=22) was 
substantial for the principle psychotic disorder diagnosis (kappa=0.74, p<0.001). Similarly, for the SCID-I DSM-IV 
substance use disorder (abuse or dependence) diagnoses, interrater reliability ranged from substantial to near perfect 
(any SUD, kappa=0.82; alcohol use disorder, kappa=0.84, p<0.001; cannabis use disorder, kappa=0.85, p<0.001, 
methamphetamine use disorder, kappa=0.71, p<0.001). 
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Substance use screening tools: ASSIST and SDS scales 
The screening instruments (ASSIST and SDS) were also translated from English into isiXhosa using the same 
translation design described for the SCID-I.  The WHO-ASSIST version 3 assesses lifetime and past 3 month 
substance use with eight response weighted items/questions for a total of 10 different substances (a-j: tobacco, alcohol, 
cannabis, cocaine, amphetamines, inhalants, sedatives, hallucinogens, opioids and other drugs), leading a total of 71 
items (Humeniuk et al., 2008b, World Health Organization, 2002). Question 1 (Q1a-j) assesses substances ever used, 
question 2 (Q2a-j) ascertains the frequency of use in the past 3 months, question 3 (Q3a-j) the urge or desire to use in 
past 3 months, question 4 (Q4a-j) health, social, legal or financial problems due to substance use in the past 3 months, 
question 5 (Q5a-j) impaired role functioning in past 3 months, question 6 (Q6a-j) concerns ever expressed by others 
over substance use, question 7 (Q7a-j) any unsuccessful attempts to cut-down or control use, and question 8 (Q8), any 
intravenous use. Each item/question is differentially weighted, with Q1 (yes=3, no=0), Q2 (5-item Likert-type scale 
with score range  0 to 6), Q3 (5-item Likert-type scale with score range 0 to 6), Q4 (5-item Likert-type scale with 
score range 0 to 7), Q5 (5-item Likert-type scale with score range 0 to 8), Q6 (3-item Likert type scale with score 
range 0 to 6), Q7 (3-item Likert type scale with score range 0 to 6), Q8 (3-item Likert type scale with score range 0 to 
2). The total score of the ASSIST can range from 0 to 422. Three separate measures were derived from the ASSIST 
(Humeniuk et al., 2008b, Newcombe et al., 2005a), a global continuum of risk/ total substance involvement score 
(ASSIST-TSI) to capture items that measure use across all substance classes with tobacco excluded (∑ Q1b-j- Q8b-j) 
and another score for dependence (ASSIST-TSI-dep: ∑ Q1b-j + Q2b-j +Q3b-j +Q6b-j Q7b-j). In turn, the specific 
substance involvement scores (SSI) for alcohol (SSI-alcohol: ∑Q2b to Q7b) were also calculated. As the prevalence of 
illicit drug use was very low for most substances a variable was created to capture illicit drug use, similar to a prior 
method in the SA setting (van der Westhuizen et al., 2016) excluding alcohol use (ASSIST-SSI-illicit: ∑ Q2c-j + Q3c-j 
+ Q4c-j + Q5c-j + Q6c- + Q7c-j). Depending on the number of substances used, the ASSIST takes approximately 10-15 
minutes to complete. 
Compared to the ASSIST which has a total of eight questions and 71 items,  the Severity of Dependence Scale (SDS) 
assesses substance use on only five questions, rated on a 4-point Likert-type scale (“Never/almost never”=0, 
“Sometimes”=1, “Often”=2, “Always, nearly always”=3) for questions 1 to 4 and a 4-point Likert-type scale for 
question 5 (“Not difficult”=0,  “quite difficult”=1, “very difficult”=2, ”impossible”=3), leading to a total score ranging 
from 0 to 15 (Gossop et al., 1995b). Question 1 assesses loss of control over drug use, question 2 anxiety over missing 
an opportunity for use, question 3 worries over drug use, question 4 desire to quit and question 5 difficulties to stop or 
go without using.  As substantial polydrug use was anticipated (characterised by concurrent drug use and no clear 
preference for any one specific drug) participants were asked to respond to the SDS questions with their lifetime use 
of substance, or in case of polydrug users, substances used. A total score for the SDS across all substances was 
calculated to make it comparable to the ASSIST-TSI (global substance involvement score). The SDS takes under 2 
minutes to complete. 
At various phases of enrolment of the parent study (SAX study), separate add-on studies ensued. Different add-on 
instruments were rotated (i.e. ASSIST then the SDS) with some overlap (both ASSIST and SDS), so as therefore to 
59 
 
reduce the burden on participants as the SCID interview alone typically lasted 2 and up to 3.5 hours.  All participants 
who completed the ASSIST or SDS had also completed the SCID-I gold standard instrument. 
5.2.3 Ethics 
All participants gave informed consent to participate in the study. Screening for capacity to consent was conducted 
using  the University of California, San Diego Brief Assessment of Capacity to Consent Questionnaire (UBACC) 
(Jeste et al., 2007) which was translated into isiXhosa and used as an iterative learning tool to improve participants’ 
understanding of the various study elements where necessary (Campbell et al., 2017b).  The study was approved by 
the University of Cape Town Human Research Ethics Committee, The Walter Sisulu University Research Ethics and 
Biosafety Committee, The Rhodes University Ethical Standards Committee, The Columbia University Internal 
Review Board and the University of Washington Institutional Review Board. 
5.2.4 Statistical analyses 
Data were inspected for normality using graphical methods. Square-root or square transformations were used to 
normalise skewed data. Where data transformations did not improve the normality of distributions, non-parametric 
methods were used to analyse data. Categorical variables were analysed using Pearson’s Chi-square tests, and for 
continuous data student’s t-test and Wilcoxon rank-sum tests were used. Internal consistency was determined by 
calculating the Cronbach-alpha coefficients.  
Concurrent validity was determined by calculating Spearman’s rank order correlations between the ASSIST-TSI and 
SDS scores.  Discriminant validity was determined by comparing the scores achieved on the ASSIST and SDS; firstly, 
by comparing the scores between non-problematic users (no-SUD) vs. abuse/dependence (any-SUD) categories, and 
then for substance use divided into three categories, namely non-problematic use, abuse and dependence. For 
comparisons across three groups one-way analysis of variance (ANOVA) for data that met homogeneity of variance 
assumptions was used, and for sparse and heavily skewed data, Kruskall-Wallace ANOVA, with post-hoc pairwise 
comparisons using Dunn’s test with Sidak’s correction for multiple testing was used. Discriminant validity for the 
ASSIST and SDS was further determined against the SCID-I gold standard defined, DSM-IV diagnoses of alcohol and 
drug use disorders, by calculating receiver operating characteristics curves (ROC curves) including the sensitivity, 
specificity, positive predictive and negative predictive values and the likelihood ratios for cut-points that optimised the 
balance between sensitivity and specificity.  On a subsample of participants who received both SDS and ASSIST 
scales (N=138), the discriminative ability of the ASSIST was compared with the SDS in unadjusted and covariate 
adjusted models using logistic regression. In addition, the impact of covariates (age, sex, education, marital status and 
GAF score) on the ASSIST and SDS ROC-AUC (ROC area-under-the-curve) was explored using probit ROC-
regression with maximum likelihood estimation (Pepe et al., 2009).  
Finally, a series of logistic regression models were constructed to determine the incremental gain of conducting the 
lengthier ASSIST beyond the shorter SDS, after taking into account baseline covariates (Janes et al., 2009). For 
regression models, missing at random (MAR) data (for marital status, educational level and GAF scores) were 
imputed using multiple imputation with chained equations (MICE) across 20 imputed datasets followed by pooling of 
regression estimates according to the rules of Rubin et. al (Rubin, 1987). Two-tailed tests were used throughout and 
60 
 
p<0.05 was considered statistically significant. Stata version 13 for Windows was used to conduct analyses 
(StataCorp, 2013). 
5.3 Results 
5.3.1 Sample characteristics 
The total sample consisted of 351 participants who completed the WHO ASSIST (N=190) or SDS (N=299) or both 
instruments (N=138). The mean age of the total sample was 36.2 years (SD=8.9) and the majority (n=303, 86.3%) 
were male. Table 5.1 contains a summary of the demographic and clinical characteristics of the sample. Participants 
with a DSM-IV substance use disorder were significantly more likely to be male, and there were no differences in 
terms of age, marital status, educational level and GAF scores between those with and without SUDs. The prevalence 
of any SUD was 60.9%, with as many as 25.6% of the total sample using more than one substance, constituting just 
under half (42.1%) of those who had any SUD. Among participants with SUDs, cannabis use disorders were most 
prevalent followed by alcohol and then other drugs (Table 5.1). 
Table 5.1 Sample characteristics (N= 351) 
  Lifetime DSM-IV substance 
use disorder 
  
Variable Total sample 
(n=351) 
Diagnosis 
present 
Diagnosis 
absent 
Statistic (df) p value 
 n % n % n %   
Age          
 21-34 158 (45.1) 100 (46.7) 58 (42.3) χ2=0.65(1) 0.420 
 35-60 193 (54.9) 114 (53.3) 79 (57.7)   
Sex: male         
 Male 303 (86.3) 208 (97.2) 95 (69.3) χ2=54.89(1) < 0.001 
 Female 48 (13.7) 6 (2.8) 42 (30.7)   
Marital status1         
 Never married 283 (75.0) 180 (84.9) 103 (76.8) χ2=3.56(1)  0.059 
 Ever married 63 (25.0) 32 (15.1) 31 (23.1)   
Education1         
 ≤ 7 years 119 (34.1) 73 (34.3) 46 (33.8) χ2=3.23 (2) 0.198 
 8-11 years 166 (47.6) 107 (50.2) 59 (43.4)   
 ≥ 12 years 64 (18.3) 33 (15.5) 31 (22.8)   
GAF score1          
mean (sd) 61.3 (18.1) 61.7 (17.8) 60.6 (18.5) t=-0.46 
(288) 
0.645 
Substance use 
disorders 
        
 Alcohol 113 (32.2) 113 (52.8) - - - - 
 Cannabis 166 (47.3) 166 (77.5) - - - - 
 Methamphetamine 14 (3.9) 14 (6.5) - - - - 
 Methaqualone  24 (6.8) 24 (11.2) - - - - 
 Cocaine 3 (0.85) 3 (1.4) - - - - 
 Opioids - - - - - - - - 
 Hallucinogens - - - - - - - - 
 Other2 2 (0.6) 2 (0.9) - - - - 
 Polydrug use (≥2) 90 25.6 90 (42.1)     
1. Missing data for marital status: n=5, education level: n=2, GAF (Global Assessment of Functioning) 
score: n=61 
2. Other: volatile solvents 
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5.3.2 Reliability: internal consistency 
The Cronbach alpha for the ASSIST-TSI score was 0.77, and the ASSIST substance specific scores yielded lower 
alpha values (SSI-alcohol: α=0.60; SSI-illicit: α=0.69) For the SDS scale the Cronbach alpha coefficient was α= 0.80.  
5.3.3 Concurrent validity 
For participants who received both the ASSIST and SDS scales (N=138), both the ASSIST-TSI and the ASSIST-TSI-
dep (for dependence items (i.e. ASSIST Q1 Q2 Q3 Q6 Q7) had significant positive correlations with the SDS score 
(TSI: rs=0.50, p<0.001; TSI-Dep: rs=0.51, p<0.001).  
5.3.4 Discriminant validity 
The ASSIST-TSI, SSI-alcohol, SSI-illicit drug and SDS scores were significantly higher in participants with DSM-IV 
alcohol or drug use disorders compared to those with no SUD (Table 5.2). In order to determine the ability of the 
ASSIST to discriminate between non-problematic use, abuse and dependence the scores obtained between these three 
categories were compared (Table 5.3). Overall there were significant differences in the ASSIST-TSI, SSI-alcohol, and 
SSI-illicit and SDS scores across all three categories as demonstrated by ANOVA results (Table 5.3). For post-hoc 
tests, when comparing non-problematic use with abuse, after correction for multiple comparisons the ASSIST-TSI, 
SSI-illicit drugs and SDS scores were significantly higher in the participants for substance abuse vs. those with non-
problematic use. Similarly, the ASSIST-TSI and SSI-alcohol scores were significantly higher in those with 
dependence vs. abuse; however, for the SSI-illicit and SDS scores there were no significant differences (Table 5.3)  
Table 5.4 contains a summary of the ROC characteristics of the various scores of the ASSIST and SDS at the cut-
points for optimizing both sensitivity and specificity. A cut score of ≥6 on the TSI had a high positive predictive value 
(PPV), with those screening positives having a 78% chance of having any SUD. Similarly, an SDS score of ≥4 yielded 
an 86% chance of having any SUD. A higher cut-score of ≥13 on the ASSIST-TSI yielded a higher specificity 
(96.9%), but much lower detection rates with sensitivities of only 28.5% and a test false positive rate (TFP: percentage 
who test positive but do not have any SUD, 1-PPV) of 10.3% (PPV=89.6) (Table 5.4). At higher cut-points the 
sensitivity (i.e. ability to detect those with SUDs) of the ASSIST decreased less compared to the SDS as observed in 
both the ROC curves (Fig.5.1 and Fig. 5.2) and the corresponding likelihood ratios of positive test (LR+: true positive: 
false positive tests) that also increased and remained high for the ASSIST-TSI but not for the SDS (also due to higher 
increases in the specificity for the ASSIST-TSI compared to the SDS) (Table 5.4).  
In the bivariate, unadjusted logistic regression models an ASSIST-TSI score ≥6 had a significant, twenty-three-fold 
increase in the odds of having any SUD (OR=23.0, p<0.001, 95% CI= 10.66 - 49.77). This association remained 
significant in the model adjusted for covariates (age, sex, educational level, marital status and GAF score) 
(ORadj=19.33, p<0.001, 95% CI= 8.41 - 44.45). For an SDS score ≥ 4 in the unadjusted regression model the odds of 
having a SUD was increased 9-fold (OR=9.13, p<0.001, 95% CI= 5.21 - 16.01). This association remained significant 
in the model adjusted for covariates (ORadj=7.18, p<0.001, 95% CI= 3.92 - 13.12). ROC regression analysis 
demonstrated that no covariates (age, sex, education level, marital status or GAF score) had any significant impact on 
the ROC curve for either the ASSIST or the SDS scales. 
 
62 
 
Table 5.2 Comparison of ASSIST and SDS scores between participants with and without 
substance use disorders  
 DSM-IV substance use disorder   
 Diagnosis present Diagnosis absent   
 Mean  (SD) Mean  (SD) Wilcoxon rank-sum test p-value 
       
TSI score (N=298) 11.24 (9.2) 2.77 (4.4) z = -8.82 <0.001 
SSI alcohol 4.45 (7.9) 2.04 (4.6) z = -2.43 0.014 
SSI illicit drugs 6.94 (6.4) 1.01 (2.5) z = -10.07 <0.001 
SDS score (N=453) 6.75 (3.9) 3.00 (4.4) z = -7.41 <0.001 
 
 
Table 5.3 Comparison of ASSIST and SDS scores across non-problematic use, abuse and 
dependence categories 
 Mean 
difference 
ANOVA Pairwise 
comparisons 
  Test statistic (df) p-value 
ASSIST (N=190)    
TSI score     
 Use vs. abuse 4.65 F(2)=60.7*** <0.001 
 Abuse vs. Dependence 4.95 - 0.012 
SSI alcohol    
 Use vs. abuse 0.52 χ2(2)=12.3** 0.869 
 Abuse vs. Dependence 3.46 - 0.016 
SSI illicit drugs    
 Use vs. abuse 3.54 F(2)=72.2*** <0.001 
 Abuse vs. Dependence 3.03 - 0.134 
SDS score (N=299)    
 Use vs. abuse 3.79 F(2)=27.*** <0.001 
 Abuse vs. Dependence -0.04 - ns 
* p<0.05, ** p<0.01, ***p<0.001, ns= non-significant 
1. Post-hoc, multiple pairwise comparisons with Sidak corrected p-values  
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Table 5.4 Sensitivity, specificity, area under the curve (AUC), positive likelihood ratio, negative 
likelihood ratio and positive and negative predictive values of ASSIST-TSI, SSI-alcohol, TSI-illicit 
drugs and SDS scores at optimal and varied cut-points for any SUD. 
Measure  Cut-
point 
Sens Spec Corr. 
class. 
LR+ LR- PPV NPV TFP TFN 
ASSIST (N=190)           
 Any SUD           
 TSI            
  ≥ 6 86.8 77.8 82.1 3.90 0.16 78.2 86.5 21.7 13.4 
  ≥ 9 45.1 89.9 68.4 4.46 0.61 80.3 64.0 19.6 35.9 
  ≥ 11 38.4 92.9 66.8 5.43 0.66 83.3 62.2 16.6 37.8 
  ≥ 13 28.5 96.9 64.2 9.42 0.73 89.6 59.6 10.3 40.3 
  ≥ 14 28.5 97.9 64.7 14.1 0.72 92.8 59.8 7.1 40.1 
  ≥ 16 22.0 98.0 61.5 10.8 0.79 90.9 57.7 9.1 42.3 
 SSI alcohol           
  ≥ 3 43.5 79.2 70.5 2.10 0.71 40 81.4 60 18.6 
  ≥ 4 37.0 83.3 72.1 2.21 0.75 41.5 80.5 38.5 19.5 
  ≥ 10 13.0 93.8 74.2 2.08 0.92 40.0 77.1 60 22.9 
 SSI illicit drugs           
  ≥ 3 97.3 80.0 86.8 4.86 0.03 76.0 97.8 23.9 2.1 
  ≥ 5 45.3 92.1 73.6 5.79 0.59 79.0 72.1 20.9 27.8 
  ≥ 9 29.3 96.5 70 8.43 0.73 84.6 67.6 15.3 32.3 
SDS (N=299)           
 Any SUD           
  ≥ 2 91.7 58.7 81.6 2.22 0.13 83.3 76.0 16.6 23.9 
  ≥ 4 78.3 71.7 76.3 2.76 0.30 86.2 59.5 13.8 40.5 
  ≥ 7 45.4 77.1 55.1 1.99 0.70 81.7 38.6 18.3 61.4 
  ≥ 10 24.6 87.0 43.8 1.88 0.86 81.0 33.9 19.0 66.1 
  ≥ 12 14.0 92.4 69.2 1.84 0.93 80.6 32.3 19.4 67.6 
 Dependence only           
  ≥ 4 79.7 63.7 73.5 2.20 0.31 77.7 66.7 22.3 33.3 
  ≥ 10 23.5 82.7 46.5 1.36 0.92 68.3 40.6 31.7 59.3 
            
TFP= test false positive: percentage who do not have a SUD following a positive test; TFN= test false 
negative: percentage who have a SUD following a negative test 
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Figure 5.1 Receiver operating characteristics (ROC) curve of the ASSIST scale with SCID-I gold-standard. 
 
Figure 5.2 Receiver operating characteristics (ROC) curve of the SDS scale with SCID-I gold-standard. 
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5.3.5 Comparison of ASSIST vs. SDS  
For a subsample of participants who completed both the ASSIST and the SDS (N=138), the AUC of the ASSIST-TSI 
scores was compared against the AUC of the SDS scores. In both the unadjusted and covariate (age, sex, educational 
level, marital status and GAF score) adjusted analysis there were no significant differences between the ASSIST-TSI 
and SDS areas under the curve (ASSIST-TSI: AUCunadj= 0.80 vs SDS: AUCunadj = 0.79, χ2(df)=0.02(1), p=0.879; 
ASSIST-TSI: AUCadj= 0.83 vs SDS: AUCadj = 0.80, χ2(df)=0.56(1), p=0.455). 
5.3.6 Incremental gain of the ASSIST on the SDS and baseline covariates 
For participants who completed both the ASSIST and SDS (N=138), in order to determine the gains of the lengthier 
ASSIST over the briefer SDS in predicting the outcome of any SUD, a series of logistic regression models were 
constructed in which  the incremental gain in ROC-AUC was examined  firstly for the model fitted only with baseline 
covariates (age, sex, educational level and GAF scores), then baseline covariates plus the SDS score,  and finally the 
gain in AUC of also adding the ASSIST to the model with baseline covariates + SDS score. After adding the SDS 
scale to the model with only the baseline covariates (AUC-baseline covariates= 0.70) the AUC showed a statistically 
significant increase (AUC-baseline covariates + SDS= 0.80; χ2(df=1)=5.96, p<0.014, Sidak-corrected p-values) (Table 
5). However, when adding the ASSIST-TSI score to the model with covariates + SDS score, there was no statistically 
significant gain in the AUC (ROC AUC-baseline + SDS + ASSIST-TSI= 0.85; χ2(df=1)=4.41, p=0.062, Sidak-
corrected p-values). Nevertheless, like the SDS, the ASSIST also showed a significant improvement when added to 
the model with only the baseline covariates (ROC AUC 0.72 vs. AUC 0.83; χ2(df=1)=20.10, p<0.001, Sidak-corrected 
p-values). 
5.4 Discussion 
5.4.1 Summary of main findings and comparison with other studies 
Four main findings emerged from this study. First, both the ASSIST-TSI and the SDS demonstrated high levels of 
internal consistency and good concurrent validity. Second, the discriminant power to accurately detect SUDs for both 
the ASSIST (AUC=0.86) and the SDS (AUC=0.76) were high, and for participants who completed both the SDS and 
ASSIST simultaneously, there were no significant differences in the AUC for these two instruments. Third, both 
instruments were able to discriminate well between participants with any SUD vs. those without any SUD, however 
ASSIST SSI-illicit and SDS performed somewhat worse in discriminating participants with abuse from those with 
dependence. Scoring above cut-offs of 6 and 4 for the ASSIST (TSI) and the SDS respectively lead to a significant 
increase in the odds of having a SUD diagnosis. Fourth, the SDS lead to a significant increase in the ROC AUC over 
and above demographic and clinical characteristics alone but adding the lengthier ASSIST did not significantly 
improve the discriminative power to determine the presence of a substance use disorder over and above the briefer 
SDS.  
The findings in this study of the psychometric properties of the SDS are in agreement with that of Hides et. al. , (Hides 
et al., 2007) who found a cut-point for the SDS of ≥4  had a sensitivity of 71%, specificity = 89%, PPV= 88%, 
NPV=72%. For the ASSIST, Hides et.al. found an ASSIST-TSI cut-point of ≥ 16 produced sensitivities of 81% and 
specificities of 64% (AUC=0.78)(Hides et al., 2009a), which is a higher cut-point compared to the optimal cut-point 
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of ≥ 6 in this study. Similarly, for SZ participants the SSI-alcohol ≥ 4 in the current sample produced lower 
sensitivities and AUCs. Nevertheless, SSI-illicit cut-score in this study was comparable to scores for the SSI cannabis 
and amphetamine scores in the study by Hides et. al. (cut-scores of 1 and 2)(Hides et al., 2009a). Reasons for these 
differences are unclear but may include that the population in the study by Hides et. al. was quite different from this 
South African sample. The SAX sample comprised of a more homogenous population that included patients with 
more advanced stages of schizophrenia (minimum illness duration of 2 years since illness onset) compared to the 
Hides et. al. sample of first episode psychosis (FEP) of which only 23% of patients had a diagnosis of schizophrenia 
and 35% had schizophreniform disorder, with the remaining participants having bipolar and unipolar mood disorders 
or other psychotic disorders. Moreover, in this sample SSI-illicit cut-scores that optimised sensitivity/specificity were 
higher (≥3 ) compared to another South African study that found exceptionally low cut-scores in a sample of 
emergency room attendees (SSI-illicit ≥1) (van der Westhuizen et al., 2016). Whereas the ASSIST was able to 
discriminate abuse from dependence in some studies in non-psychotic populations (Humeniuk et al., 2008b, 
Newcombe et al., 2005a), others found less favourable results (van der Westhuizen et al., 2016). Similarly, in the SAX 
study sample the ASSIST SSI-illicit and SDS scores did less well in discriminating abuse from dependence. This lack 
of ability to distinguish may abuse from dependence may be explained by the finding that latent trait severity for the 
DSM-IV items for abuse and dependence significantly overlap, which have led to the collapse of the abuse and 
dependence categories in the DSM-5 (Hasin et al., 2013).  
5.4.2 Clinical implications 
Test properties like sensitivity, specificity and likelihood ratios are good for evaluating test operating performance 
which has public health relevance on a population level.  However, clinicians are more interested in the clinical 
implications of positive or negative tests, i.e. in measures such as the PPV (positive predictive value) and NPV 
(negative predictive value) as well as the percentage of people who test positive but do not have the underlying 
condition (TFP, test false positive or 1-PPV). Good tests are inexpensive, quick to conduct and have low false test 
positive rates. As SUDs in patients with schizophrenia are likely to carry a high risk of additional stigma, and as there 
is only low to very low quality evidence on the efficacy of pharmacological or psychosocial treatments compared to 
treatment as usual (Hunt et al., 2013a, NICE, 2011a), a good screening test will need to have a very low false test 
positive rates (TFP) and high PPVs, probably TFPs lower than 20% even 15%. On the other hand, strategies 
optimising case identification (i.e. maximizing sensitivity) may be important for other reasons such as prognostication 
and treatment planning. One strategy in patients with SZ in which we expect a relatively high (60% baseline) 
prevalence of SUDs would be to start by conducting the briefer SDS scale, with cut-points of ≥4 which will have a 
PPV=86.2% and a low test false positive rate of TFP=13.8% (this will still yield acceptable detection ability with 
sensitivity of 78.3%). However, under lower baseline prevalence rates, in order to maximise PPV and minimise false 
test positives, one could use the ASSIST-TSI score instead, which produced higher positive likelihood ratios (+LR’s) 
for various cut-points. Applying Bayes theorem, for a baseline prevalence of 40% (pre-test odds=0.4/0.6=0.66) using a 
cut-score of ≥9 on the ASSIST-TSI will yield a PPV=74.6% [0.66x4.46/1+(0.66x4.46)]and a TFP=25.4%. This will 
however have a much lower sensitivity of only 45.1%.  
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5.4.3 Strengths, limitations and recommendations for future research 
Strengths of this study include the novelty of the validation of the ASSIST and SDS Xhosa language versions in 
homogenous sample of patients with an established diagnosis of schizophrenia, measuring the impact of covariates on 
the psychometric properties as well as the incremental gain of conducting longer ASSIST over the briefer SDS. 
Limitations include not being able to determine the SSI-specific scores for different drugs population as their 
prevalence was very low. Caution is required in generalisation of the findings from this study to heterogeneous 
populations of patients with major-affective and non-affective psychotic disorders or populations who are in an earlier 
phase of illness (e.g., first episode psychosis). Although numerous covariates were adjusted for in this analysis, 
psychotic symptom severity was not measured, and models were not adjusted for its potential impact.  Future studies 
should take into account such measures to determine the impact of these variables on the psychometric properties of 
these scales. Another limitation could be the differences in the timing of assessment of SUDs in the SCID-I (past 
month and lifetime, i.e. more than 1 month ago) versus the ASSIST which assesses past 3 month and lifetime (more 
than 3 months ago). We analysed lifetime including past month/3month data together across both the test and gold-
standard instruments, but as past month and past 3-month data vs. lifetime data, may have been subject to differences 
in recall, possibly introducing recall bias, analysing these separately may yield different results. Although future 
analyses could explore this, current findings remain of practical use in clinical settings. 
5.4.4 Conclusion 
Both the ASSIST and SDS Xhosa language versions had good psychometric properties in a population of patients 
with an established diagnosis of schizophrenia. For both the ASSIST and SDS cut-points on ROC curves at lower true 
false positive rates (1-specificity) yielded lower detection rates. The SDS, regardless of diagnosis or other covariates, 
significantly improved case detection, and conducting the ASSIST added little additional benefit. However, using the 
ASSIST in a context of a lower background prevalence of SUDs may yield superior sensitivity without inflating false 
test positive rates. 
Following the screening, identification and assessment for SUDs, treatment planning can start. In part III of this thesis, 
I examine aspects in the pharmacotherapy of severe mental disorders with co-occurring SUDs. In chapter 6, I examine 
antipsychotic induced extra-pyramidal side-effects (EPSE) in people with co-occurring methamphetamine use 
disorders, including the role of antipsychotic type and dosage. Finally, in chapter 7, in a systematic review of 
randomised trials, I examine and compare the differential impact of risperidone vs. other antipsychotics on mental 
state, substance use and a number of potential effect-modifiers such as drug craving, subjective-wellbeing under 
neuroleptics, side-effects (such as EPSE) and treatment adherence. 
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Part III: Chapter 6 
Methamphetamine use and extrapyramidal symptoms in people with major affective and non-
affective psychosis 
6.1 Introduction 
In the preceding chapters, I have examined the prevalence and clinical characteristics of dual diagnosis. In the two 
studies conducted from datasets #1 and #2, approximately half of patients with a psychotic disorder had a lifetime SUD. 
From chapters 1 and 2, cannabis use disorders were most prevalent followed by alcohol use disorders, and with some 
variation, methamphetamine (MA) and methaqualone use disorders. These findings on the ranking of prevalence for 
various co-occurring SUDs corresponds well to systematic reviews and meta-analyses of prevalence studies in people 
with non-affective or affective-psychoses (Koskinen et al., 2009, Koskinen et al., 2010, Sara et al., 2015) Moreover, the 
stimulant MA is highly prevalent in many parts of the world, including the United States, Mexico, Eastern and Southeast 
Asia, Eastern Europe; and it seems to be on the increase in Western Europe (Degenhardt et al., 2010). In South Africa, 
in addition to the findings from previous chapters, other studies from have also described a high occurrence of MA use 
among patients attending psychiatric and drug treatment units (Pluddemann et al., 2013). 
Chronic use of cocaine, MA and alcohol has been associated with lower dopamine receptor availability in the striatum, 
a finding not replicated in cannabis and opiate addictions (Nutt et al., 2015). In addition, MA is a known neurotoxin 
associated with striatal dopaminergic neuronal cell loss and neurotransmission deficits as well as structural deficits in 
the substantia nigra (Jan et al., 2012, Rumpf et al., 2017). Large population-based cohort studies have found an 
association between MA use and the development of Parkinson’s disease (Callaghan et al., 2010, Callaghan et al., 2012). 
Moreover, in people with schizophrenia treated with antipsychotics (AP) the presence of a comorbid substance abuse is 
associated with significantly more extrapyramidal symptoms (EPS) (Potvin et al., 2009b, Wobrock et al., 2013, Miller 
et al., 2005). However, the majority of randomised trials (RCTs) investigating the use of antipsychotic agents in people 
with schizophrenia and bipolar disorder typically exclude participants with comorbid SUDs, making it difficult to 
estimate the risk of antipsychotics for EPS in populations with serious mental illness (SMI) such as schizophrenia and 
bipolar disorder with comorbid SUDs (Leucht et al., 2008).  
Whereas the magnitude of the effect on EPS risk for specific substances of abuse remains unclear, we do know from 
observational studies of people treated with APs that exposure to stimulant drugs in particular (e.g. cocaine) are strongly 
associated with EPS such as parkinsonism (Maat et al., 2008, Potvin et al., 2009b). Previous research on EPS has 
examined the effect of stimulants as a group on EPS in patients treated with antipsychotics (Maat et al., 2008, Potvin et 
al., 2009b, Zhornitsky et al., 2010b), but the specific effect of MA use has not been examined. Moreover, past research 
has focused on specific groups such as schizophrenia, whereas the impact of MA on EPS across various psychotic 
disorders has not been explored.  
In this chapter I therefore aimed to examine the effect of MA use on EPS in patients with major affective and non-
affective psychotic disorders and to compare it with the effect of alcohol or cannabis use on EPS in these patients. In 
addition, I examined whether there were differences between MA use and EPS across different psychotic disorders, 
different types of APs, and AP dosing. 
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6.2 Method 
6.2.1. Sample and setting 
This study is a secondary analysis of data from three studies conducted concurrently in the same clinical population 
attending a large psychiatric hospital in Cape Town, South Africa. The first study contributing data to this analysis, the 
PRP study (Presentation and Risk Factors in the Psychobiology of Psychosis study) was a cross-sectional study that 
randomly sampled adult inpatients enlisted as residing in pre-discharge wards between January 2009 and March 2014 
(Shelly et al., 2016). This study included adult participants with a diagnosis of a major affective or non-affective 
psychotic disorder and excluded patients with mental disorders due to general medical conditions, dementia, intellectual 
disability and neurological disorders. This study included assessment of EPS. In addition, patients who were taking part 
in two related studies were also invited to participate in the PRP study. Participants recruited via these other studies 
included inpatients from the same pre-discharge ward who were taking part in a pilot RCT investigating a treatment 
partner and text messaging intervention on treatment adherence (Social Inclusion in Psychosis study, SIP) (Sibeko et 
al., 2017). This pilot RCT used identical inclusion and exclusion criteria to the current study. Furthermore, outpatients 
taking part in an EEG and neuroimaging study (Cortical Inhibition and Attentional Modulation in Psychosis Study -
CIAM) also consented to the PRP study (Howells et al., 2018). This study recruited stable outpatients with a diagnosis 
of schizophrenia, MA psychosis and bipolar I disorder with psychotic features.  The current analysis included adult 
patients in the combined database, aged 18 to 65 years, taking antipsychotic medications and who took part in an 
assessment of EPS. As there are differences in the neurobiological mechanisms between MA and other stimulants (i.e. 
cocaine, MDMA, amphetamines) (Fleckenstein et al., 2000), participants with other stimulant disorders were excluded, 
therefore isolating the potential effect of MA on EPS.  
6.2.2. Measures and procedures 
Across all studies diagnoses of DSM-IV psychiatric disorders, including alcohol and drug use disorders were determined 
using the Structured Clinical Interview for DSM-IV-TR (SCID-I) (First et al., 1994a). The presence of threshold or 
subthreshold depressive symptoms (defined as depressed mood or anhedonia plus any other symptoms characteristic of 
depression) were recorded using Module A of the SCID-I.  To optimize the accuracy of assessments for substance use 
disorders, interviewers were trained in non-judgemental interviewing styles, clear phrasing of initial open-ended 
questions and the use of normalising statements about drug use. In addition, longitudinal data on substance use were 
considered from multiple sources including case files, members of the multidisciplinary team and family reports. Good 
to excellent interrater reliability was obtained for the various principle psychotic disorder diagnoses (kappa=0.70) and 
comorbid substance use disorders (kappa=0.80) in a smaller subsample of eight patients. 
Data on the APs prescribed, including dosing and anticholinergic co-prescriptions, were collected from patient’s 
prescriptions charts. APs were classified into first-generation agents (FGAs: haloperidol, chlorpromazine, 
trifluoperazine, zuclopenthixol decanoate, flupentixol decanoate, fluphenazine decanoate, sulpiride) and second-
generation agents (SGAs: risperidone, olanzapine amisulpride, quetiapine, aripiprazole, clozapine). AP dose was 
standardised using chlorpromazine equivalents (CPZeq) calculated according to the international consensus method by 
Gardner et. al. (2010). This method allows for equivalence data for all oral and long acting injectable antipsychotics 
(Gardner et al., 2010, Leucht et al., 2016, Patel et al., 2013). 
70 
 
The main outcome variables were the presence of EPS according to the Simpson-Angus Scale (SAS) for parkinsonism 
(Simpson and Angus, 1970), the Barnes Akathisia Rating Scale (BARS) for akathisia (Barnes, 1989), and the Abnormal 
Involuntary Movement Scale (AIMS) for tardive dyskinesia (Guy, 1976b). All study staff conducting assessments 
received training in the conduct of neurological examinations using these instruments and received regular supervision 
and were blind to the study hypothesis. The presence of the various movement disorders was assessed using defined 
cut-points as reported in prior studies and parkinsonism was defined as a score of ≥ 3 on the SAS (Peluso et al., 2012), 
akathisia as a Global rating of ≥2 on the BARS (Barnes, 2003), and tardive dyskinesia by a score of  ≥ 3 on any one 
item or a score of  ≥ 2 on any two items from the 7 body areas assessed on items 1 to 7 of the AIMS (Schooler and Kane, 
1982). All participants provided written informed consent and the study was approved by the Human Research Ethics 
Committee of the University of Cape Town, South Africa.  
6.2.3. Statistical analysis 
Normally distributed continuous data was analysed using Student’s t-test and skewed data was analysed using Wilcoxon 
rank-sum test. For categorical data Chi-squared tests and Fisher’s exact tests were used where appropriate. Multivariable 
logistic regression models were constructed with the presence of any extrapyramidal disorder (parkinsonism, akathisia, 
tardive dyskinesia) as the dependent variable (any EPS = 1 and absence of any EPS = 0). First the presence of any MA 
use disorder (abuse or dependence) was entered into the model as the main independent variable of interest. Following 
this a logistic regression model was constructed with the independent variable structured according the level of MA use 
disorder severity by creating a 3-level categorical variable using dummy coding, i.e. abuse and dependence with a 
reference category of no MA use disorder. The estimates for the effect of MA use disorder on EPS risk were adjusted 
for variables that have been demonstrated to be related to EPS and included age, gender, diagnosis, depressive 
symptoms, medical treatment for hypertension or diabetes, AP type (FGA vs. SGA), standardised antipsychotic dosage, 
anticholinergic use and the presence of alcohol, cannabis and/or methaqualone use disorder (Miller et al., 2005, Potvin 
et al., 2009b, Keck et al., 2000, Richardson et al., 1985). In order to account for any potential bias introduced by the 
different sampling methods across the three source studies (PRP, SIP, CIAM), and to adjust for inpatient vs. outpatient 
status as an approximate measure of non-adherence (assuming that medication adherence was potentially lower in 
outpatients as opposed to directly observed consumption for inpatients) the analyses was adjusted for a variable that 
captured source study and patient setting (Inpatients: PRP study or SIP study vs. outpatients: CIAM study). Duration of 
the psychotic disorder in years from age at diagnosis was added as covariate measure of the length of lifetime AP 
exposure. In order to determine whether the effect of MA on EPS was dependent on the type of principle diagnosis or 
the type and dose of AP, interaction terms between MA use disorder and these variables were also fitted using 
multivariable logistic regression analysis. As the propensity of SGA’s to induce EPS vary, with risperidone having a 
comparative low D2 dissociation constant (Seeman, 2002b),  a sensitivity analysis was conducted re-classifying 
risperidone as a FGA, in order to determine if this would have an impact on effect estimates. In addition, a sensitivity 
analysis was conducted examining the effect of duration of MA use on EPS. Two tailed tests with a significance level 
of 5% were used throughout. Analyses were conducted using Stata version 13 for Windows (StataCorp, 2013). 
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6.3 Results 
6.3.1. Sample characteristics 
The total sample consisted of 102 participants with a mean age of 31.3 years (SD =10.2) and 65.7% males. Of the total 
sample, 54.9% had a schizophrenia spectrum disorder (schizophrenia, schizophreniform disorder, brief psychotic 
disorder, psychotic disorder not otherwise specified), 20.6% a bipolar type I disorder, 11.7% a schizoaffective disorder 
and 12.7% a substance induced psychotic disorder. MA use disorders (abuse or dependence) occurred in 25.5% (MA 
abuse= 3.9%, MA dependence= 21.6%), cannabis use disorders in 38.2%, alcohol use disorders in 29.4% and 
methaqualone use disorders in 6.8% of participants. Most participants with a MA use disorder (84.6%) had at least one 
other co-occurring, non-stimulant SUD, the most common co-occurring SUD being cannabis use disorders (76.9%), 
followed by alcohol use disorder (42.3%) and methaqualone use disorders (15.3%). Of the total sample 61.8% were 
inpatients (PRP study: n=47, 46.1%; SIP study: n=15, 15.7%) and 38.2 % outpatients (CIAM study: n= 39, 38.2%). The 
median length of stay for inpatients was 36 days (interquartile range, IQR= 24 days). Table 6.1 contains a summary of 
the sample characteristics. Compared to patients with other substance use disorders, participants with a MA use disorder 
were significantly more likely to belong to the youngest age group (81% vs. 45%), to be diagnosed with a substance 
induced psychotic disorder (42% vs. 3%), have a comorbid cannabis use disorder (77% vs. 25%) and to have a shorter 
duration of illness. Furthermore, participants with a MA use disorder tended to be male more often (81% vs. 61%) and 
to be diagnosed more often with a comorbid alcohol and methaqualone use disorder (42% vs. 25% and 15% vs. 4%, 
respectively). 
As many as 38.2% of participants had at least one extrapyramidal movement disorder, with 35.3% having parkinsonism, 
8.8% akathisia and 0.9% tardive dyskinesia.  
First-generation APs (FGA’s) were used by 74.5%, and second-generation APs (SGA’s) by 39.2% of all participants, 
with some overlap, indicated by the fact that 13.7% received both FGA’s and SGA’s. Table 6.2 contains a summary of 
the sample AP treatment profiles.  There were no significant differences between participants with and without a MA 
use disorder in terms of the type or dose of APs prescribed, however there was a trend for more SGAs being prescribed 
to participants without a MA use disorders (p=0.051). 
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Table 6.1 Sample demographic and clinical characteristics 
Variables Total 
sample 
Methamphetamine use 
disorder 
Test statistic (df) p value 
 N=102 Present 
N=26 
Absent 
N=76 
  
 n (%) n (%) n (%)   
Age         
 18-29 55 (53.9) 21 (80.7) 34 (44.7) χ2=11.19(2) 0.004 
 30-44 34 (33.3) 5 (19.2) 29 (38.1) -  
 45-65 13 (12.7) 0 (0.0) 13 (17.1) -  
Sex         
 Male 35 (34.3) 21 (80.7) 46 (60.5) χ2=3.52(1) 0.061 
 Female 67 (65.6) 5 (19.2) 30 (39.5) -  
Diagnosis         
 Schizophrenia spectruma 56 (54.9) 11 (42.3) 45 (59.2) Fisher’s exact test <0.001 
 Bipolar disorder type I 21 (20.5) 3 (11.5) 18 (23.6) -  
 Schizoaffective  12 (11.7) 1 (3.8) 11 (14.4) -  
 Substance induced psychosis 13 (12.7) 11 (42.3) 2 (2.6) -  
Symptoms of depression 47 (46.1) 8 (30.7) 39 (51.3) χ2=3.29(1) 0.070 
Duration of illness (years)          
 median (IQR) 5 10 2.5 5 7 13 Wilcoxon ranksum, z=2.60 0.009 
Comorbid substance use disorder         
 Cannabis 39 (38.2) 20 (76.9) 19 (25) χ2=22.11(1) <0.001 
 Alcohol 30 (29.4) 11 (42.3) 19 (25) χ2=2.79(1) 0.095 
 Methaqualone 7 (6.8) 4 (15.3) 3 (3.9) Fisher’s exact test 0.068 
Duration of MAb use         
 ≤ 3years - - 8 (30.8) - - - - 
 ˃ 3 years - - 18 (69.2) - - - - 
Medical comorbidity         
 Diabetes 2 (1.9) 1 (3.8) 1 (1.3) Fisher’s exact test 0.447 
 Hypertension 3 (2.9) 0 (0.0) 3 (3.9) Fisher’s exact test 0.568 
Source study and setting         
 Inpatients (n=63, 61.8%)         
 PRPc 47 (46.1) 9 (34.6) 38 (50) χ2=2.26(2) 0.323 
 SIPd 16 (15.7) 4 (15.4) 12 (15.8) - - 
 Outpatients (n=39, 38.2%)         
          CIAMe 38 (38.2) 13 (50) 26 (34.2) - - 
a.  Schizophrenia, schizophreniform disorder, brief psychotic disorder, psychotic disorder not otherwise specified 
b. MA: Methamphetamine 
c. PRP: Presentation and Risk Factors in the Psychobiology of Psychosis Study 
d. SIP: Social Inclusion in Psychosis Study 
e. CIAM: Cortical Inhibition and Attentional Modulation in Psychosis- Study 
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Table 6.2 Antipsychotic and anticholinergic treatment 
 Total Sample  Methamphetamine use 
disorder 
  
Antipsychotics 
prescribed 
    N=102 Present 
N=26 
Absent 
N=76 
Test(df) p value 
 n % n % n %   
FGAsa         
 Any FGA  76 (74.5) 22 (84.6) 54 (71) χ2=1.87(1) 0.171 
 Chlorpromazine 11 (10.7) 3 (11.5) 8 (10.5) Fisher’s exact test nsd 
 Haloperidol   48 (47) 16 (61.5) 32 (42.1) χ2=2.93(1) 0.087 
 Sulpiride 3 (2.9) 1 (3.8) 2 (2.6) Fisher’s exact test ns 
 Trifluoperazine 2 (1.9) 0 (0.0) 2 (2.6) Fisher’s exact test ns 
FGA long acting 
injectable (LAI) 
        
 Any FGA LAI 28 (27.4) 6 (23.1) 22 (28.9) χ2=0.33(1) 0.563 
 Fluphenazine LAI 4 (3.9) 0 (0.0) 4 (5.2) Fisher’s exact test 0.570 
 Flupentixol LAI 9 (8.8) 2 (7.6) 7 (9.2) Fisher’s exact test ns 
 Zuclopenthixol 
LAI 
15 (14.7) 4 (15.3) 11 (14.4) Fisher’s exact test ns 
SGAsb         
 Any SGA 40 (39.2) 6 (23) 34 (44.7) χ2=3.81(1) 0.051 
 Clozapine 15 (4.7) 2 (7.6) 13 (17.1) Fisher’s exact test 0.343 
 Olanzapine 1 (0.9) 0 (0.0) 1 (1.3) Fisher’s exact test ns 
 Risperidone 14 (13.7) 2 (7.6) 12 (15.7) Fisher’s exact test 0.510 
Polypharmacy         
Antipsychotics ≥2 29 (28.4) 6 (23.0) 23 (30.2) χ2=0.49(1) 0.483 
Anticholinergic 
agents 
34 (33.3) 12 (46.1) 22 (28.9) χ2=2.58(1) 0.108 
Total antipsychotic 
dose (Standardised) 
        
CPZeqc  mean (SD) 436.8 265.5 385.2 (265.3) 454.4 (265.1) -  
median (IQR) 400 (390) 345 (270) 435 (300) Wilcoxon ranksum,  z=1.38 0.164 
a. FGA: First-Generation Antipsychotic 
b. SGA: Second-Generation Antipsychotic 
c. CPZeq: Chlorpromazine equivalents; international consensus method (Gardner, 2010) 
d. ns: non-significant 
 
6.3.2. Association between MA use and EPS 
Table 6.3 shows the results of the multivariable logistic regression models for the unadjusted, adjusted main and 
interaction effects. In the unadjusted analysis patients with MA use disorders had a significantly increased odds for EPS 
(ORunadj =2.95, 95% CI= 1.18-7.38, p=0.020). After adjustment for covariates this association became even stronger and 
remained significant (ORadj = 4.01, 95% CI= 1.07-14.98, p=0.039). Compared to patients without a MA use disorder, 
patients with MA dependence were significantly more likely to have EPS (ORadj= 5.48, 95% CI= 1.30 – 23.06, p=0.020), 
whereas for MA abuse this association was nominally much weaker and non-significant (ORadj = 1.04, 95% CI= 0.08-
13.80, p=0.975). The presence of cannabis, alcohol or methaqualone use disorders were not significantly associated with 
increased EPS. 
A significant interaction was found between the presence of a MA use disorder and standardised AP dosage (CPZeq) 
(Table 6.3, Fig 6.1). From the regression equation, participants with a MA use disorder and a CPZeq dose of 300mg had 
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no significant increase in the odds of having EPS (ORadj = 2.03, 95% CI= 0.45- 9.08,  p=0.354), whereas a CPZeq dose 
of 450mg resulted in an significant increase in the odds of EPS (ORadj = 5.80, 95% CI= 1.14- 29.62,  p=0.034) as did a 
CPZeq dose of 600mg (ORadj = 16.60, 95% CI= 1.72- 159.39,  p=0.015). There was no significant interaction between 
MA use disorder and treatment with FGAs. It was not possible to fit a model to examine interaction between MA and 
diagnosis due to multicollinearity. 
6.3.3. Sensitivity analyses 
Refitting the multivariable logistic regression model to include FGAs redefined to include risperidone 
(FGA+risperidone) or adding SGAs did not have any impact on the association between MA use disorder and EPS in 
the main or interaction models with AP dose. Compared to non-MA users there was a non-significant increase in the 
odds for EPS for patients using MA ≤ 3 years (ORadj = 2.42, 95% CI= 0.28- 21.03,  p=0.422), but a statistically significant 
increase in the odds of EPS in patients using MA for > 3 years (ORadj = 4.36, 95% CI= 1.12- 16.96,  p=0.033). Removing 
anticholinergic prescriptions from the full model resulted in a small decrease in the odds of EPS, but the association 
between MA use disorder and EPS remained significant (ORadj = 3.88, 95% CI= 1.03- 14.65,  p=0.045).  
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Table 6.3 Multivariable logistic regression models with main and interaction effects (N=102) 
Variables Presence of any EPS   
 Unadjusted 
Odds Ratio 
Adjusted 
Odds Ratio 
p value 95% CI 
Main effectsa     
 Methamphetamine use disorder 2.95 4.01 0.039 1.07 – 14.98 
 Alcohol use disorder 1.11 0.87 0.814 0.28 – 2.71 
 Cannabis use disorder 1.44 0.66 0.480 0.21 – 2.08 
 Methaqualone use disorder 1.22 0.93 0.948 0.13 – 6.60 
Diagnosis     
 Schizophrenia spectrum (ref) 1.0 1.0 ref ref 
 Bipolar disorder type I 0.48 0.64 0.514 0.17 – 2.39 
 Schizoaffective  1.10 1.56 0.590 0.31 – 7.94 
 Substance induced psychosis 1.80 1.36 0.756 0.19 – 9.58 
Symptoms of depression 0.71 1.00 0.999 0.36 – 2.75 
Duration of illness (years) 1.00 0.99 0.878 0.92 – 1.06 
Antipsychotic (FGA) 1.23 1.07 0.899 0.34 – 3.43 
Antipsychotic dosage (CPZ equivalents) 1.0 1.0 0.368 0.99 – 1.00 
Anticholinergic co-prescription 1.73 1.67 0.320 0.60 – 4.61 
Age     
 18-29 (ref) 1.0 1.0 ref ref 
 30-44 1.00 1.64 0.427 0.48 – 5.60 
 45-65 1.01 3.76 0.199 0.49 – 28.37 
Sex: Male 2.34 2.53 0.147 0.72 – 8.90 
Medical comorbidity (diabetes or hypertension) 0.38 0.17 0.192 0.01 – 2.41 
Source study and setting     
 PRP study ref ref ref ref 
 SIP study 1.76 1.53 0.526 0.41 – 5.70 
 CIAM study 0.98 0.93 0.911 0.26 – 3.25 
Interaction effects     
 MA use disorder x FGAb 0.30 0.33 0.469 0.01 – 6.57 
 MA use disorder x  FGA+risperidonec 0.39 0.54 0.705 0.02 – 13.14 
 MA use disorder x CPZeqd 1.02 1.01 0.042 1.00 – 1.01 
a. Hosmer-Lemeshow goodness of fit test, χ2=3.36 (df=8), p=0.910  
b. Hosmer-Lemeshow goodness of fit test, χ2=3.22 (df=8), p=0.920 
c. Hosmer-Lemeshow goodness of fit test, χ2=6.52 (df=8), p=0.589 
d. CPZeqcons: Chlorpromazine equivalents; international consensus method (Gardner, 2010), Hosmer-Lemeshow 
goodness of fit test, χ2=9.91(df=8), p=0.271 
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Figure 6.1 Relationship between standardised antipsychotic dose and probability of EPS in MA and non-MA SUDs 
 
6.4 Discussion 
6.4.1 Summary of main findings and comparison with other studies 
To date there has been only a single case study reporting on the development of Parkinsonism in a MA user receiving 
AP treatment (Matthew and Gedzior, 2015), making this the first clinical study to examine the specific association 
between MA and EPS in psychotic patients using APs. Firstly, it was demonstrated that in patients with major affective 
or non-affective psychotic disorders and comorbid MA dependence the odds of having EPS is 4 times higher compared 
to patients with no MA use disorder. These results are consistent  with the finding that psycho-stimulants such as cocaine 
are strongly associated with EPS (Maat et al., 2008). Moreover, the current study included a broader range of psychiatric 
disorders, extending the generalizability to other disorders for which AP treatments may be indicated.  
Second, the current study suggests that MA use disorder severity and duration are related to the risk of EPS, in that there 
was a significant association between MA dependence and EPS and no significant association between MA abuse and 
EPS. In turn, patients with a MA use disorder of more than 3 years duration were significantly more likely to have EPS, 
compared to those with MA use of 3 or less years, who had no association with EPS. 
Third, the findings of the current study indicate some degree of specificity; there was no association between alcohol or 
cannabis use disorders and EPS. This is consistent with the evidence from a previous meta-analysis (Potvin et al., 
2009b). Data on the effect of cannabis use disorders is limited, but the current study findings of no significant association 
are again consistent with other studies (Maat et al., 2008), but differ from a post-hoc analysis of a RCT which found no 
difference in EPS at baseline but an increased risk of parkinsonism in cannabis users after longitudinal follow up at 6 
months (Wobrock et al., 2013).  
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Fourth, there was a significant interaction between the presence of a MA use disorder and standardised AP dose on the 
risk of EPS, with increases in AP dose being significantly associated with the likelihood of EPS in patients with MA 
use disorders but not in those without MA use disorders.  
6.4.2 Study strengths and limitations 
Limitations of this study include the cross-sectional design. Furthermore, the possibility that participants were trying 
(unsuccessfully) to self-medicate EPS with MA cannot be excluded. Psychosis symptom severity was not adjusted for 
in this study. However, a previous study suggests that non-adjustment for psychotic symptom severity is likely to result 
in an underestimation of the effect of SUD on EPS risk (Potvin et al., 2009b) and therefore the observed effect of MA 
use disorder on EPS seems to be a robust finding. Nevertheless, there seems to be a relation between symptom severity 
and tardive dyskinesia (Miller et al., 2005), and therefore it would be important for future studies to take into account 
psychotic symptom severity. In addition, as the total sample size precluded separate analyses of individual EPS disorders 
and their association with MA use disorders, extension and replication of this study’s results in larger samples is needed. 
Although a strength of this study was the use of regression models to adjust for a number of covariates such as age, sex, 
diagnosis, depressive symptoms, AP dose, duration of MA use, duration of illness, sampling variation across source 
studies and treatment setting (in an attempt to adjust for medication non-adherence), this approach has limitations and 
future studies with larger samples may need to use longitudinal designs with matching on some of these variables and 
careful measuring of AP adherence in order to adjust for cumulative AP exposure and changes in the influence of 
different SUDs over time. 
6.4.3 Clinical implications 
These findings may have important implications for clinicians considering AP treatment. Treatment of co-occurring 
MA use will be important in the management of patients with psychiatric disorders. In addition, AP type and dosage 
may need careful consideration and regular monitoring of EPS is required in this population. Up-titration of AP dose 
needs to proceed from lower dosages and practices that may lead to higher total AP doses such as AP polypharmacy 
should be avoided. In participants with bipolar disorders the use of alternatives to APs, such as non-neuroleptic mood 
stabilisers may be important for maintenance treatment, and in participants with substance induced psychosis, prolonged 
exposure to neuroleptics needs to be weighed against the risk of EPS (and other side effects). 
6.4.4 Conclusions: 
This study found that AP related medication side-effects such as EPS are more likely in patients with a psychotic disorder 
and a co-occurring MA use disorder. In turn, medication side-effects such as EPS may be an important effect-modifier 
by having a negative impact on treatment-adherence, ultimately leading to a worsening of symptoms. In addition, some 
APs such as risperidone have been associated with lower levels of EPS, greater reduction of drug craving and positive 
symptoms and lower attrition in amphetamine and MA users (Hunter et al., 2003a, Farnia et al., 2014, Wang et al., 
2016). This leads to the question whether certain APs such as risperidone have a more favourable profile in people with 
co-occurring SUDs. In the next chapter I address this question in a Cochrane systematic review of randomised trials that 
examines and compares the effect of risperidone, one of the first second-generation APs to be marketed, to other APs 
on a number of outcomes such as mental state, substance use, drug craving, subjective well-being, side-effects and 
adherence.  
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Part III: Chapter 7 
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring 
substance misuse 
 
This chapter incorporates work from the following publication:  
 
Henk S Temmingh, Taryn Williams, Nandi Siegfried, Dan J Stein. Risperidone versus other antipsychotics for people 
with severe mental illness and co-occurring substance misuse. Cochrane Database of Systematic Reviews 2018, Issue 
1. Art. No.: 011057 DOI:10.1002/14651858.CD011057.pub2 [ http://dx.doi.org/10.1002/14651858.CD011057.pub2.] 
 
7.1. Introduction 
In part I of this thesis I examined the prevalence and clinical characteristics of co-occurring SUDs in people with 
schizophrenia and other psychotic disorders. In accordance with systematic reviews of prevalence studies of SUDs in 
people with serious mental disorders, as well as existing studies in the South African context, SUDs occurred in about 
half of participants in our studies (Koskinen et al., 2009, Koskinen et al., 2010, Sara et al., 2015, Weich and Pienaar, 
2009b).  Co-occurring substance use disorders have a negative impact on the course of mental disorders and are 
associated with lower remission rates, higher symptoms levels, higher relapse rates, lower level of medication adherence 
and worse clinical outcomes (Ascher-Svanum et al., 2006a, Katz et al., 2010, Lacro et al., 2002a, Lambert et al., 2005a, 
Owen et al., 1996a, Potvin et al., 2009a, Salyers and Mueser, 2001a, Swofford et al., 1996a, Wade et al., 2006a). In 
addition to these negative impacts, in chapter six I demonstrated that co-occurring methamphetamine use in people with 
SMI was associated with a higher, dose-related antipsychotic occurrence of EPS, which in turn may be an important 
effect-modifier ultimately impacting on treatment adherence and mental state. 
In addition to the potential for MA related structural changes in the striatum and substantia nigra and its association with 
parkinsonism (Jan et al., 2012, Rumpf et al., 2017), chronic substance use is associated with lower dopaminergic receptor 
density in the striatum which in turn may aggravate craving for substances, leading to increased drug taking (Siris, 1990, 
Volkow et al., 1997, Volkow et al., 2007). Moreover, the effects of substances of abuse on brain functioning may impact 
on the neurobiological mechanisms whereby antipsychotics exert their effects (Zhornitsky et al., 2010a). It has been 
hypothesized that antipsychotics (D2 receptor antagonists) with a high affinity for D2 receptors may in fact accentuate 
a “reward deficit syndrome” present in chronic substance abusers (Blum et al., 2000). This in turn may lead to a 
worsening of negative affective states (anxiety and depression), more drug craving, lower levels of subjective-wellbeing 
(Vothknecht et al., 2011a), increased sensitivity to extrapyramidal side-effects (Potvin et al., 2009a), attempts to self-
medicate with drugs of abuse, lower adherence to antipsychotics and ultimately a worsening  in the course of mental 
disorder (Siris, 1990). Some have suggested that “atypical” antipsychotics such as risperidone, with lower D2 affinity 
and higher 5HT2a antagonism (Seeman, 2002a), may have an advantage over agents with higher D2 affinity in patients 
with a dual diagnosis (Green, 2001, Horacek et al., 2006, Machielsen and de Haan, 2009, Zhornitsky et al., 2010a, 
Machielsen and De Haan, 2011, Siris, 1990, Wobrock and Soyka, 2009b). Newer second-generation agents, such as 
risperidone are thought to have a beneficial impact on mental state and substance use via several effect modifiers in a 
complex causal pathway (see Fig 7.1). Compared to aripiprazole, risperidone has been associated with greater reductions 
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in positive psychotic symptoms and methamphetamine craving, as well as lower levels of EPS such as akathisia and 
lower treatment drop-out (Wang et al., 2016, Farnia et al., 2014). It is postulated that second-generation agents may 
exert their beneficial effect on mental state via lower D2 receptor antagonism resulting in less craving for substances, 
higher levels of subjective-wellbeing, less medication side-effects, ultimately resulting in improved adherence, 
decreased substance use and improved mental states.  
Risperidone is one such agent and was the first “atypical” antipsychotic to be marketed. It is currently widely available 
across most high,  low and middle income countries, (Janssen et al., 1988b). Yet risperidone’s role in the treatment of 
dual diagnosis remains unclear, as although some studies have shown potential benefits in this population (Smelson et 
al., 2002b), others have not (Green et al., 2003, Machielsen et al., 2014). Moreover, most randomised trials investigating 
the efficacy of risperidone in schizophrenia have excluded patients with dual diagnosis as participants (Hunter et al., 
2003a). In turn, even though risperidone differs from higher potency first-generation agents (FGAs), and is classified as 
a second-generation antipsychotic  (SGA), “atypical drug” (with a higher affinity for serotonin 5HT2A  receptors,  lower 
affinity for D2 receptors and a relatively high D2 receptor dissociation rate), there are in fact  similarities in its 
pharmacological properties to some FGAs and even differences with other agents in the same SGA class (Seeman, 
2002a). 
Together with my co-authors I therefore aimed to conduct a systematic review of randomised trials of risperidone versus 
any other antipsychotic in the treatment of people with serious mental illness and co-occurring substance use disorders.  
We aimed to determine the treatment effects of risperidone versus other antipsychotics on mental state, substance use 
and clinically significant adverse effects, as well as secondary outcome measures of craving, subjective-wellbeing, 
medication adherence, study retention, other adverse effects, mortality and quality of life. 
 
 
Figure 7.1 Complex causal pathway of risperidone effect on mental state and substance use in people with dual diagnosis 
 
 
 
80 
 
7.2 Methods 
A protocol was published in the Cochrane Library in 2014 outlining the study aims and methods. 
7.2.1 Identification and selection of studies 
Types of studies and participants 
We included randomised controlled trials (RCTs), in which risperidone was randomised. If a trial was described as 
'double blind' but randomisation was implied, we included such trials after confirming randomisation with the study 
investigators. We excluded quasi-randomised studies, such as those allocating by alternate days of the week. We 
included trials with adults, aged 17 to 65 years, with a severe mental illness and a co-occurring substance use disorder, 
where severe mental illness is defined to include schizophrenia, schizoaffective disorder, and schizophreniform disorder, 
major affective disorders such as bipolar disorder and major depressive disorder with psychotic features. Co-occurring 
substance use disorders included disorders diagnosed by any means or scale and included alcohol abuse or dependence. 
In case studies did not randomize dual diagnosis patients at outset but contained only subgroups of patients with a dual 
diagnosis, we included such trials in case >70% of participants had a co-occurring SUD. For secondary analysis of RCT 
data we included such studies and reported on the likelihood of selective outcome reporting in risk of bias assessments. 
We excluded studies that aimed to primarily investigate the effect of antipsychotics on nicotine/tobacco smoking or 
volatile solvents. We excluded trials with participants with predominantly moderate to severe intellectual disability, 
organic mental disorder, drug-induced mental disorders, personality disorders, non-severe forms of depression and 
anxiety, factitious disorder or malingering. We did not place restrictions on comorbid anxiety or mood symptoms, type 
of treatment setting (country, i.e. high income or low and middle income) or phase of illness. 
Types of intervention 
We included randomised trials investigating risperidone in any dose or formulation compared to any other antipsychotic 
(first- or second-generation antipsychotics). We allowed for the inclusion of studies where co-treatment with other 
psychopharmacological agents (mood stabilisers, antidepressants) or psychosocial treatments occurred in all treatment 
arms. Where imbalances existed between the treatment arms in terms of the dose, timing or duration of the additional 
treatments, we intended to note and discuss the impact of such imbalances in the section on assessment of risk of bias. 
Outcome measures 
Primary outcomes included any clinically important change in general mental state, positive, negative or anxiety 
symptoms (as defined by trial authors); any reduction in substance use or the presence or absence of substance use at 
study endpoint; or any clinically important side-effect as defined by trial authors. Secondary outcomes included any 
change in subjective well-being, substance craving, improvements in medication adherence, and any other adverse 
effects, reductions in leaving the study early, mortality or clinically important change in quality of life. 
Electronic search strategy 
On January 6, 2016, and again on 9 October 2017 the Cochrane Trials Search Co-ordinator (TSC) searched the Cochrane 
Schizophrenia Group’s Study-Based Register of Trials using the following search strategy: *Risperidone* in 
Intervention AND *Substance Abuse* in Healthcare Condition Fields of STUDY.  In such a study-based register, 
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searching the major concept retrieves all the synonym keywords and relevant studies because all the studies have already 
been organised based on their interventions and linked to the relevant topics. The Cochrane Schizophrenia Group’s 
Register of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, 
EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, hand-searches, 
grey literature, and conference proceedings. On January 8, 2016, and again on 10 October 2017 the TSC of Cochrane 
Common Mental Disorders Group searched the trials register, using select keywords (see appendix to chapter for full 
search details). There is no language, date, document type, or publication status limitations for inclusion of records into 
these registers. In addition, we inspected reference lists of all included studies for further relevant studies. The first 
author of each included study as well as pharmaceutical companies were also contacted for information regarding 
unpublished trials (see Appendix for full search strategy).  
Study selection 
Citations from the searches were independently inspected by HT and TW, who then identified relevant abstracts. 
Included abstracts were also independently re-inspected by NS to ensure reliability. Full reports of the abstracts meeting 
the review criteria were obtained and inspected by HT and TW. Where disputes arose, reports were re-inspected by NS 
in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, we attempted to 
contact the authors of the study for clarification. 
7.2.2 Assessment of the quality of included studies 
Risk of bias in included studies   
Review authors HT and TW worked independently to assess risk of bias by using criteria described in the Cochrane 
Handbook  (Higgins and Green S). This set of criteria is based on evidence of associations between overestimate of 
effect and high risk of bias of the article, and included assessments of sequence generation, allocation concealment, 
blinding, incomplete outcome data, selective reporting and other forms of bias. Measures to prevent risk of bias were 
assessed as either 'high', "low" or "unclear", according to the definitions of these ratings in the Cochrane Handbook. If 
the raters disagreed, the final rating was made by consensus, with the involvement of another review author (NS). Where 
inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies 
in order to obtain further information. The level of risk of bias for each included study was noted in both the text of the 
review and within risk of bias tables and was incorporated in the judgement of overall quality across studies in the 
'Summary of findings' table (Tables 7.3 to 7.7). 
Overall quality of evidence across studies 
We used the GRADE approach to interpret findings (Guyatt et al., 2011, Schünemann et al.) and used GRADEpro to 
export data from our review to create 'Summary of findings' tables (Tables 7.3 to 7.7). These tables provide outcome-
specific information concerning the overall quality of evidence from each included study in the comparison, the 
magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important 
to patient care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' 
table: Mental state: General - clinically important change - at study endpoint; substance use: a reduction in substance 
use - at study endpoint; subjective well-being - improvement in measures of subjective well-being; craving for 
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substances - improvement in measures of substance craving; adherence to antipsychotic medication - improvement in 
measures of medication adherence; adverse effects - clinically important adverse effect; leaving the study early - a 
reduction in the proportion of participants leaving the study early for any reason. GRADE assesses overall quality based 
on risk of bias (as per Cochrane risk of bias domains), inconsistency (heterogeneity) across studies, imprecision (related 
to sample size), indirectness (of comparisons, study population or outcomes) and downgrades quality of randomised 
trials according to these domains from high quality to moderate, low or very low-quality evidence. 
7.2.3 Data management and analysis 
Data extraction and management 
Review authors HT and TW independently extracted data from all included studies. Again, any disagreement were 
discussed, decisions documented and, if necessary, authors of studies were contacted for clarification. With remaining 
problems NS helped to clarify issues and final decisions were documented. We extracted data onto a standardised form 
and piloted it on one study prior to use. For scale-derived data we used only data from rating scales with psychometric 
properties that have been described in peer reviewed literature and where authors did not modify the scale in any way. 
We extracted primarily endpoint data (means and standard deviations) where available but used change data in case the 
latter was not available. For skewed continuous data (where the standard deviation multiplied by 2 was greater than the 
mean) from samples of <200 we did not combine data in analyses but presented them separately in tables. For multi-
level data  such as repeated measures on one participant (i.e. number of positive /clean urine tests or number of joints 
smoked over a period of follow-up) we asked authors to derive a mean and SD over the period of time, in accordance 
with the method described by Mattick (Mattick et al., 2014). For studies with multiple arms in order to avoid double 
counting of data we only used data from the relevant comparison to independently derive comparisons (Higgins and 
Green S). 
Statistical analysis 
For binary outcomes treatment effects are presented as risk ratios (RR) and its 95% confidence interval (CI). For 
continuous data we estimated the mean difference and in case of different scales being combined, the standardized mean 
difference. For missing binary data we would have had an intention to treat approach whereby those who failed to 
complete the study were assumed to have the same rate of negative outcomes as those who remained in the study. 
However, due to the small study sample sizes we were not able to conduct such a sensitivity analysis in order to test 
how prone the primary outcomes are to change when 'completer' data only are compared to the intention-to-treat analysis 
using the above assumptions. In order to account for attrition we extracted and reported on completer only data in case 
of attrition <50% for continuous outcomes. Where studies contained mixed populations (substance users and non-users), 
in case such studies had >70% of dual diagnosis clients, we would report complete case analysis for all particiaptns as 
if they had a dual diagnosis. We report on clinical and methodological heterogeneity where studies have been combined 
and we explored statisical heterogeneity using the Chi-square test for hetergeneity and the I2 measure for the the degree 
of signifcance of heterogeneity. I2 values between 0% to 40% were interpreted as possibly unimportant, 30% to 60% as 
possibly significant, 50% to 90% as possibly substantial, and 75% to 100% as possibly considerable (Deeks et al.). Had 
substantial levels of heterogeneity been found in the primary outcome, we would have explored reasons for 
heterogeneity, and although subgroup analyses were planned (different subtance use disorders, different preparations of 
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risperidone) there were too few studies used in meta-analyses to conduct such subgroup analyses. Similary, we aimed 
to conduct sensitivity analyses excluding studies with high risk of bias or substantial attrition; yet the few studies 
included in the review precluded such an analysis. There were too few studies to conduct a funnel plot to explore 
publication and other bias. As there was substantial heterogeneity across the included  studies, we used a random-effects 
model to combine data in a meta-analysis. All analyses were conducted using Cochrane Revman software, version 5.3. 
(RevMan, 2014). 
7.3 Results 
7.3.1 Studies included and excluded 
A total of 201 records were retrieved of which 56 were relevant, containing information on 37 studies of which 29 
studies were excluded, leaving 8 studies that met inclusion criteria (Fig. 7.2) (Akerele and Levin, 2007, Brunette et al., 
2011, Machielsen et al., 2014, Noordsy and Green, 2010, Sevy et al., 2011, Smelson et al., 2006, Swartz et al., 2008, 
van Nimwegen et al., 2008b). Reasons for excluding studies were: not including participants with a substance use 
disorder (Blin et al., 1996, Gaebel et al., 2010, Harvey et al., 2007, Ikuta et al., 2014, Liemburg et al., 2011, Perlis et al., 
2006, Rezayat et al., 2014, Sachs et al., 2002, Sajatovic et al., 2002, Smulevich et al., 2005, van Nimwegen et al., 2008a, 
Yatham et al., 2007), protocol for planned studies with no data (Green, 2001, Nct, 2016b, Nct, 2016a), pseudo-
randomisation (Rubio et al., 2006a, Rubio et al., 2006b, Zhangyue and Liu, 2005), no comparison of risperidone versus 
another medication (Kerfoot et al., 2011a), alcohol induced mental illness (Liu et al., 2008), retrospective observational 
study (Nct, 2016d), comparison of risperidone oral versus depot formulation (Nct, 2016e), participants without psychotic 
disorder (Nejtek et al., 2008). In addition, 5 studies were awaiting classification (Greenspan et al., Johnsen et al., 2010, 
Nct, 2016f, San et al., 2012, Yatham and et, 2003) as they appeared to meet eligibility criteria but no clarification or 
data was provided after contact with study authors.  One was classified as ongoing (Nct, 2016c) (see appendix tables 
9.1,9.2, 9.3). 
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Figure 7.2 PRISMA flow diagram of study selection from 2016 and 2017 searches 
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7.3.2 Characteristics of the included studies 
Seven studies, containing a total of 1073 participants randomised with a dual diagnosis, provided useable data (Table 
7.1) (Akerele and Levin, 2007, Machielsen et al., 2014, Sevy et al., 2011, Smelson et al., 2006, Swartz et al., 2008, van 
Nimwegen et al., 2008b). One study did not provide usable data (Brunette et al., 2011). Four studies were parallel design, 
superiority trials that randomised participants with a serious mental illness and co-occurring substance use (Akerele and 
Levin, 2007, Brunette et al., 2011, Machielsen et al., 2014, Noordsy and Green, 2010), three studies were secondary 
analyses of subgroups of patients with a dual diagnosis from existing randomised trials (Sevy et al., 2011, Smelson et 
al., 2006, Swartz et al., 2008), and one study included a large subgroup of participants with a dual diagnosis (van 
Nimwegen et al., 2008b).  Studies were from the United States of America (USA) or the Netherlands and the majority 
contained outpatients. With the exception of two studies (Machielsen et al., 2014, Noordsy and Green, 2010) 
sponsorship or funding from the pharmaceutical industry, or ties by the investigators with drug companies was present 
for all the included studies. In two studies only first episode patients (Noordsy and Green, 2010, Sevy et al., 2011) were 
included and in one study only multi-episode patients (Swartz et al., 2008). Three studies specified participants as mixed 
ethnic origin (Akerele and Levin, 2007, Smelson et al., 2006, Swartz et al., 2008), two studies contained mostly or 
exclusively Caucasian participants (Brunette et al., 2011, Noordsy and Green, 2010), and the majority of studies 
contained male participants. In five studies participants had exclusively cannabis use disorders (Brunette et al., 2011, 
Machielsen et al., 2014, Noordsy and Green, 2010, Sevy et al., 2011, van Nimwegen et al., 2008b) and in three studies 
participants had a variety of drug or alcohol use disorders (Akerele and Levin, 2007, Smelson et al., 2006, Swartz et al., 
2008). Risperidone (oral formulation) was compared to clozapine in three studies (Brunette et al., 2011, Machielsen et 
al., 2014, Noordsy and Green, 2010), to olanzapine in five studies (Akerele and Levin, 2007, Sevy et al., 2011, Smelson 
et al., 2006, van Nimwegen et al., 2008b), to first-generation antipsychotics (perphenazine, loxapine, haloperidol, 
fluphenazine, thiothixene) in two studies (Smelson et al., 2006, Swartz et al., 2008), to quetiapine in one study (Swartz 
et al., 2008), and ziprasidone in one study (Swartz et al., 2008). 
7.3.3 Measures used across studies 
Across studies the Structured Clinical Interview for DSM-IV (SCID-I)(First et al., 1994b) or DSM-IV diagnostic criteria 
were used to determine diagnosis of the principle psychiatric disorder (Table 7.2). Substance use disorders were 
determined in a variety of different ways using a combination of scales such as the SCID-I, ASI (Addiction Severity 
Index)(McLellan et al., 1992a, McLellan et al., 1980), CIDI (Composite International Diagnostic Interview)(Robins et 
al., 1988), TLFB (Time-Line Follow-Back)(Sobell and Sobell, 1992), as well as locally derived instruments i.e. 
Substance Use Questionnaire (Sevy et al., 2011), Quantitative Substance Use Inventory (Akerele and Levin, 2007). 
Primary outcomes of relating to mental state changes were measured using the PANSS for positive and negative 
psychotic symptoms (Kay et al., 1987), Schedule for the Assessment of Negative Symptoms (SANS) (Andreasen, 1982) 
for negative symptoms, SADS-C-PD for positive symptoms (Endicott and Spitzer, 1978), Brief Psychiatric Rating Scale 
(BPRS) (Lukoff et al., 1986) for positive and negative symptoms of psychosis, Hamilton Depression Rating Scale 
(HAM-D)(Hamilton, 1960) for depression and the Clinical Global Impression Scale (Guy, 1976a), for clinical global 
change. Primary outcomes relating to substance use were measured using a combination of methods, in many cases a 
combination of urine testing and substance use screening and diagnostic instruments (i.e. TLFB, ASI, Quantitative 
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Substance Use Inventory, Substance use Questionnaire). Subjective-wellbeing under neuroleptics was measured by the 
Subjective-wellbeing Under Neuroleptics Scale (SWN) (de Haan et al., 2002, Naber, 1995) and craving for substances 
by a variety of scales across studies, i.e. the Cocaine Craving Report (Weddington et al., 1990), Desires for Drug 
Questionnaire (Franken et al., 2002), Marijuana Craving Report (Weddington et al., 1990), Marijuana Craving 
Questionnaire (Heishman et al., 2009), Obsessive Compulsive Drug Use Scale (Dekker et al., 2012). Adherence to 
medication was not formally measured using scales but missed medication doses and medication discontinuation was 
recorded. Adverse effects were measured using the Barnes Akathisia rating scale (Barnes, 1989), Simpson Angus Scale 
(parkinsonism) (Simpson and Angus, 1970) and the Abnormal Involuntary Movement Scale (AIMS) (Schooler and 
Kane, 1982).  
7.3.4 Quality of included studies 
Risk of bias pertaining to allocation concealment or sequence generation was unclear for most studies with the exception 
of two studies (Machielsen et al., 2014, Sevy et al., 2011) for which sequence generation was adequate and judged to 
be at low risk of bias, and one study (Machielsen et al., 2014) for which allocation concealment was judged to be at low 
risk of bias (Fig 7.3). For blinding of personnel, performance bias was judged as high for five studies for which either 
the personnel or participants were aware of the treatments received or where blinding due to weekly blood tests for 
clozapine in the absence of any arrangement to maintain blinding was not reported (Brunette et al., 2011, Machielsen et 
al., 2014, Noordsy and Green, 2010, Sevy et al., 2011, Smelson et al., 2006). For blinding of outcome assessment, two 
studies where outcomes assessors were blinded were judged as low risk of bias (Brunette et al., 2011, Sevy et al., 2011), 
but for all the remaining studies risk of bias was unclear. For four studies we judged the risk of attrition bias as being 
high, due to large numbers of attrition (Swartz et al., 2008), unbalanced numbers in leaving between treatments (Akerele 
and Levin, 2007) differing reasons for attrition between medications (Noordsy and Green, 2010), the use of only single 
imputation methods (Swartz et al., 2008, van Nimwegen et al., 2008b) and the absence of data on baseline differences 
in groups that dropped out (van Nimwegen et al., 2008b). For one study (Smelson et al., 2006), for which the primary 
and only outcome was attrition, we judged the risk of bias to be low. For three studies (Brunette et al., 2011, Machielsen 
et al., 2014, Sevy et al., 2011), risk of attrition bias was judged as unclear as the number of participants that failed to 
complete the study was either not reported across the randomised groups, or only simple imputation methods were used 
to account for missing data in analyses, or the impact of attrition on the study specific outcomes were not clear. We 
judged risk of selective outcome reporting to be low for two studies (Brunette et al., 2011, Machielsen et al., 2014) 
where the study protocols were published and where there were no differences in the outcomes stated in protocol and 
the studies. In one study (Noordsy and Green, 2010) the method of determining the outcome differed from the protocol 
and we judged selective outcome reporting to be high, whereas the remainder of studies had unclear risk of selective 
outcome reporting. Four studies, sponsored by the pharmaceutical industry were judged as having high risk of “other 
bias” (Akerele and Levin, 2007, Brunette et al., 2011, Smelson et al., 2006, van Nimwegen et al., 2008b), three studies 
for which the authors received support from the pharmaceutical industry was judged as unclear for “other bias” (Noordsy 
and Green, 2010, Sevy et al., 2011, Swartz et al., 2008), and one study sponsored only by an academic department as 
low risk for “other bias” (Machielsen et al., 2014).
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Table 7.1 Characteristics of included studies 
Authors and year Design + setting Population Comparisons Outcomes 
Akarele, 2007 Superiority, parallel group, 
single site, 14-week duration 
Outpatients, USA 
 
N=28, SCID-Ia schizophrenia or 
schizoaffective disorder and co-
occurring cannabis and cocaine use 
disorders.  
Risperidone (N=14) (oral) vs. 
olanzapine (N=14) 
Useable data: HAM-Dd change score, SASe , leaving study early 
Unable to use: PANSSf scores, Substance use, Marijuana and Cocaine 
Craving Report, adherence, AIMSg  
Brunette, 2011 Superiority, parallel group, 
randomised trial, 12 weeks 
duration Outpatients, USA. 
N=31, SCID-I schizophrenia or 
schizoaffective disorder and cannabis 
use disorder.  
Other antipsychotics (N=16, 
with N=5 risperidone) vs. 
clozapine (N=15) 
Unable to use:  
Mental state: (BPRSh, CGIi, SANSj), Cannabis use (TLFBk), SATSl 
Single-Item Contemplation ladder, SAS, BARSm, AIMS   
Machielsen, 2014 Superiority, parallel group, 
randomised trial. Duration: 4 
weeks. Inpatients and 
outpatients. Netherlands 
 
N=39, DSM-IV schizophreniform, 
schizophrenia, schizoaffective 
disorder, N=31 with co-occurring 
CIDIb diagnosed cannabis use 
disorder. 
Risperidone (oral) (N=16) vs. 
clozapine (N=15) 
Useable data: 
Mental state: PANSS  
Substance use: Number discontinuing cannabis use, SWNn scale, MCQo, 
OCDUSp, Adherence to medication, EPSE, Leaving the study early 
Noordsy, 2010 Superiority, parallel group, 
randomised trial, 24-week 
duration, outpatients. USA 
N=14, SCID-I schizophrenia or 
schizoaffective disorder and co-
occurring cannabis use disorder. 
Risperidone (N=7) vs. 
Clozapine (N=7) 
Useable data: Mental state: worsening of psychotic, anxiety symptoms  
Cannabis use (TLFB), urine tests, collateral reports, and monthly clinician 
ratings, final expert clinician rating. Adverse effects, Leaving the study early 
Unable to use: Mental state: BPRS, CGI, SANS 
Sevy, 2011 Secondary data-analysis of 
existing superiority, parallel 
group, randomised trial, 4 
months duration, Inpatients. 
USA 
N=120, SCID-I schizophreniform, 
schizophrenia, schizoaffective 
disorder and N=49 subgroup with co-
occurring cannabis sue disorder. 
Risperidone (N=21) vs. 
olanzapine (N=28) 
Useable data: 
SADS-C-PDq scale, 
Substance use: stopped using cannabis or alcohol, leaving the study early 
 
Smelson, 2006 Secondary data-analysis from 
existing superiority, parallel 
group, randomised trial, 12-
month duration, mainly 
outpatient clinics, USA.  
N=664, DSM-IV schizophreniform, 
schizophrenia and schizoaffective 
disorder, N=236 subgroup with ASIc 
defined co-occurring illicit drug or 
alcohol use disorder. 
Risperidone (N=76) vs. 
Olanzapine 
(N=85) vs.  
Conventional antipsychotics 
(perphenazine, loxapine, 
haloperidol, fluphenazine, 
thiothixene) (N=75) 
Unable to use: 
Time to discontinuation  
Numbers discontinuing treatment  
Swartz, 2008 Secondary data-analysis from 
an existing superiority, 
parallel group, randomised 
trial, 18-month duration. 
Setting 57 sites in USA. 
N=1432, SCID-I multi-episode 
schizophrenia, N=643 subgroup with 
alcohol or illicit drug use (CDUS, 
CAUS, SCID-I and urine testing) 
 
Risperidone (N=157) 
 vs. Quetiapine (N=137) vs. 
Olanzapine (N=142) vs. 
Perphenazine (N=124) vs. 
Ziprazidone (N=83) 
Leaving the study early (any reason) 
Unable to use: PANSS, CGI, Readmission rate, Adherence to antipsychotic 
medication, Adverse events: weight gain, neurological side-effects 
Van Nimwegen, 
2008 
Subgroup with substance 
(cannabis), superiority, 
parallel group, 6-week 
duration. Outpatients. 
Netherlands. 
N=138, SCID-I schizophreniform, 
schizophrenia, schizoaffective 
disorders, N=41 subgroup with co-
occurring cannabis use disorder 
Risperidone (N=21) vs. 
olanzapine (N=20) 
Cannabis use self-report scores- change data (joints per week) 
OCDUS, DDQ, Leaving the study early 
Unable to use: SWN 
 
a. Structured Clinical Interview for DSM-IV, b. Composite International Diagnostic Interview, c. Addiction Severity Index, d. Hamilton Depression Rating Scale, e. Simpson Angus Scale, f. Positive and 
Negative Symptom Scale, g. Abnormal Involuntary Movement Scale, h. Brief Psychiatric Rating Scale, i. Clinical Global Impression scale, j. Schedule for the Assessment of Negative Symptoms, k. Time-Line 
Follow-back, l. Substance Abuse Treatment Scale, m. Barnes Akathisia Rating Scale, n. Subjective-wellbeing Under Neuroleptics Scale, o. Marijuana Craving Questionnaire, p. Obsessive-Compulsive Drug Use 
Scale, q. Schedule for Affective Disorders and Schizophrenia- Change Version - Psychosis and Disorganization items 
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Table 7.2 Scales, diagnostic instruments and other outcome measures used in included studies 
Diagnostic tools Abbreviation Source of scale/ instrument Study using instrument Results reported or usable data for re-analysis 
Structured Clinical Interview for DSM Disorders SCID-I First 1994 Akerele 2007; Sevy 2011; Swartz 2008; van 
Nimwegen 2008 
Not an outcome measure 
Mental state scales     
Brief Psychiatric Rating Scale BPRS Lukoff 1986  Noordsy 2010  No results or usable data reported or obtained 
Clinical Global Impression scale CGI Guy 1976  Akerele 2007; Noordsy 2010 No results or usable data reported or obtained 
Hamilton Depression Rating Scale HAM-D Hamilton 1960  Akerele 2007  Results reported; usable data for quantitative synthesis 
Positive and Negative Syndrome Scale PANSS Kay 1986  Akerele 2007;Greenspan 2005; Machielsen 
2014; Swartz 2008 
Results reported; usable data for quantitative synthesis 
Schedule for Affective Disorders and Schizophrenia SADS-C-PD Endicott 1978  Sevy 2011  Results reported; usable data for quantitative synthesis 
Schedule for the Assessment of Negative Symptoms SANS Andreasen 1982  Noordsy 2010  No results or usable data reported or obtained 
Substance use scales     
Addiction Severity Index ASI McLellan 1980; McLellan 1992 Akerele 2007  No results or usable data reported or obtained 
Composite International Diagnostic Interview CIDI Robins 1988  Machielsen 2014  Not an outcome measure 
Substance Use Questionnaire SUQ Sevy 2011, Locally derived Sevy 2011  Results reported; usable data 
Time-Line Follow-Back TLFB Sobell 1992  Noordsy 2010  Results reported in dichotomised  
Quantitative Substance Use Inventory 
 
Locally derived instrument/ non-validated Akerele 2007  Non-validated scale 
Subjective-Wellbeing Scales     
Subjective Well-being Under Neuroleptics Scale SWN de Haan 2002; Naber 1995 Machielsen 2014; van Nimwegen 2008 Results reported; usable data for quantitative synthesis 
Craving for substances measures     
Cocaine Craving Report   Weddington 1990  Akerele 2007  No usable data for quantitative synthesis 
Desires for Drug Questionnaire DDQ Franken 2002  van Nimwegen 2008  Results reported; usable data for quantitative synthesis 
Marijuana Craving Report   Weddington 1990  Akerele 2007  No usable data for quantitative synthesis 
Marijuana Craving Questionnaire MCQ Heishman 2009  Machielsen 2014  Results reported; usable data for quantitative synthesis 
Obsessive Compulsive Drug Use Scale OCDUS Dekker 2012  Machielsen 2014;van Nimwegen 2008 Results reported; usable data for quantitative synthesis 
Adverse effect scales     
Abnormal Involuntary Movement Scale AIMS National Institute of Mental Health 1988  Akerele 2007  No results or usable data reported or obtained 
Barnes Akathisia Rating Scale BARS Barnes 1989  Brunette 2011  No results or usable data reported or obtained 
Simpson Angus Scale SAS Simpson 1970  Akerele 2007  Results reported; usable data for quantitative synthesis 
Other measures      
Urine assay for cannabis and cocaine use      Akerele 2007  No usable data for quantitative synthesis 
Substance use improved/not-improved/unchanged     Noordsy 2010  Results reported; usable data for quantitative synthesis 
Days of self-reported drug use in past week     Akerele 2007  No usable data for quantitative synthesis 
Weeks in treatment     Akerele 2007; Smelson 2006 Results reported; usable data for quantitative synthesis 
Number of participants not completing the study     Akerele 2007; Machielsen 2014; Noordsy 
2010; Sevy 2011; Swartz 2008 
Results reported, usable data for quantitative synthesis 
Compliance with medication (missed doses)     Akerele 2007  No usable data for quantitative synthesis 
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Across the body of evidence for the various pooled outcomes, we identified 7 outcomes as critical or important as per 
GRADE methodology. The quality of evidence was often downgraded by two or more levels from high quality to low 
or very low quality due to serious/ very serious risk of bias or in many cases due to  imprecision as a result of small 
samples sizes (See “Summary of Findings” tables 7.3 to 7.7). 
Figure 7.3. Summary of risk of bias assessment 
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7.3.5 Comparison 1: Risperidone versus clozapine 
Two studies containing short term (up to 6 months) data on 50 participants contributed to this comparison (Machielsen 
et al., 2014, Noordsy and Green, 2010). (See Summary of Findings tables 7.3; figures 7.4 to 7.8 and tables 9.5 in 
appendix for analyses). For the primary outcomes  of mental state there were no clear differences between risperidone 
and clozapine at study endpoint in the PANSS general psychopathology (fig. 7.4) (Analysis 1.1) or positive subsubscale 
measures (fig.7.6)(Analysis 1.1, Analysis 1.3) (Machielsen et al., 2014), and  no signifcant differences in terms of 
worsening of psychotic symptoms (fig. 7.5)(Analysis 1.2) (Noordsy and Green, 2010). For negative symptoms patients 
on clozapine had significantly lower scores (fig. 7.6)(Analysis 1.3.2) (Machielsen et al., 2014) No significant differences 
were found for the worsening of anxiety symptoms (fig. 7.7)(Analysis 1.4) (Noordsy and Green, 2010). There were no 
significant differences between risperidone and clozapine in the number of participants who reduced or stopped using 
cannabis (fig 7.8)(Analysis 1.5.) (Machielsen et al., 2014, Noordsy and Green, 2010). 
For secondary outcomes, in the one study that contributed data (Machielsen et al., 2014) there were no signifcant 
differnces in endpoint scores on the subjective well-being under neuroleptics scale (Appendix table 9.5, Analysis 1.6). 
However, for cannabis craving participants on clozapine had significantly lower scores on the Marijuana Craving 
Questionnaire (MCQ) and Obsessive-Compulsive Craving Scale (OCDUS)(Appendix table 9.5, Analysis 1.7). There 
were no significant differences in the number of participants who discontinued antipsychotic treatment (Appendix table 
9.5, Analysis 1.8). Two studies reported no significant differences in the number of participants who experienced any 
extrapyramidal side-effects (Appendix table 9.5, Analysis 1.9) (Machielsen et al., 2014, Noordsy and Green, 2010), and 
one study (Noordsy and Green, 2010) reported  no significant differences for akathisia (Appendix table 9.5, Analysis 
1.9). For non-movement disorder related side-effects one study (Noordsy and Green, 2010) reported no significant 
differences for central-nervous system, cardiovascular, gastrointestinal,  renal, musculoskeletal, dermatological, 
metabolic, endocrinological related adverse effects (Appendix table 9.5, Analysis 1.10). In turn, there were no 
significant differences between risperidone and clozapine in participants in leaving the study early for any reason 
(Machielsen et al., 2014, Noordsy and Green, 2010) (Appendix table 9.5, Analysis 1.11). 
7.3.6 Comparison 2: Risperidone versus olanzapine 
A total of five studies contributed data (N=1023) to this comparison (Akerele and Levin, 2007, Sevy et al., 2011, 
Smelson et al., 2006, Swartz et al., 2008, van Nimwegen et al., 2008b). All outcomes, with the exception of leaving the 
study early were short term, i.e. up to 6 months (See Summary of Findings table 7.4). For primary mental state outcomes, 
there were no significant differences in depression scores on the HAM-D (Akerele and Levin, 2007) (fig. 7.9)(Appendix 
table 9.6, Analysis 2.1), SADS-C-PD measured overall positive psychotic symptoms (fig. 7.10)( Appendix table 9.6, 
Analysis 2.2) (Sevy et al., 2011), or negative symptoms as measured by the SANS (Sevy et al., 2011) (fig. 
7.11)(Appendix table 9.6, Analysis 2.4). For substance use outcomes there were no significant differences in the number 
of cannabis joints smoked per week(van Nimwegen et al., 2008b)(fig. 7.12)( Appendix table 9.6, Analysis 2.5) or the 
number of participants discontinuing cannabis or alcohol use during the study (Sevy et al., 2011)(fig. 7.13)( Appendix 
table 9.6, Analysis 2.6). There were no significant differences in craving for substances as measured either by the 
OCDUS or the DDQ (van Nimwegen et al., 2008b)( Appendix table 9.6, Analyses 2.7 and 2.8). There were no significant 
differences between risperidone treated or olanzapine treated patients in terms of parkinsonism (Akerele and Levin, 
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2007) or BMI measured weight gain (Sevy et al., 2011)( Appendix table 9.6, Analysis 2.9). There were no significant 
differences between risperidone and olanzapine treated patients for leaving the study early for any reason short term (up 
to 6 months) (Akerele and Levin, 2007, Sevy et al., 2011), or any reason medium term (up to 12 months)(Swartz et al., 
2008), due to readmission to hospital, intolerable adverse effects or loss of interest (Akerele and Levin, 2007) (Appendix 
table 9.6, Analysis 2.10). 
7.3.7 Comparison 3: Risperidone versus perphenazine 
One study (Swartz et al., 2008) reported useable data on only one outcome (long term> 12 months), i.e. leaving the 
study early, for which there was no signifcant difference between the risperidone and perhenapzine treated groups 
(Summary of Findings table 7.5)(Appendix table 9.7, Analysis 3.1). 
7.3.8 Comparison 4: Risperidone versus quetiapine 
One study (Swartz et al., 2008) reported useable data on only one outcome (long term> 12 months), i.e. leaving the 
study early, for which there was no signifcant difference between the risperidone and quetiapine treated groups 
(Summary of Findings table 7.6)(Appendix table 9.8, Analysis 4.1). 
7.3.9 Comparison 5: Risperidone versus ziprasidone 
One study (Swartz et al., 2008) reported useable data on only one outcome (long term> 12 months), i.e. leaving the 
study early, for which there was no signifcant difference between  the risperidone and ziprasidone treated groups 
(Summary of Findings table 7.7)(Appendix table 9.9, Analysis 5.1). 
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Table 7.3 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months) for people with severe mental 
illness and co-occurring substance misuse 
Outcomes Anticipated absolute effects* (95% CI) Relative 
effect 
(95% CI) 
№ of 
participa
nts 
(studies) 
Quality of the 
evidence 
(GRADE) 
Comments 
Risk with 
Clozapine 
Risk with Risperidone 
Mental state: Positive 
symptoms - average 
endpoint score 
(PANSS positive 
subscale, lower=better) 
 
The mean positive symptoms 
(PANSS positive subscale, 
lower=better) in the 
intervention group was 0.9 
higher (2.21 lower to 4.01 
higher) 
- 36 
(1 RCT) 
⊕⊝⊝⊝ 
very low 1 2 
No trial reported 
"improvement in 
symptoms of severe 
mental illness"- this 
continuous measure is 
the nearest proxy for 
this. 
Substance use: 
Improvement - (at 
least 20% reduction in 
use, TLFB scale) 
Study population RR 1.00 
(0.30 to 3.35) 
14 
(1 RCT) 
⊕⊝⊝⊝ 
very low 3 4 
 
429 per 
1,000 
429 per 1,000 
(129 to 1,000) 
Moderate 
429 per 
1,000 
429 per 1,000 
(129 to 1,000) 
Subjective Well-being: 
Subjective well-being 
under neuroleptics 
scale- average 
endpoint scores (SWN 
scale, higher=better) 
 
The mean subjective well-
being under neuroleptics scale 
score (SWN scale, 
higher=better) in the 
intervention group was 6 
lower (14.82 lower to 2.82 
higher) 
- 36 
(1 RCT) 
⊕⊝⊝⊝ 
very low 1 2 
 
Craving for 
substances: Marijuana 
Craving 
Questionnaire- average 
endpoint scores (MCQ, 
lower=better) 
 
The mean craving for 
substances score on the 
Marijuana Craving 
Questionnaire (MCQ, 
lower=better) in the 
intervention group was 7 
higher (2.37 higher to 11.63 
higher) 
- 28 
(1 RCT) 
⊕⊝⊝⊝ 
very low 1 2 
 
Adherence to 
antipsychotic 
medication: 
discontinued 
medication 
Study population RR 4.05 
(0.21 to 78.76) 
36 
(1 RCT) 
⊕⊝⊝⊝ 
very low 1 2 
 
0 per 
1,000 
0 per 1,000 
(0 to 0) 
Moderate 
0 per 
1,000 
0 per 1,000 
(0 to 0) 
Adverse effects. 1. 
Movement disorders - 
any extrapyramidal 
Study population RR 2.71 
(0.30 to 24.08) 
50 
(2 RCTs) 
⊕⊝⊝⊝ 
very low 5 6 
Many adverse effects 
reported - none 
designated 'clinically 
important' 
(extrapyramidal used 
as proxy). 
0 per 
1,000 
0 per 1,000 
(0 to 0) 
Moderate 
0 per 
1,000 
0 per 1,000 
(0 to 0) 
Leaving the study 
early - any reason 
Study population RR 0.49 
(0.10 to 2.51) 
45 
(2 RCTs) 
⊕⊝⊝⊝ 
very low 5 6 
 
318 per 
1,000 
156 per 1,000 
(32 to 799) 
Moderate 
386 per 
1,000 
189 per 1,000 
(39 to 968) 
1 High risk of performance bias and detection bias 
2 Sample size is very small, optimal information size (OIS) not met to detect 25% difference 
3 Performance bias, attrition bias, selective outcome reporting 
4 Sample size is very small (n=14) 
5 High risk of performance bias, detection bias, attrition bias and selective outcomes reporting 
6 Total sample size is very small (n<300), total event rate is very low and optimum information size (OIS) is not met 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative 
effect of the intervention (and its 95% CI).CI: Confidence interval; RR: Risk ratio 
93 
 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate 
of effect 
 
Table 7.4 RISPERIDONE versus OLANZAPINE- all data short term (up to 6 months) for people with severe 
mental illness and co-occurring substance misuse 
Outcomes Anticipated absolute effects* (95% CI) Relative 
effect 
(95% CI) 
№ of 
particip
ants 
(studies) 
Quality of 
the evidence 
(GRADE) 
Comments 
Risk with 
Olanzapine 
Risk with Risperidone 
Mental state: 2. 
Specific- Positive 
symptoms, total score- 
average endpoint 
scores (SADS-C-PD 
scale, lower=better) 
 
The mean positive symptoms 
total score at endpoint (SADS-
C-PD scale, lower=better) in 
the intervention group was 1.5 
lower (3.82 lower to 0.82 
higher) 
- 37 
(1 RCT) 
⊕⊝⊝⊝ 
very low 1 2 
 
Substance use: 1. 
Reduction of cannabis 
use-change data 
(number of joints 
smoked/week) 
 
The reduction of cannabis 
joints smoked (number of 
joints smoked/week-short 
term data, up to 6 months) in 
the intervention group was 0.4 
higher (4.72 lower to 5.52 
higher) 
- 41 
(1 RCT) 
⊕⊝⊝⊝ 
very low 3 4 
 
Subjective well-being 
 
- - - No trial reported on 
this important 
outcome  
Craving for 
substances: 2. Drug 
Desires Questionnaire- 
average endpoint 
scores (DDQ, 
lower=better) 
 
The mean endpoint. Drug 
Desires Questionnaire- 
endpoint scores (DDQ, 
lower=better), short term, up 
to 6 months-in the 
intervention group was 5 
higher (4.86 lower to 14.86 
higher) 
- 41 
(1 RCT) 
⊕⊝⊝⊝ 
very low 2 3 
 
Adherence to 
antipsychotic 
medication: number of 
missed doses, average 
endpoint data, short 
term (up to 6 months)  
- - - - no useable data 
available for this 
outcome 
Adverse effects: 
Parkinsonism - 
average endpoint score 
(SAS, high = worse) 
 
The mean adverse effects: - 
Parkinsonism- average 
endpoint score (SAS, high = 
worse)- short-term- up to 6 
months in the intervention 
group was 0.08 lower (1.21 
lower to 1.05 higher) 
- 16 
(1 RCT) 
⊕⊝⊝⊝ 
very low 2 5 
 
Leaving study early: 
any reason 
Study population RR 0.68 
(0.34 to 
1.35) 
77 
(2 RCTs) 
⊕⊝⊝⊝ 
very low 4 6 
 
357 per 
1,000 
243 per 1,000 
(121 to 482) 
Moderate 
411 per 
1,000 
279 per 1,000 
(140 to 554) 
1 High risk for performance bias, allocation concealment, unknown risk for attrition and slective reporting 
2 Very low sample size, optimal information size (OIS) not met 
3 High risk of attrition bias, study sponsored by pharmaceutical industry 
4 Very low sample size, optimal information criterion not met, CI crosses both appreciable harm and benefit 
5 High attrition risk, high other risk of funding by pharmaceutical industry, all other risk items unclear risk of bias 
6 High risk of performance, attrition and funding bias. Several domains with unclear risk of bias 
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group 
and the relative effect of the intervention (and its 95% CI).CI: Confidence interval; RR: Risk ratio 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of 
the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different 
from the estimate of effect 
 
Table 7.5 RISPERIDONE versus PERPHENAZINE-long term data (>12 months) for people with severe 
mental illness and co-occurring substance misuse 
Outcomes Anticipated absolute effects* (95% CI) Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Quality of the 
evidence 
(GRADE) 
Comments 
Risk with 
PERPHENAZINE 
Risk with 
RISPERIDONE 
Leaving the study 
early: any reason 
Study population RR 1.05 
(0.92 to 
1.20) 
281 
(1 RCT) 
⊕⊕⊝⊝ 
low 1 2 
 
750 per 1,000 788 per 1,000 
(690 to 900) 
Moderate 
750 per 1,000 788 per 1,000 
(690 to 900) 
1 High risk of attrition bias, but this does not affect this particular outcome 
2 Optimal information size criterion is met but the estimate includes no effect with both appreciable harm and benefit 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group 
and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of 
the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different 
from the estimate of effect 
 
Table 7.6 RISPERIDONE versus QUETIAPINE- short- and long-term data (up to 6months and > 12 
months) for people with severe mental illness and co-occurring substance misuse 
Outcomes Anticipated absolute effects* (95% 
CI) 
Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Quality of the 
evidence 
(GRADE) 
Comments 
Risk with 
QUETIAPINE 
Risk with 
RISPERIDONE 
Leaving the study early: 
1. any reason, long term 
(>12 months) 
Study population RR 0.96 
(0.86 to 
1.07) 
294 
(1 RCT) 
⊕⊕⊝⊝ 
low 1, 2 
 
825 per 1,000 792 per 1,000 
(709 to 883) 
Moderate 
825 per 1,000 792 per 1,000 
(709 to 883) 
1 Outcome not affected by risk of attrition bias 
2 Optimal information criterion not met, estimate includes both appreciable harm and benefit 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group 
and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of 
the effect 
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Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different 
from the estimate of effect 
 
 
Table 7.7 RISPERIDONE versus ZIPRASIDONE- all data long term data (>12 months) for people with severe mental 
illness and co-occurring substance misuse 
Outcomes Anticipated absolute effects* (95% CI) Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Quality of the 
evidence 
(GRADE) 
Comments 
Risk with 
ZIPRASIDONE 
Risk with 
RISPERIDONE 
Leaving the study early: 
any reason 
Study population RR 0.96 
(0.85 to 
1.10) 
240 
(1 RCT) 
⊕⊕⊝⊝ 
low 1 2 
 
819 per 1,000 787 per 1,000 
(696 to 901) 
Moderate 
819 per 1,000 787 per 1,000 
(696 to 901) 
1 Risk of attrition bias high but this does not affect this outcome 
2 Optimal information size criterion met but estimate includes both appreciable harm and benefit. Total sample size small 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative 
effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate 
of effect 
 
Figure 7.4 Risperidone vs. Clozapine: Mental state outcomes: PANSS general psychopathology endpoint score 
 
Figure 7.5 Risperidone vs. Clozapine: Mental state outcome: Any change (worsening) in psychotic symptoms 
 
Figure 7.6. Risperidone vs. Clozapine: Mental state outcome: Differences in end-point PANSS positive and negative 
subscales  
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Figure 7.7 Risperidone vs. Clozapine: Mental state outcome: Reduction in anxiety symptoms 
 
Figure 7.8 Risperidone vs. Clozapine: Substance use: Reduction (TLFB) or cessation of substance use  
 
Figure 7.9 Risperidone vs. Olanzapine: Mental state: reduction in HAM-D depression scores 
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Figure  7.10  Risperidone vs. Olanzapine: Mental state: reduction positive symptoms (SADS-C-PD) 
 
 
 
 
 
 
Figure 7.11   Risperidone vs. Olanzapine: Mental state: reduction negative symptoms (SANS) 
 
Figure 7.12  Risperidone vs. Olanzapine. Substance use: reduction in cannabis joints/week 
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Figure 7.13 Risperidone vs. Olanzapine: Substance use: cessation of cannabis or alcohol use 
 
7.4. Discussion 
7.4.1 Summary of main results 
For the comparison of risperidone versus clozapine only two studies, containing useable data for 50 participants, 
provided data (Machielsen et al., 2014, Noordsy and Green, 2010). We were unable to extract useable data from a third 
study (Brunette et al., 2011). We found no statistically significant differences between risperidone and clozapine for 
most of the primary mental state outcomes (improvement in general psychopathology, positive symptoms or anxiety), 
substance use outcomes, subjective-wellbeing, medication adherence, movement disorder related side-effects, other 
side-effects or leaving the study early. Exceptions were significantly lower negative symptoms and craving for 
clozapine, although this was found only in one very small study (N=36). No results were reported on mortality or quality 
of life, and side-effects such as weight gain and metabolic syndrome were inconsistently reported. 
For risperidone vs. olanzapine five studies containing data on 997 participants provided data for this comparison 
(Akerele and Levin, 2007, Sevy et al., 2011, Smelson et al., 2006, Swartz et al., 2008, van Nimwegen et al., 2008b). 
Studies differed in design, measure of outcomes as well as in the quality of data reporting, precluding pooling and re-
analysis of data. There were no significant differences between risperidone and olanzapine for primary outcome data, 
i.e. reduction in any mental symptoms (depression, positive or negative symptoms). In turn, for substance use outcomes 
there were no differences in the number of cannabis joints smoked or participants discontinuing alcohol or cannabis, 
and in another study no differences in drug craving were found (van Nimwegen et al., 2008b). In turn there were no 
significant differences in risperidone vs. olanzapine in terms of side-effects (Parkinsonism or weight gain) or time to 
medication discontinuation. For risperidone versus perphenazine, quetiapine and ziprasidone, there were no differences 
in the time to all reason medication discontinuation for any of these comparisons. 
Our findings agree with the findings of a number of other reviews that drew similar conclusions, i.e. that there seems to 
be little difference between risperidone and other antipsychotics in people with serious mental illness and co-occurring 
substance use disorders (Baker et al., 2010, Baker et al., 2012a, Lazary, 2012a, Machielsen and de Haan, 2009, 
McLoughlin et al., 2014a, Wobrock and Soyka, 2009b). Some reviews (Machielsen and de Haan, 2009) place more 
emphasis on the possibility of there being some superiority for clozapine over other antipsychotics including risperidone, 
although they emphasise caution due to a paucity of studies. Of note other reviews used different methods to appraise 
quality of evidence and derive recommendations (other than the GRADE methodology), as well as differences on the 
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type of studies included in these reviews (which in some cases included observational, pseudorandomised and 
randomised trials).  
7.4.2 Quality of included studies 
Overall, of the 8 studies included in this review, across most studies reporting of results were poor and did not adhere 
to CONSORT standards (1996). As a result, many outcomes reported on, yielded unusable data. In turn, many outcomes 
such as adverse metabolic effects, subjective well-being, quality of life, mortality and craving were either not reported 
or incompletely reported. Sample sizes were small across most studies. Risk of bias was unclear in most domains across 
the included studies, however in some instances there was high risk of bias particularly with regards to performance 
bias, attrition bias, selective outcome reporting and other forms of bias. Moreover, due to heterogeneity in design and 
poor outcome reporting, pooling of data in meta-analyses was not possible for most outcomes leading to imprecise effect 
estimates and precluding any meaningful analysis of results and yielding low to very low-quality evidence for the main 
outcomes. 
7.4.3 Generalisability of findings 
Six of the studies were conducted in the United States of America (Akerele and Levin, 2007, Brunette et al., 2011, 
Noordsy and Green, 2010, Sevy et al., 2011, Smelson et al., 2006, Swartz et al., 2008) and two in the Netherlands 
(Machielsen et al., 2014, van Nimwegen et al., 2008b). With the exception of one study comparing risperidone to a first-
generation antipsychotic (perphenazine) (Swartz et al., 2008) and another with a combined outcome group with several 
different first-generation antipsychotics grouped together (Smelson et al., 2006),  there was a paucity of studies with 
useable comparing risperidone with other fist-generation antipsychotics. This limits the applicability of the findings to 
low and middle income and developing countries where first-generation antipsychotics may be more readily available. 
Most participants were male, limiting generalisability of findings to female populations.  
7.4.4 Limitations, potential biases of the review 
Our search was conducted within the Cochrane Schizophrenia Group’s Trials Register and the Cochrane Collaboration 
Depression, Anxiety and Neurosis Controlled Trials Register. We did not include searches of the Drugs and Alcohol 
group register. This may have led to some studies being missed that examine treatments for substance use disorders that 
may have contained some participants with serious mental illness, although this is unlikely. 
We also contacted authors to clarify reporting of studies and to provide missing data. Following our extensive search, 
we are not aware of any additional studies in this field, but we are open to review the evidence and would call upon 
authors to contact us should there be any trial that warrant consideration for inclusion. 
7.4.5 Implications for treatment and future research 
Reviews and pharmacological treatment guidelines for people with a dual diagnosis that suggest that second-generation 
antipsychotics (SGAs) such as risperidone may be the preferred treatment in this population needs to be interpreted with 
caution. In particular, we found no evidence that risperidone was superior to clozapine, olanzapine, perphenazine, 
quetiapine or ziprasidone. Overall the quality of the existing evidence is low to very low and includes a very small 
number of studies with very small sample sizes. We did not find evidence suggesting superiority of risperidone over 
clozapine, olanzapine, perphenazine, quetiapine or ziprasidone for any of the primary or secondary outcomes in our 
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review. All studies were conducted in developed world, high-income country settings. Due to the paucity of comparisons 
with first-generation antipsychotics (i.e. such as haloperidol, chlorpromazine), little can be said about the treatment 
effects of risperidone compared to first-generation antipsychotics. Therefore, it may be beneficial to include less 
expensive medications such as first-generation antipsychotics (i.e. such as haloperidol, chlorpromazine) in future in 
clinical trials in people with a dual diagnosis. 
Even though people with co-occurring mental illness and addiction face a multitude of medical, social, financial and 
legal adversities, making recruitment and retention in clinical trials difficult, the conduct of multisite clinical trials is 
urgently needed. Trails investigating antipsychotics such as risperidone should not exclude people with co-occurring 
disorders.  Future trials should contain large enough samples (minimum of 300 participants), employ consistent 
methodologies in outcome assessment and adhere to CONSORT guidelines of reporting. 
7.5 Conclusion 
There currently exists no high-quality evidence that risperidone is superior to other antipsychotics in the treatment of 
people with serious mental illness and co-occurring substance use disorders. 
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Chapter 8  
Discussion of thesis findings 
8.1 Summary of main findings 
8.1.1 Part I. Epidemiology of dual diagnosis: summary of main findings 
In Part I of this thesis I aimed to investigate the prevalence, distribution and associated clinical characteristics of 
substance use disorders in patients with serious mental illness. I expected to find a high prevalence of SUDs. In 
addition, I anticipated significant associations with male sex, younger age, depressive, anxiety and post traumatic 
symptoms, risky behaviours such as suicidality and legal involvement. I achieved these objectives in a secondary 
analysis of two datasets, the first based on data from a large case-control study in a homogeneous clinical and ethnic 
population across two provinces in South Africa (dataset #1, SAX study, N=1420); the second based on data from a 
dataset  that combined data from three studies (dataset #2, PRP, CIAM, SIP studies, N=248), conducted in the same 
geographic area in Cape Town in a diagnostically and ethnically heterogeneous population with a variety of major 
affective (i.e. bipolar) and non-affective (schizophrenia spectrum disorders) psychotic disorders.  
Across both studies (dataset #1 and #2) a high prevalence of any SUD was found, with approximately half of patients 
(dataset#1: 47.8% and dataset#2: 55.6%) having at least one SUD. Polysubstance use was common with 40% of 
Xhosa patients with schizophrenia (dataset#1) having more than one SUD in their lifetime, and 100% of patients 
having at least two lifetime SUDs in the analysis of dataset#2. In turn, in both studies there were strong associations 
between the various SUDs; cannabis, alcohol and methamphetamine use disorders often being associated with one 
another. The distribution of various types of SUDs was different in dataset #1 (SAX study) from that in dataset#2 
(PRP, CIAM, SIP studies). In dataset#1 (SAX study) we found the most prevalent SUD was cannabis use disorders 
(39.6%) followed by alcohol (20.5) and methaqualone (sedative hypnotic, 6.2%), and finally methamphetamine 
(4.8%). In the Cape Town sample from dataset#2, cannabis use was also the most prevalent (34.3%), even though it 
occurred at a somewhat lower level. In turn, alcohol was also the second most prevalent SUD, but occurred at higher 
levels (30.6%), whereas methamphetamine use disorders had a substantially higher prevalence of 27.4% in the Cape 
Town sample, followed by methaqualone use disorders at 10.4%. Younger age and male sex stood out as significant 
predictors of SUDs across most SUD categories in both datasets. These findings are consistent with international as 
well as local South African findings (Cantor-Graae et al., 2001b, Koskinen et al., 2009, Koskinen et al., 2010, Sara et 
al., 2015, Weich and Pienaar, 2009b). Possible reasons for the variation in distribution of cannabis, alcohol and 
methamphetamine use disorders across dataset #1 and #2, may include the fact that dataset #1 included both rural and 
urban settings across two provinces, whereas dataset#2 was confined to the Western Cape Province, in a solely urban 
environment and containing an ethnically more diverse group. Higher rates of use of methamphetamine in the Western 
Cape, in particular among Coloured participants, the predominant ethnic group in dataset #2, may also explain the 
high levels of methamphetamine use in dataset #2, with high alcohol levels due to being a solely urban sample (Myers 
et al., 2013, Herman et al., 2009, van Heerden et al., 2009). 
In turn, the odds of having a methamphetamine use disorders were statistically significantly lower for Xhosa patients 
with schizophrenia who resided in the Eastern Cape as compared to those who resided in the Western Cape. Echoing 
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these findings, in the Cape Town sample, participants self-identified as of black ethnic origin had significant reduced 
odds of having a methamphetamine use disorder compared to people from a coloured (mixed ethnic) background. 
These findings were similar to that found in non-psychiatric substance users in the Western Cape province, where 
coloured (mixed ethnic) groups were more likely to use methamphetamines compared to black African patients who 
were more likely to use cannabis (Myers et al., 2013). 
From dataset #1 a significant association between inpatient status and cannabis and methamphetamine use disorders 
was found. This finding was less clear in dataset#2 (with contributing studies in the dataset having heterogeneous 
sampling methods) where only methaqualone use disorders were associated with studies that exclusively sampled 
inpatients. These findings as well as the significant association with more prior hospitalisations in cannabis users 
(dataset#1), resonate with current thinking that cannabis and methamphetamine may contribute to worse outcomes and 
may be associated with readmissions to hospital due a potential for worsening psychosis (Weich and Pienaar, 2009b, 
Hermens et al., 2009). 
In Xhosa patients with schizophrenia a significant association was found between lifetime post-traumatic stress 
symptoms and any SUD, alcohol use disorders in particular; and with anxiety disorders (panic disorder, agoraphobia 
without a history of panic, social phobia, specific phobia, generalised anxiety disorder) and other SUDs (cocaine, 
ecstasy and opioids). For the Cape Town sample this finding was somewhat different in that anxiety symptoms and 
prior suicide attempts were associated with alcohol use disorders and no association with PTSD and any SUD were 
found.  Reasons for these differences may include the differences in distribution of ethnic groups in datasets, but also 
differences in the prevalence and distribution of various SUDs and differences in anxiety, post-traumatic and 
obsessive-compulsive disorder prevalence across the two datasets. Interestingly, in chapter 3 dataset #1 revealed a 
very low prevalence of anxiety disorders, PTSD and OCD among Xhosa speaking patients. This contrasts with higher 
a prevalence of anxiety, post-traumatic and OCD in the Cape Town sample in chapter 4, dataset #2, a finding which is 
more in keeping with research in non-psychotic, community based samples in South Africa (Stein et al., 2008). 
Reasons for this are unclear, and although application of diagnostic hierarchy rules could have led to lower anxiety 
disorder diagnoses, other reasons such as differences across two datasets in terms of  phase of illness (> 2 year history 
of schizophrenia diagnosis in dataset #1 and various durations of illness in dataset #2), geographic location (urban and 
rural in dataset #1, only urban in dataset #2), treatment setting ( more outpatients in dataset #2, i.e. 42% vs. only 32% 
in dataset #1), may have contributed and may warrant further investigation (Achim et al., 2011). Moreover, for 
dataset#1, only current MDE symptoms and suicidality was available, whereas for dataset#2, lifetime major 
depressive symptoms and suicidality were also available. These findings are in accordance with other studies that have 
found an association with panic and alcohol use disorders (Goodwin et al., 2003) and PTSD and having a dual 
diagnosis (Scheller-Gilkey et al., 2004b). The finding of an association of suicide attempts with alcohol use disorders 
(dataset#2) is in agreement with other studies that have found associations with suicide attempts, impulsivity and 
SUDs (Gut-Fayand et al., 2001, Rush and Koegl, 2008), and an association with suicide attempts and alcohol use 
disorders in particular (Soyka et al., 1993). 
In both datasets there was a significant association between legal problems and SUDs. In dataset #2, a common 
association was between SUDs and reported arrests for less serious and non-violent crimes, i.e. possession of illegal 
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substances, weapons offense, prostitution, disorderly conduct in public, major driving violations and driving under the 
influence of substances. In fact, less serious crimes were more than twice as prevalent compared to major and serious 
violent crimes. Nevertheless, major crimes as well as serious and violent crimes were also associated with SUDs; 
methaqualone and other SUDs in particular. These findings resonate with findings from the US where the most 
common crimes in patients with schizophrenia and related psychoses were crimes against public order, however 
serious and less serious violent crimes were also associated with co-occurring SUDs (McCabe et al., 2012). 
In turn, despite the high occurrence of SUDs, histories of treatment for SUDs were very low and were only reported 
by 23.9% of those with a SUD. This finding is somewhat higher than a previous finding from another Cape Town 
sample (Weich and Pienaar, 2009b). This difference in findings may be due to the fact the methods of ascertaining 
whether someone had received an intervention for their SUD, differed between the two studies, with the Weich et.al. 
study based on clinical records and the current study based on case records and particular questions asking specifically 
about any in or outpatient treatment for drugs and alcohol (see appendix).  
8.1.2 Part II. Screening and diagnosis: summary of main findings 
In part II of the thesis, in a population of Xhosa patients with schizophrenia, it was demonstrated that both the SDS 
and ASSIST had good internal reliability, concurrent and discriminant validity. The receiver operating characteristics 
of the ASSIST yielded an AUC=0.86 and the SDS and AUC=0.76, meaning that for a randomly selected patient with 
schizophrenia, 86% of the time the ASSIST will yield a higher score in patients with a SUD compared to those 
without a SUD. Likewise, in 76% of patients randomly selected from a population with schizophrenia, the SDS will 
have higher scores in patients with SUDs compared to in those without SUDs. In turn, for the ASSIST a cut-off score 
of ≥6, revealed an optimal balance between sensitivity (86.8) and specificity (77.8), with positive predictive values 
(PPV) of 78.2, meaning that 78.2% of participants with a score above the cut-point will have a SUD as per the gold-
standard, SCID-I for DSM-IV defined diagnosis. Similarly, the SDS had an optimal cut-point of ≥4, which yielded a 
sensitivity of 78.3 and specificity of 71.7, a PPV of 86.2. It was also found that adding the lengthier ASSIST to the 
briefer SDS did not add any additional discriminative power to the AUC. Yet the ASSIST had somewhat more 
favourable properties at low false positive (1-specificity) levels, with higher positive likelihood ratios (LR+), therefore 
conferring better performance in lower prevalence settings. These findings are in agreement with previous studies 
using the ASSIST and SDS that found similar discriminative power, although the optimal cut-scores in our population 
were different (Hides et al., 2009a, Hides et al., 2007). Potential reasons for these differences include that fact that 
these studies had focused on a diagnostically heterogeneous, first episode psychosis sample (Hides et al., 2009a), and 
for the SDS, on a schizophrenia spectrum sample with cannabis use disorders (Hides et al., 2007), whereas the sample 
in chapter five from the SAX study was comprised of an ethnically and diagnostically homogenous group of patients 
with an established diagnosis of schizophrenia and more than a single SUD (Lijmer et al., 2002). 
8.1.3 Part III. Aspects of pharmacotherapy in dual diagnosis: summary of main findings 
Medication side-effects such as extrapyramidal symptoms (EPS) may be an important effect modifier, together with 
other factors such as substance craving, subjective-wellbeing in people treated with antipsychotic medication, and can 
ultimately influence factors such as medication adherence and subsequently mental state and substance use 
(Temmingh et al., 2018). In part III of this thesis it was demonstrated in a diagnostically heterogeneous sample of 
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patients with major affective and non-affective psychotic disorders that a striatal neurotoxin, methamphetamine was 
associated with increased odds of having EPS in patients requiring treatment with antipsychotics. Furthermore, this 
risk was significant for those who had more severe methamphetamine use disorders (i.e. dependence) and those who 
had methamphetamine use disorders >3 years.  A significant interaction between methamphetamine use and 
antipsychotic dose was also found, with increased dosage being associated with significantly higher odds of EPS in 
patients with methamphetamine use disorders compared to those without MA use disorders. The impact of 
antipsychotic class on EPS likelihood was also explored, but no significant interaction between antipsychotic class 
(defined as first-generation vs. second-generation) and methamphetamine use on the likelihood of EPS was found. 
Sensitivity analyses also revealed no interaction between antipsychotic type/class and MA use, even after risperidone 
was reclassified as FGA. These findings are in agreement with meta-analyses that substances, stimulants in particular, 
are associated with increased odds of EPS (Potvin et al., 2009b). As the categories of abuse and dependence in the 
DSM-IV have been collapsed into one category in the DSM-5, our finding of any SUD (abuse or dependence) having 
an increased association with EPS, emphasizes the generalizability of our findings to DSM-5 derived SUD diagnoses. 
In a systematic review of randomised trials, we also investigated the hypothesis that second-generation antipsychotics 
are associated with superior outcomes in terms of mental state and substance use via several potential effect modifiers 
such as medication side-effects, substance craving, subjective-wellbeing and adherence, which may result in more 
favourable impact on reward deficit syndromes in people with psychotic disorders and co-occurring SUDs. Ultimately 
due to the dopamine receptor binding profiles of SGAs, which include higher serotonin 5HT2A receptor antagonism 
and varying, but higher D2 receptor dissociation, these medications, have been postulated to exert a less negative 
impact on reward deficit syndromes characterised by low D2 receptor density in patients with psychotic disorders and 
co-occurring SUDs (Blum et al., 2000, Siris, 1990, Volkow et al., 1997).   Only very low to low quality evidence was 
found for risperidone, a widely available SGA within a LMIC context, indicating no superior effects compared to the 
FGA perphenazine, and SGAs, clozapine, olanzapine, quetiapine or ziprasidone. This finding is in agreement with 
other reviews in this area, even though some treatment guidelines have singled out clozapine as a potentially superior 
treatment for dual diagnosis patients with alcohol use disorders (Baker et al., 2012b, Hasan et al., 2015, Lazary, 
2012b, McLoughlin et al., 2014b, Wobrock and Soyka, 2009a). 
8.2 Implications of thesis findings for clinical practice, public health and future research 
In this thesis the clinical profile of a dual diagnosis patient was characterised as likely to be a younger male, with 
lower levels of education and a past history of legal involvement. For clinicians working in psychiatric settings, 
screening for substance use disorders in patients with psychosis has important implications for treatment planning, 
prognostication and assessment of patient needs. 
It could be argued that, in order to be acceptable and ethical, a screening test needs to minimise false test positives 
(have a very high PPV and low TFP rate), in particular as existing psychosocial interventions for dual diagnosis 
populations have limited efficacy (Hunt et al., 2013b, NICE, 2011b), and a diagnosis of a co-occurring SUD may 
potentially further stigmatise and marginalize people with psychiatric disabilities. Despite these potential problems, 
identification of a SUD may have some value in pointing to a particular illness course and prognosis, sensitizing 
clinicians as to the particular needs of this population, which is likely to span across the biopsychosocial spectrum.  In 
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addition, identification of SUDs will address patient treatment needs and improve treatment planning to focus on both 
mental disorders and co-occurring SUDs. 
In settings where there is a likely high prevalence of dual diagnosis (i.e. among younger male patients, where we 
found a prevalence of 53% in dataset #1 and 68% in dataset#2), it would suffice to conduct the briefer SDS scale, 
which at a cut-off score of ≥4 has a PPV= 86.2%, and a test false positive rate (percentage who test positive and don’t 
have a SUD) of only 13.8%. In lower prevalence settings, the ASSIST has been shown to have somewhat better 
performing properties, with higher positive likelihood ratios (LR+) leading to higher post-test probabilities. Whereas 
properties like the PPV has value for clinicians who deal with individual patients, from a public health perspective 
maximizing the sensitivity or specificity of tests may be more desirable. In this respect it can be demonstrated that 
sequential or simultaneous use of the SDS and ASSIST used in tandem or at the same time, can either maximize 
sensitivity (at the expense of specificity) or specificity (at the expense of sensitivity). In a population of 5 million 
people, given a prevalence of schizophrenia of 1%  (i.e. 50 000 potential cases) with a 50% prevalence of any SUD in 
the schizophrenia population, using the SDS (≥4) as initial screen (sensitivity 78%, specificity 72%), followed by the 
sequential administration of the ASSIST (≥6) only to those who screened positive on the SDS, it can be demonstrated 
that the specificity will be increased to 93.7% and sensitivity reduced to 67.9% (See tables 1 and 2). In turn, 
simultaneous administration of both tests, where any positive test on either or both tests are taken as positive and 
screen negative on both SDS and ASSIST as negative, the net gain in sensitivity will be 97% with a reduction in 
specificity to 55% (See tables 8.1 to 8.4 for illustration). 
 
Table 8.1 Sequential, two-stage screening of a population of 5 million with 1% schizophrenia prevalence 
and 50% prevalence of co-occurring SUDs. First screening wave (briefer assessment with SDS) Cut-off 
score ≥ 4 Sensitivity=78.3; Specificity=71.7 
 SUD+ SUD-  
SDS+ 19575 7075 26650 
SDS- 5425 17925 23350 
Total 25000 25000 50000 
 
Table 8.2 Sequential, two-stage screening. Second screening (lengthier assessment with ASSIST) Cut-off 
score ≥ 6 Sensitivity=86.8 Specificity=77.8 
 SUD+ SUD-  
ASSIST+ 16991 1571 18562 
ASSIST- 2584 5504 8088 
 19575 7075 26650 
 
Loss in net sensitivity: 
 
16991/25000=67.9% 
  
 
Nett gain in specificity 
 
17925+5504/25000=93.7% 
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Table 8.3 Sensitivity and specificity of ASSIST in population of 50000 patients with schizophrenia and 
50% SUD prevalence. 
 SUD+ SUD-  
ASSIST+ 21700 5550  
ASSIST- 3300 19450  
Total 25000 25000 50000 
 
Table 8.4 Combined sensitivity and specificity of SDS when used simultaneously with the ASSIST. 
 SUD+ SUD-  
ASSIST+ 16991 5550  
ASSIST- 2584 19450  
Total 19575 25000 50000 
 
Simultaneous use of SDS and ASSIST: impact on net sensitivity and specificity 
 
Additional gains in sensitivity of SDS and ASSIST 
beyond that when both are used simultaneously 
 
16991+2584+4709 
         25000                =97% 
 
Net loss in specificity: 
 
13946/25000= 55% 
 
A significant association was found between alcohol use disorders and lifetime anxiety symptoms (panic disorder, 
agoraphobia without a history of panic, specific phobia, social phobia and generalised anxiety disorders) and post-
traumatic stress disorder symptoms. This emphasises the importance of a wide diagnostic assessment in patients with 
a dual diagnosis, with sensitivity toward potential anxiety symptoms, trauma and post-traumatic sequelae. This may 
trigger referral to psychological therapies, and if indicated additional pharmacological management.  A significant 
association was also found between a past history of suicide attempts and alcohol use disorders. This emphasizes 
careful risk assessment and assessment of suicidality, in patients with SMI and co-occurring SUDs.  
In addition, in both samples found a strong significant association was found between having a dual diagnosis and the 
presence of legal problems, in particular the presence of police arrests for involvement in minor and more serious 
crimes. Legal involvement of dual diagnosis patients poses a number of ethical dilemmas to clinical practitioners.  
Practitioners need to assess for the presence of legal problems and may need to communicate from time to time with 
practitioners from the criminal justice system. This may include liaising with the police or state prosecutors, but also 
pertain to policy development for hospitals and facilities in terms of the searches for illegal substances, whilst 
maintaining and respecting patient rights, privacy and confidentiality. Although South African law provides for 
diversion sentences for minor drug related crimes through The Prevention and Treatment of Substances Act (i.e. civil 
committal or “involuntary rehabilitation”)(The Prevention of and Treatment for Substance Abuse Act, 2008), the 
efficacy of drug courts in reducing re-arrests have been disputed. (Perry et al., 2015). Moreover, “involuntary” 
treatment for substance use in patients who are in the pre-contemplative phase of readiness for change may have 
questionable benefits (Migneault et al., 2005). Furthermore, traditional court systems may lack the ability to deal with 
patients who have degrees of disability and impairment in their capacity to cope with court proceedings, often 
resulting in the use of the Mental Health Care Act Legislation to motivate for involuntary inpatient treatment, as this 
may be seen as more appropriate in patients with psychotic symptoms who are at risk of harming themselves or others. 
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On the one hand viewed from a medical model perspective the use of the criminal justice system may be seen as 
inappropriately criminalising addiction related illness behaviour. On the other hand, disability rights approaches and 
the South African constitution emphasise equality before the law of individuals with disabilities. It is therefore likely 
that these patients may enter the criminal justice system at points in their lives, further underlining the need to support 
such patients within this system. Although having no impact on substance use and re-arrests, some therapeutic 
approaches such as therapeutic communities within the criminal justice system have some encouraging results and 
have been demonstrated to reduce re-incarceration rates significantly (Perry et al., 2015). Recurrent difficulties with 
the law and arrests were part DSM-IV criteria for abuse. Of note the DSM-5 excludes recurrent legal difficulties as a 
diagnostic criterion for substance use disorder diagnoses. The absence of this criterion in DSM-5 further emphasizes 
the need for assessments to include detailed assessment of legal involvement in order to assist patients in a 
comprehensive manner. 
 In this thesis it was also found that economic problems occurred significantly more frequently in patients with a dual 
diagnosis, emphasizing the impact of substance son financial well-being of patients. This aspect is important for 
clinicians to consider as it is likely a direct consequence of drug use behaviour and may sensitize patients as to the 
consequences of their substance use. 
For psychotic disorders requiring treatment with antipsychotics, care is required in antipsychotic dose up-titration 
which should always be accompanied by ongoing assessment of extra-pyramidal motor side-effects. Some patients, 
notably those with methamphetamine use disorders are more likely to develop antipsychotic induced movement 
disorder related side-effects. For patients with mood disorder this may mean maximizing the dose and effects of mood 
stabilisers as a priority and the use of low dosages of antipsychotics and agents that have a lower potential at higher 
dosages to induce extrapyramidal side-effects. 
8.3 Limitations of thesis findings 
A number of limitations are important when considering our thesis findings. In chapter 3 and 4 a secondary analysis of 
two datasets was conducted, investigating the demographic and clinical factors associated with a dual diagnosis. 
Studies contributing data to both datasets were based on studies that collected data in a cross-sectional manner. As the 
diagnosis of SUDs was primarily based on self-report and did not include a systematic biological verification process 
it is therefore possible the participants recall bias could have led to an underestimation of substance use.  Nevertheless, 
we used a well validated and detailed diagnostic instrument, the Structured Clinical Interview for DSM-IV (SCID-I) 
and as part of the SCID-I interviews additional information such as clinical case records, family reports and 
information on referral forms and emergency rooms urine drug testing were included where available in the 
determination of SUD diagnoses. Anxiety, post-traumatic and obsessive-compulsive symptoms were assessed as 
present based on threshold or subthreshold symptoms in the SCID-I and continuous measures of anxiety symptoms or 
psychosis severity were not used. Future studies may need to incorporate such measures in assessments. 
As all the participants contributing data to the datasets analysed were all in treatment within psychiatric settings (i.e. 
community clinics, outpatients’ departments and hospitals), the generalisability of our findings to other settings such 
as primary care may be limited. Furthermore, due to the cross-sectional nature of the data collection it was not 
possible to determine the temporal sequence of substance use and extrapyramidal side-effects and it cannot ruled out 
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that in some instances substance use may have been and attempt to unsuccessfully treat medication side-effects such 
as antipsychotic induced movement disorders. 
Finally, in the systematic review of randomised trials, although we conducted and exhaustive search, few studies 
(n=8) were found and methodological heterogeneity in design and outcome measures often precluded pooling of 
results. Our systematic review included studies where at outset all participants had a dual diagnosis prior to 
randomization, but subsequently as a result of few studies found, we adapted our protocol to included studies where > 
70% of participants in the study had a dual diagnosis. This may have led to us excluding some studies that may have 
had very low numbers of patients with SUDs where only subgroup analyses were conducted.   We also excluded 
substance induced disorders as well as non-psychotic mood disorders, which may limit the generalisability of our 
findings to people with major affective and non-affective psychotic disorders. Although we conducted and exhaustive 
search of both the schizophrenia and common mental disorder literature, we did not search trials where antipsychotics 
were used in substance using populations that may have potentially included subgroups of people with serious mental 
disorders. In addition, we did not include observational research in this area, but limited our review to randomised 
trials. 
8.4 Conclusion 
This thesis addressed a number of important questions for the first time in the South African, broader low-and-middle 
income country and global context pertaining to co-occurring SUDs in people with SMI. In this thesis I investigated 
the prevalence and clinical correlates in a large adult clinical sample from two geographic regions in patients with an 
established diagnosis of schizophrenia in an understudied part of the population, namely the South African Xhosa 
population. In addition, the prevalence and clinical correlates are also determined in a clinically more heterogeneous 
sample from the Cape Town. In these samples substance use disorders occurred in as many as half of patients with 
serious mental disorders. The clinical profile of dual diagnosis was characterized by male sex, younger age, lower 
education, more anxiety, post traumatic symptoms and suicidal behaviours, legal and economic problems. These 
findings provide key clinical recommendations relevant in the assessment and treatment planning in this understudied 
and often marginalised population. Assessment of comorbid anxiety, post-traumatic and suicide risk as well as 
economic and legal problems should form part of a comprehensive assessment. In this thesis I also demonstrate for the 
first time in a clinically homogenous population with schizophrenia, the validity and accuracy of two brief screening 
instruments, the SDS and ASSIST in identifying dual diagnosis patients. Moreover, higher levels of antipsychotic 
associated movement disorders were found, in particular in participants with methamphetamine use disorders. I also 
investigate the hypothesis that certain antipsychotics, i.e. second-generation agents, risperidone in particular, one of 
the first SGAs developed, have a superior effect on a number of clinical outcomes, and found only low to very low-
quality evidence demonstrating no difference between risperidone versus other antipsychotics.  Whereas the current 
level of evidence does not support the preferential use of particular psychotic agents such as risperidone over other 
agents, clinicians need to be cognizant of the development of extrapyramidal side-effects in methamphetamine users 
and conduct regular assessments to detect these complications and adjust treatment accordingly.  
These clinical recommendations and related findings have relevance to the South African and low-and-middle income 
country context but also speak to a broader global audience and provide important directions for future research. 
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9. Appendix 
 
9.1 Additional tables from part III, chapter 8 
Table 9.1 Characteristics of excluded studies  
Study Reason for exclusion 
Blin 1996   Allocation: randomised 
Participants: people with schizophrenia who do not have co-occurring substance misuse 
Gaebel 2010 Allocation: randomised 
Participants: people with schizophrenia, schizoaffective disorder; people with schizophrenia who do not have co-
occurring substance misuse 
Green 2001 Allocation: randomised. 
Participants: patients with both schizophrenia and a cannabis use disorder. 
Intervention: risperidone vs. clozapine. 
Outcomes: cannabis use, negative symptoms, psychotic symptoms, neuropsychological function and quality of life. 
No data available: only published as study protocol, authors contacted for unpublished data: no response. 
Harvey 2007 Allocation: randomised. 
Participants: people with bipolar I disorder who do not have co-occurring substance misuse. 
Ikuta 2014 Allocation: randomised 
Participants: people with schizophrenia, schizophreniform, or psychosis not otherwise specified who do not have 
co-occurring substance misuse. 
Kerfoot 2011 Allocation: randomised. 
Participants: schizophrenia with and without co-occurring substance use. 
Intervention: risperidone versus quetiapine versus perphenazine versus olanzapine versus ziprasidone. 
Outcomes: psychotic symptoms, depression, quality of life, neurocognition 
No data available comparing risperidone with other medications. Study examined the impact of substance use on 
prognosis. 
Liemburg 2011 Allocation: randomised. 
Participants: people with schizophrenia who do not have co-occurring substance misuse. 
Liu 2008 Allocation: randomised. 
Participants: not people with dual diagnosis ‒ people with 'mental disorders due to alcohol use'. 
NCT00063349 Allocation: trial suspended, reported as non-randomised, retrospective observational study. 
Participants: schizophrenia, schizoaffective disorder, cannabis and/or alcohol use disorder 
Intervention: risperidone, clozapine. Outcomes: cessation of substance use. 
NCT00130923   Allocation: randomised 
Participants: schizophrenia, schizoaffective disorder and alcohol use disorder (abuse or dependence) 
Intervention: risperidone oral formulation compared to risperidone long-acting injectable formulation (RLAI). Not 
risperidone versus another antipsychotic. 
NCT00169026   Allocation: randomised 
Participants: schizophrenia, schizoaffective disorder and alcohol or substance use disorder. 
Intervention: clozapine, conventional antipsychotics, atypical antipsychotics. 
Outcomes: substance and alcohol use (breathalyzer, urine tests, TLFB, Alcohol and Drug Use Scale), mental state 
(BPRS), SANS, CGI, neurological side-effects, cognitive function, quality-of-life measure 
No data available. Study protocol of terminated study. 
NCT00498550   Allocation: randomised 
Participants: schizophrenia, schizoaffective disorder and cannabis use disorder 
Intervention: clozapine, conventional antipsychotics, atypical antipsychotics. 
Outcomes: substance use measures (urine testing, breathalyzer), medication side-effects, physical and 
psychological symptoms, substance use, treatment services received, and living situation, quality of life. Study 
protocol only, authors contacted but no data provided. 
Nejtek 2008  Allocation: randomised. Participants: bipolar I and II disorder, recent manic or mixed episode with or without 
psychosis and with co-occurring cocaine- or methamphetamine-use disorder. Only 8.3% of total sample had 
psychotic features and 15.9% had bipolar type II disorder. 
Perlis 2006 Allocation: randomised 
Participants: bipolar I disorder with mania or mixed states. Patients with psychosis excluded. Patients with recent 
substance use excluded. 
Rezayat 2014 Allocation: randomised 
Participants: acute mania (bipolar disorder). Study excludes participants with drug or alcohol use in past 3 months 
Rubio 2006a Allocation: quasi-randomisation (participants allocated "alternately"). 
Rubio 2006b Allocation: quasi-randomisation (participants allocated "alternately"). 
Sachs 2002 Allocation: randomised 
Participants: bipolar with current manic or mixed episode. Study excludes participants with drug or alcohol in past 
1 month. 
Sajatovic 2002 Allocation: randomised 
Participants: psychotic disorders: schizoaffective disorder, bipolar I disorder, major depressive disorder, delusional 
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disorder, Alzheimer's dementia, schizophreniform disorder, vascular dementia, and substance abuse dementia. 
Intervention: risperidone, quetiapine 
Outcomes: psychotic symptoms (PANSS), depression (HAM-D), extrapyramidal symptoms (ESRS) 
No subgroups with substance use reported, authors contacted for unpublished data, no response. 
Smulevich 2005 Allocation: randomised 
Participants: bipolar I disorder who do not have recent drug or alcohol use. 
van Nimwegen 2008a Allocation: randomised 
Participants: schizophrenia, schizophreniform, schizoaffective disorder. No co-occurring substance use disorders. 
Intervention: haloperidol, risperidone, placebo 
Outcomes: Obsessions and compulsions (Y-BOCS), PANSS scores, CDSS scores. 
Authors contacted to determine if there were participants with co-occurring substance use disorders. Authors 
clarified that there were no participants with co-occurring substance use disorders. 
Yatham 2007 Allocation: randomised 
Participants: bipolar I and II. Excludes participants with drug or alcohol use in past 3 months. 
Zhangyue 2005 Allocation: quasi-randomisation (allocation based on admission order) 
Table 9.2 Studies awaiting classification 
Greenspan  2005 Methods Allocation: described as "double-blind" * 
Blindness: described as "double-blind" * 
Duration: 6 weeks, 2-week monotherapy phase 
Design: "double-blind" efficacy study 
Setting: unclear 
 Participants Patients with schizophrenia and co-occurring alcohol, cocaine, amphetamine, marijuana, opiate 
use disorder. 
N = 111 with substance use disorders 
 Interventions Risperidone; (dose and delivery method unclear) N = 51. 
Quetiapine; (dose and delivery method unclear) N = 40. 
Placebo. N = 20** 
 Outcomes Mental state: psychotic symptoms, PANSS scale 
 Notes * Randomisation could not be confirmed from authors, no response to e-mails sent. 
** Data from placebo group not used for this review. 
Johnsen 2010 Methods Allocation: randomised, rater blinded, prospective head-to-head trial 
 Participants Participants: schizophrenia, schizoaffective disorder, delusional disorder, affective psychosis 
(supplementary data with sample characteristics indicate that 3.8% of risperidone group had 
alcohol use disorder at baseline and 21.2% of risperidone group had drug misuse at baseline). 
 Interventions risperidone, clinician determined dose, N = 53 (2 alcohol misuse in past 6 months, 11 drug 
misuse in past 6 months) 
olanzapine, clinician determined dose, N = 52 (5 alcohol misuse in past 6 months, 9 drug 
misuse in past 6 months) 
quetiapine, clinician determined dose, N = 50 (10 alcohol misuse in past 6 months, 7 drug 
misuse in past 6 months) 
ziprasidone, clinician determined dose, N = 58 (5 alcohol misuse in past 6 months, 11 drug 
misuse in past 6 months) 
 Outcomes Outcomes: time to antipsychotic discontinuation, discharge and readmission. Improvement in 
PANSS, Calgary Depression Scale for Schizophrenia, CGI-S, GAF, adverse effects, UKU Side 
Effect Rating Scale (UKU-SERS). Baseline, 6 weeks, 3-, 6-, 12- and 24-month measures. 
 Notes Authors contacted for any subgroup data or analysis, no response to e-mails sent. 
NCT00208143 Methods Open (no masking), randomised, parallel assignment, superiority trial 
 Participants Adults age 19 to 65 years with a diagnosis of schizophrenia or schizoaffective disorder and co-
occurring cocaine or methamphetamine abuse or dependence as diagnosed by Structured 
Clinical Interview for DSM-IV. 
 Interventions quetiapine or risperidone oral formulation 
 Outcomes Primary: 50% or greater decrease in the drug use determined by the Time Line Follow Back 
(TLFB) method versus baseline 
Secondary: psychiatric symptoms assessed with the CGI, PANSS, BPRS, HAM-D, and HAM-
A. Safety and tolerability assessed by patient- and physician-reported adverse events and 
AIMS. Quality of life assessed with QoLI. 
 Notes Authors were contacted via e-mail but no response received. 
San 2002 Methods Allocation: randomised 
 Participants Participants: schizophrenia, schizophreniform, schizoaffective, bipolar, psychotic disorder 
NOS. Substantial subgroup used substances (cannabis: N = 64, 56.1%; alcohol: N = 87, 76.3%; 
cocaine: N = 24, 21.1%). 
 Interventions Open-label flexible-doses of antipsychotic treatment with the following dose ranges: 
haloperidol 1.5 mg to 8.5 mg, N = 21 (cannabis = 14, alcohol = 17, cocaine = 7) 
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olanzapine 7.5 mg to 40 mg, N = 25 (cannabis = 15, alcohol = 19, cocaine = 4) 
risperidone 1.5 mg to 7.0 mg, N = 25 (cannabis = 14, alcohol = 17, cocaine = 5) 
quetiapine 100 mg to 1500 mg, N = 23 (cannabis = 11, alcohol = 17, cocaine = 2) 
ziprasidone 40 mg to 240 mg, N = 20 (cannabis = 10, alcohol = 17, cocaine = 6) 
 Outcomes Time to medication discontinuation, PANSS scores, CDSS scores, Adverse effects 
 Notes No data provided for substance misuse subgroup ‒ authors contacted and responded, no data 
provided. 
Yatham 2003 Methods Allocation: multicentre, randomised, placebo-controlled trial 
Blindness: described as "double blind" 
Duration: 52 weeks 
Setting: Canadian and Brazilian academic centres 
 Participants Bipolar I disorder in remission from recent manic or mixed episode on treatment with mood 
stabiliser (valproate or lithium) and either risperidone or olanzapine (N = 159, not clear how 
many had psychotic features). Total of 39% (62/159) of total sample had co-occurring alcohol 
or substance use disorder. 
 Interventions Discontinuation of risperidone or olanzapine at either 0 weeks, 24 weeks or 52 weeks and 
substitution with placebo. 
 Outcomes Time to any mood episode, YMRS, HAMD-21, MADRS, CGI-BP, CGI-S, Side-effects UKU 
scale, ESRS, weight, metabolic measures (glucose, lipid profile). 
 Notes Authors contacted. Responded that no data or analyses available at present for subgroups. No 
information provided on how many participants had bipolar type I with psychotic features. 
   
Table 9.3 Ongoing studies 
NCT01639872 Study name Clozapine for Cannabis Use in Schizophrenia (CLOCS) 
 Methods Double blind (subject, caregiver, investigator, outcomes assessor), randomised, parallel 
assignment, superiority trial, comparing the efficacy of clozapine with risperidone, Estimated 
recruitment target N = 132 
 Participants Adults 18 to 55 years, males and females, clinical diagnosis of schizophrenia and a co-occurring 
cannabis use disorder (abuse or dependence) 
 Interventions clozapine with target dose of 400 mg/day and maximum of 550 mg/day; risperidone with target 
dose of 4 mg/day and maximum of 6 mg/day 
 Outcomes Primary: intensity (amount of cannabis used); frequency (number of days in past week) 
Secondary: symptoms of schizophrenia as measured by the BPRS, SANS, CGI; 
neuropsychological function by means of MATRICS Consensus Cognitive Battery; and reward 
responsiveness by means of a computerised Probabilistic Reward Task. 
 Starting date April 2013 
 Contact 
information 
alan.i.green@dartmouth.edu; christopher.okeefe@dartmouth.edu 
 Notes Estimated completion in Oct 2016 (recruitment); Oct 2017 (results) 
Table 9.4 Suggested design for future trial 
Methods Allocation: centralised sequence generation with table of random numbers or computer-generated code, stratified by 
severity of illness, sequence concealed till interventions assigned. 
Blinding: could be optional, depending on choice of outcome. 
Duration: 12 months. 
Participants Diagnosis: schizophrenia and co-occurring ongoing substance misuse (clinical criteria). 
N = 300*. 
Age: adults. 
Sex: men and women. 
Setting: any. 
Interventions 1. Risperidone: clinically indicated dose. N = 150. 
2. Olanzapine: clinically indicated dose. N = 150. 
Outcomes Global state: CGI-I and CGI-S. 
Substance use: pragmatic binary/continuous measure. 
Well-being: pragmatic binary/continuous measure. 
Craving: pragmatic binary/continuous measure. 
Service outcomes: re-hospitalisation, days in hospital, time attending psychiatric outpatient clinic. 
Quality of life: important change. 
Adverse effects: including mortality, weight change and extrapyramidal symptoms. 
Satisfaction with care: patients/carers. 
Leaving the study early. 
Economic data. 
Other routine data, such as incidents with the police, 
Notes * size of study to detect a 10% difference in improvement with 80% certainty. 
For all outcomes there should be binary cut-off points of clinically important improvement, defined before the study 
starts. 
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Table 9.5 Analyses of primary and secondary outcomes: Risperidone vs. Clozapine comparison across primary and 
secondary outcomes 
Outcome or Subgroup 
Studies 
 
(RCTs) 
Participants 
 
(N) 
Statistical Method Effect Estimate 
1.1 Mental state: 1. General: average endpoint scores (PANSS 
subscale, lower=better) 
1 36 
Mean Difference (IV, 
Random, 95% CI) 
2.70 [-2.14, 7.54] 
1.2 Mental state: 2. General: any change in general symptoms: 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.14 [0.01, 2.34] 
1.3.1 Mental state: Positive symptoms - average endpoint score 
(PANSS positive subscale, lower=better) 
1 36 
Mean Difference (IV, 
Random, 95% CI) 
0.90 [-2.21, 4.01] 
1.3.2 Mental state: Negative symptoms - average endpoint score 
(PANSS negative subscale, lower=better) 
1 36 
Mean Difference (IV, 
Random, 95% CI) 
4.00 [0.79, 7.21] 
1.4 Mental state: 4. Specific: anxiety symptoms 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
3.00 [0.14, 63.15] 
1.5.1 Substance use: Improvement (at least 20% reduction in use, 
TLFB scale) 
1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
1.00 [0.30, 3.35] 
1.5.2 Substance use: Discontinued substance use 1 28 
Risk Ratio (M-H, 
Random, 95% CI) 
1.13 [0.41, 3.12] 
1.6 Subjective Well-being: average endpoint scores (Subjective 
Well-being under Neuroleptics scale, SWN scale, higher=better) 
1 36 
Mean Difference (IV, 
Random, 95% CI) 
-6.00 [-14.82, 2.82] 
1.7.1 Craving for substances: 1. Specific: current craving- average 
endpoint scores (Marijuana Craving Questionnaire, MCQ, 
lower=better) 
1 28 
Mean Difference (IV, 
Random, 95% CI) 
7.00 [2.37, 11.63] 
1.7.2 Craving for substances: 2. Specific: past week craving- 
average endpoint scores (Obsessive Compulsive Drug Use Scale, 
OCDUS, lower=better) 
1 28 
Mean Difference (IV, 
Random, 95% CI) 
14.20 [4.45, 23.95] 
1.8 Adherence to antipsychotic medication: discontinued 
medication 
1 36 
Risk Ratio (M-H, 
Random, 95% CI) 
4.05 [0.21, 78.76] 
1.9 Adverse effects. 1. Movement disorders 2  
Risk Ratio (M-H, 
Random, 95% CI) 
Subtotals only 
1.9.1 any extrapyramidal side-effects 2 50 
Risk Ratio (M-H, 
Random, 95% CI) 
2.71 [0.30, 24.08] 
1.9.2 akathisia 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
2.00 [0.23, 17.34] 
1.10 Adverse effects: 2. Non-movement disorder related side-
effects 
1  
Risk Ratio (M-H, 
Random, 95% CI) 
Subtotals only 
  1.10.1 Cardiovascular: palpitations 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
3.00 [0.14, 63.15] 
  1.10.2 Cardiovascular: hypotension 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.33 [0.02, 7.02] 
  1.10.3 Central nervous system: headache 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.20 [0.01, 3.54] 
  1.10.4 Central Nervous System: somnolence 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.20 [0.03, 1.30] 
  1.10.5 Dermatological: acne 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
3.00 [0.14, 63.15] 
  1.10.6 Endocrinological: decreased libido 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.33 [0.02, 7.02] 
  1.10.7 Ear and labarynthine: ear canal blockage 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
3.00 [0.14, 63.15] 
  1.10.8 Gastrointestinal: abdominal pain 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
3.00 [0.14, 63.15] 
  1.10.9 Gasstrointesinal: elevated liver function tests 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
3.00 [0.14, 63.15] 
  1.10.10 Gastrointestinal: hypersalivation 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.11 [0.01, 1.74] 
  1.10.11 General adverse effects: fatigue 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.33 [0.02, 7.02] 
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  1.10.12 Injuries: sprain 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.33 [0.02, 7.02] 
1.10.13 Metabolic: increased appetite 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.33 [0.02, 7.02] 
1.10.14 Metabolic: weight gain 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
1.00 [0.19, 5.24] 
1.10.15 Musculosceletal: ankle pain 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.33 [0.02, 7.02] 
1.10.16 Musculosceletal: knee and foot pain 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.33 [0.02, 7.02] 
1.10.17 Musculosceletal: muscle twitch 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
3.00 [0.14, 63.15] 
1.10.18 Renal: urinary retention 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.33 [0.02, 7.02] 
1.10.19 Renal: urinary urgency 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
0.33 [0.02, 7.02] 
1.11 Leaving the study early 2  
Risk Ratio (M-H, 
Random, 95% CI) 
Subtotals only 
1.11.1 any reason 2 45 
Risk Ratio (M-H, 
Random, 95% CI) 
0.49 [0.10, 2.51] 
1.11.2 due to inefficacy 1 14 
Risk Ratio (M-H, 
Random, 95% CI) 
Not estimable 
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Table 9.6 Analyses of primary and secondary outcomes: Risperidone vs. olanzapine, comparison across primary and 
secondary outcomes 
Outcome or Subgroup 
Studies 
(RCTs) 
Participants 
(N) 
Statistical Method Effect Estimate 
2.1 Mental state: 1. Specific: Depression- change scores (HAM-D, 
higher = better), short term (up to 6 months) 
1  
Mean Difference (IV, 
Random, 95% CI) 
Subtotals only 
2.1.1 short-term (up to 6 months) 1 22 
Mean Difference (IV, 
Random, 95% CI) 
-0.11 [-0.78, 0.56] 
2.2 Mental state: 2. Specific: Positive symptoms, total score- 
average endpoint scores (SADS-C-PD scale, lower=better), short 
term (up to 6 months) 
1  
Mean Difference (IV, 
Random, 95% CI) 
Subtotals only 
2.2.1 short term, up to 6 months) 1 37 
Mean Difference (IV, 
Random, 95% CI) 
-1.50 [-3.82, 0.82] 
2.3 Mental state: 3. Specific: Positive symptom subscales- average 
endpoint scores (SADS-C-PD subscores, lower=better), short term 
(up to 6 months)- skewed data 
1  Other data No numeric data 
2.4 Mental state: 4. Specific: Negative symptoms, subscales- 
average endpoint scores (SANS subscales, lower=better), short 
term (up to 6 months) 
1  
Mean Difference (IV, 
Random, 95% CI) 
Subtotals only 
2.4.1 Negative symptoms: Affective flattening 1 39 
Mean Difference (IV, 
Random, 95% CI) 
0.50 [-0.17, 1.17] 
2.4.2 Negative symptoms: alogia 1 39 
Mean Difference (IV, 
Random, 95% CI) 
0.40 [-0.22, 1.02] 
2.4.3 Negative symptoms: avolition-apathy 1 39 
Mean Difference (IV, 
Random, 95% CI) 
-0.10 [-0.73, 0.53] 
2.4.4 Negative symptoms: asociality-anhedonia 1 39 
Mean Difference (IV, 
Random, 95% CI) 
-0.10 [-0.80, 0.60] 
2.5 Substance use: 1. Reduction of cannabis use-change data 
(number of joints smoked/week, LOCF data, higher =better)- short 
term data (up to 6 months) 
1 41 
Mean Difference (IV, 
Random, 95% CI) 
0.40 [-4.72, 5.52] 
2.6 Substance use: 2. Discontinued substance use, short term (up 
to 6 months) 
1  
Risk Ratio (M-H, 
Random, 95% CI) 
Subtotals only 
2.6.1 Substance use: 2. Stopped using cannabis (Urine testing and 
Substance Use Questionnaire) 
1 37 
Risk Ratio (M-H, 
Random, 95% CI) 
1.19 [0.68, 2.08] 
2.6.2 Substance use: 2. Stopped using alcohol (Substance Use 
Questionnaire) 
1 37 
Risk Ratio (M-H, 
Random, 95% CI) 
1.31 [0.73, 2.36] 
2.7 Craving for substances: 1. Obsessive Compulsive Drug Use 
Scale- average endpoint score (OCDUS, lower=better)-short term 
(up to 6 months) 
1  
Mean Difference (IV, 
Random, 95% CI) 
Subtotals only 
2.7.1 short-term (up to 6 months) 1 41 
Mean Difference (IV, 
Random, 95% CI) 
1.30 [-3.51, 6.11] 
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2.8 Craving for substances: 2. Desires for Drug Questionnaire- 
average endpoint scores (DDQ, LOCF data, lower=better), short 
term (up to 6 months) 
1  
Mean Difference (IV, 
Random, 95% CI) 
Subtotals only 
2.8.1 Short-term (up to 6 months) 1 41 
Mean Difference (IV, 
Random, 95% CI) 
5.00 [-4.86, 14.86] 
2.9 Adverse effects: 2  
Mean Difference (IV, 
Random, 95% CI) 
Subtotals only 
2.9.1 Movement disorders: Parkinsonism- average endpoint score 
(SAS, high = worse)- short-term (up to 6 months) 
1 16 
Mean Difference (IV, 
Random, 95% CI) 
-0.08 [-1.21, 1.05] 
2.9.2 Non-movement disorder related side-effects: Weight gain- 
average endpoint score (BMI, lower=better)- short term (up to 6 
months) 
1 37 
Mean Difference (IV, 
Random, 95% CI) 
-1.00 [-3.99, 1.99] 
2.10 Leaving study early: 1. 3  
Risk Ratio (M-H, 
Random, 95% CI) 
Subtotals only 
2.10.1 any reason, short term (up to 6 months) 2 77 
Risk Ratio (M-H, 
Random, 95% CI) 
0.68 [0.34, 1.35] 
2.10.2 any reason, long term (> 12 months) 1 299 
Risk Ratio (M-H, 
Random, 95% CI) 
1.07 [0.94, 1.21] 
2.10.3 readmission, short term (up to 6 months) 1 28 
Risk Ratio (M-H, 
Random, 95% CI) 
1.00 [0.07, 14.45] 
2.10.4 intolerable adverse effects, short term (up to 6 months) 1 28 
Risk Ratio (M-H, 
Random, 95% CI) 
Not estimable 
2.10.5 participant loss of interest, short term (up to 6 months) 1 28 
Risk Ratio (M-H, 
Random, 95% CI) 
0.43 [0.14, 1.33] 
2.11 Leaving study early: 2. Weeks in the study- average endpoint 
data (high=good), short term (up to 6 months) 
1 28 
Mean Difference (IV, 
Random, 95% CI) 
0.00 [-3.35, 3.35] 
2.12 Leaving study early: 3. Weeks in study- average endpoint 
data (high=good), short term (up to 6 months)- skewed data 
1  Other data No numeric data 
 
 
Table 9.7 Analyses of primary and secondary outcomes:  Risperidone vs. Perphenzapine, comparison across primary and 
secondary outcomes 
Outcome or Subgroup 
Studies 
(RCTs) 
Participants 
(N) 
Statistical Method Effect Estimate 
3.1 Leaving the study early: all cause 
discontinuation, long term (>12 months) 
1 281 
Risk Ratio (M-H, Random, 95% 
CI) 
1.05 [0.92, 1.20] 
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Table 9.8 Analyses of primary and secondary outcomes: Risperidone vs. quetiapine, comparison across primary and 
secondary outcomes 
Outcome or Subgroup 
Studies 
(RCTs) 
Participants 
(N) 
Statistical Method Effect Estimate 
4.1 Leaving the study early: all cause 
discontinuation, long term (>12 months) 
1 294 
Risk Ratio (M-H, Random, 95% 
CI) 
0.96 [0.86, 1.07] 
 
Table 9.9 Analyses of primary and secondary outcomes: Risperidone vs. ziprasidone, comparison across primary and 
secondary outcomes 
Outcome or Subgroup 
Studies 
(RCTs) 
Participants 
(N) 
Statistical Method Effect Estimate 
5.1 Leaving the study early: all cause 
discontinuation, long term (>12 
months) 
1 240 
Risk Ratio (M-H, Random, 95% 
CI) 
0.96 [0.85, 1.10] 
 
9.2 Literature searches: 
9.2.1 Cochrane Schizophrenia Group’s Study-Based Register of Trials 
On 6 January 2016 and 9 October 2017, the Information Specialist searched the register using the following search 
strategy: 
*Risperidone* in Intervention AND *Substance Abuse* in Healthcare Condition Fields of STUDY 
In such study-based registers, searching the major concept retrieves all the synonyms and relevant studies because all 
the studies have already been organised based on their interventions and linked to the relevant topics (Shokraneh 
2017). 
This register is compiled by systematic searches of major resources (AMED, BIOSIS, CINAHL, ClinicalTrials.Gov, 
Embase, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly updates; ProQuest Dissertations and 
Theses A&I and its quarterly update; Chinese databases (CBM, CNKI, and Wanfang) and their annual updates; 
handsearches; grey literature; and conference proceedings (see Group’s Module). There are no language, date, 
document type, or publication status limitations for inclusion of records into the register. 
9.2.2 Cochrane Common Mental Disorders Group's Trials Register 
On 8 January 2016 and 10 October 2017, the Information Specialist of Cochrane's Common Mental Disorders Group 
searched the trials register of their group using the following search strategy: 
Search 1: 
#1. (*Risp* AND (*Substance* OR *Cannabis* OR *Amphetamine* OR *Alcohol* OR *Cocaine* OR *Opioid* OR 
*Drug Dependence* OR *Addict*)) [in Register] 
Search 2: 
#2. (*Risp*) 
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#3. (“substance use disorder*” or SUD or SUDs) 
#4. “drug abuse” 
#5. (abuser* or abusing or addict* or depend* or habit* or misuse or user*) 
#6. (abuse not (child* or sex*)) 
#7. (adinazolam or aerosol* or alcohol* or alprazolam or amphetamin* or anthramycin or anxiolytic* or ativan or 
barbituat* or bentazepam or benzodiazepin* or bromazepan or brotizolam or buprenorphin* or camazepam or 
cannabi* or chlordiazepoxid* or cinolazepam or clobazam or clonazepam or clorazepam or clotiazepam or 
cloxazolam or cocaine* or codeine or crack or crystal or cyprazepam or depressant* or diacetylmorphin* or 
diazepam* or doxefazepam or ecstasy or estazolam or etizolam or fentanyl or flunitrazepam or flurazepam or 
flutazoram or flutoprazepam or fosazepam or gases or GHB or girisopam or halazepam or hallucinogen* or 
haloxazepam or heroin* or hydromorphone or hydroquinone or hypnotic* or inhalant* or ketamin* or ketazolam or 
librium or loflazepate or loprazolam or lorazepam or lormetazepam or LSD or marihuana* or marijuana* or MDMA 
or meclonazepam or medazepam or meperidine or mephedrone or mescalin* or metaclazepam or methadone or 
methamphetamin* or methaqualone or mexazolam or midazepam or midazolam or morphine* or narcotic* or 
nerisopam or nimetazepam or nitrazepam or nitrites or "nitrous oxide" or "n-methyl-3,4-
methylenedioxyamphetamine" or nordazepam or opiate* or opiod* or opium or oxazepam or oxazolam or oxazypam 
or oxycodone or oxzepam or painkiller* or "pain killer*" or PCP or pethidin* or phencyclidin* or pinasepam or 
prazepam or propazepam or propoxyphene or psilocybin or psychedelic* or psychoactive* or psychostimulant* or 
quinazolinone or ripazepam or ritalin or sedative* or serazepin* or solvent* or steroid* or stimulant* or substance* or 
temazepam or tetrazepam or tofisopam or tramadol or triazolam or triflubazam or valium or vicodin) 
#8. (drug* and (recreational or street)) 
#9. #2 and (#3 or #4 or #5 or #6 or #7 or #8) 
#10. #9 not #1 [in Register] 
For previous searches, please see Appendix 1. 
9.2.3 Reference searching 
We inspected reference lists of all included studies for further relevant studies. 
9.2.4 Personal contact 
We contacted the first author of each included study for information regarding unpublished trials. In addition we 
contacted pharmaceutical companies regarding unpublished trials 
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9.3 Measures and instruments 
9.3.1 SCID-I Overview and Sociodemographic Schedules (dataset #2) 
SCID-I-RV score sheet - Overview &  
Clinical and Sociodemographic Interview Schedules 
 
Study:                                                                                     Study ID:                                            
Subject unique identification no:                                                                                                             
Rater:                                                                                      Rater No:                                                      
Date(s) of baseline interview:    
Patient/family address and contact details:                                                                                                                                       
 
Most important informants: 
 
Informant/collateral source Current contact details 
 
 
 
 
 
 
 
 
 
 
Sources of information  (check all that apply)                      Subject                                                           
                                                                                               Family/friends/associates                       
                                                                                               Health profess./nursing process 
                                                                                               Referral note                                                
                                                                                               Case records 
Duration of interview (hours):         
 
Includes: 
A) Sociodemographic data schedule 
B) Past medical and psychiatric treatment record 
C) Personal and Family history record 
 
 
P1  
P2  
P3  
P4  
P5  
P6  
P7  
P8  
P9  
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SCID-I OVERVIEW including: 
Socio-demographic /treatment / personal and family history record: 
 
A. DEMOGRAPHIC DATA:  (Circle correct number) 
Gender:                                                                                                                                                       
Age:                                                                                                                                                                                                                                              
DOB:                                                                                                        
Marital status (current): 
 
 
Children:  Do you have any children/ 
How many? Number of children:   
Living arrangement:  
Where do you currently live? 
                    
         
Comments: 
 
Expand: Where are you currently staying? (most days [on average 5d/week] for the last 6 months) 
 
 
Note:  “Wendyhouse”-specify where situated, i.e. family, friends, strangers. 
 
  
 
 
   
Urbanicity: 
How long living in urban environment? 
Notes: 
Male 1 Female 2 X1 
 X2 
 X3 
Married 1 Co-
habiting 
2 Widowed 3 Divorced 4 Separated 5 Never 
married 
6 X4 
Yes 1 No 0 X5 
 X5a 
Lives with 
family at 
their home 
1 
Lives with 
friend(s) 
at their home 
2 
Group home/stepdown 
 
 
3 
Old age 
/residential home 
 
4 
Shelter for 
homeless 
 
5 
Street/NFA 
 
 
6 
X6 
Private house/flat 
 
1 
Boarding house/hostel – no supervision                
 
2 
Board and care home – programme/supervision  
3 
Skilled nursing 
facility 
4 
Emergency accommodation  shelter/hotel/backpackers 
 
5 
Refugee centre 
 
6 
Jail 
7 
No formal residence – shack/hokkie 
8 
Roofless – street, empty building 
9 
Other 
10 
“Wendy House” in back garden of family home 
11 
Missing 
99 
Born in 
city 
1 Moved to city 2 Age moved to city? 
 
X7 
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Ethnicity:  (Self ascribed: What ethnic group would you say you belong to?) 
 
Immigration status:                                                
 
Age immigrated to SA: 
  
Parental nationality: 
 
Home Language/Mother tongue: 
    
          
 Language(s) that can communicate in fluently: 
                
 
Educational level: 
 
 Failed to 
complete a course? Reasons? 
Employment: 
Employed in past 6 months: 
Notes: 
Employment type past 6 months: 
Professional-major/high earning (CEO, doctor, lawyer, senior business) 1 
Professional-(Lesser/lower earning, i.e. teacher/social worker/pharmacist/clerical) 2 
Labor-skilled (technical qualification or learned skill) 3 
Labor-unskilled (casual worker-painter/domestic) 4 
Trade-formal (shop owner etc., small business owner) 5 
Trade informal (hawker) 6 
Student 7 
Service (army,police,rescue,municipal) 8 
Predominant employment pattern past 3 years: 
Mixed/coloured 1 Black 
African 
2 White/Caucasian 3 Asian 4 5. Other: 
 X8 
X9.1 Yes 
(immigrated) 
1 No (did not immigrate) 2 
X9.2  
X9.2 
Resident in SA since 
birth 
Immigrants 
English 1 Afrikaan
s 
2 Xhosa 3 Other: 4 X11 
English 1 Afrikaan
s 
2 Xhosa 3 Other: 4 X12 
Grade 1 2 3 4 5 6 7  8 9 10 11  12 Any tertiary  13 
Standard A B 1 2 3 4 5 6 7 8 9 Matric Define: X13 
Yes 1 No 0 X14 
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Receiving disability grant for psychiatric illness (current)?  
 
Estimated average family income per month: 
 
Functioning: 
If employment status not known. Has there ever been a time you were unable to work or go to school (These are 
GAF/axis V primers)? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Full time (40 hr's/week) 1 
Part time (reg hours) 2 
Part time (irreg hours) 3 
Retired/disability 4 
In controlled environment 5 
Unemployed 6 
X15 
Yes 1 No 0 
R0-R2000  1 
R2001-R5000 2 
R5001-R10,000 3 
R10,001- R20,000 4 
R20,000-R30,000 5 
> R30,000  6 
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B. OVERVIEW OF CURRENT ILLNESS EPISODE: 
Have you been in any kind of treatment in the past month?  
Current (past month) treatment status: 
 
 
Regional referral centre/ psych emergency unit (Circle): 
 
C15 C22 C23 NSH VHW FBH WestFleur GFJooste 
 
 
Number of days in psychiatric emergency room( district)  
 
 
Mental Health Act Status-current episode 
 
 
Involuntary 1 
Assisted 2 
Voluntary 3 
 
Date of current admission, L2(VBH): 
 
Number of days since admission to VBH and SCID interview:  
Date of most recent discharge from VBH:  
 
 
 
 
 
 
 
 
 
Current 
inpatient 
1 Current 
outpatient 
2 Other: 
12-step 
3 No current 
treatment 
4 
 
Nr days: 
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Chief compliant and description of presenting problem: (What lead your coming here? What is the main problem 
you have been having trouble with?) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Onset of the present illness or exacerbation: 
When this did begin? When did you first notice that something was wrong? 
 
 
 
When were you last feeling OK/ your usual self? 
 
 
 
New symptoms or recurrence? 
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Is this something new or a return of something you had before? 
 
What made you come for help now? 
Environmental context and possible precipitants of present illness or exacerbation (Axis IV): 
What was going on in your life when all of this began? Did anything happen or change that could have something to 
do with your illness? 
 
Course of the present illness or exacerbation: 
After it started what happened next. Did other things start to bother you? 
 
 
Since this illness started when have you felt the worst? 
 
If more than one year when did you feel the worst in the past year? 
 
 
Brief description of timeline (days,weeks,months), onset, course and chronology of current episode with 
reference to its relationship to other variables, substance abuse in particular: 
Timelines and temporal relationships: 
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C. PAST TREATMENT HISTORY (PSYCHIATRIC): (Use life chart to describe in detail) 
When was the first time you saw someone for psychiatric or emotional problems? What was that for? What treatment 
did you get? What medications? 
 
Age at onset of first illness episode: 
 
Date of first psychiatric hospitalization for psychotic illness 
 
Have you ever been an inpatient at a (APH) psychiatric hospital?  
 
Number of previous hospitalizations (do not include transfers between level 1 to VBH) 0 to number  
 
First episode? (Indicate the longest continuous period of CONSISTENT neuroleptic treatment at adequate doses –HLP 
3.5 mg equivalents) 
 
 
What about treatment for drugs or alcohol?          
                                                    
A) Ever sought 
help at Outpatient 
Drug counselling 
facility? 
Yes 1 B)  Number of 
outpatient sessions: 
C) Inpatient rehab ever 
sought? 
D) Number 
inpatient 
rehabs: 
 
No 0 Yes 1 No 0 
Date of first treatment sought for substance rehab/in or outpatient 
 
 
 
 
 
 
 
 
 Life Chart: 
 
 
Yes 1 No 0 
 
Nr of weeks of adequate treatment  
 
a) Inpatient                      b) Outpatient  
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Age ( or date)                               Description (symptoms, triggering events)                     Treatment 
 
_________            ___________________________________________________      ____________ 
 
_________            ___________________________________________________      ____________ 
 
_________            ___________________________________________________      ____________ 
 
_________            ___________________________________________________      ____________ 
 
_________            ___________________________________________________      ____________ 
 
_________            ___________________________________________________      ____________ 
 
_________            ___________________________________________________      ____________ 
 
_________            ___________________________________________________      ____________ 
 
_________            ___________________________________________________      ___________  
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D1.  MEDICATION REGIME: DURING CURRENT ADMISSION OR CURRENT OUTPATIENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medication 
Current 
treatment 
Total 
daily 
Dose in 
milligrams 
 
Dosing per 24 hour period (mg) Current
? 
Yes=1 
No=0 
Disconti
n? 
Yes=1 
No=0 
Duration 
treated 
(irrespective of 
dose) 
Nr of days: am midday evening night 
Typical 
neuroleptics 
        
Haloperidol 
 
        
Chlorpromazine 
 
        
Trifluoroperazine 
 
        
Sulpiride         
Combination (Nr)         
Atypical 
neuroleptics 
        
Risperidone 
 
        
Quetiapine 
 
        
Amisulpride         
Olanzapine         
Clozapine 
 
        
Other:         
Combination (nr)         
Depot 
Neuroleptics 
        
Flupenthixol 
decanoate 
        
Zuclopenthixol 
decanoate 
        
Fluphenazine 
decanoate 
        
Risperdal Consta         
Mood stabilizers         
Sodium Valproate 
 
        
Lithium 
 
        
Carbamazepine 
 
        
Lamotrigine         
Combination (Nr)         
Antidepressants         
Fluoxetine         
Citalopram 
 
        
Amytriptyline 
 
        
Venlafaxine         
Combination (nr)         
Other         
 
Orphenadrine 
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E. PAST/CURRENT MEDICAL HISTORY: 
How has your physical health been? 
Do you have any medical illnesses? (list them) 
 
 
Head injuries:   
 
 
HIV status (as ascertained from medical or laboratory records) 
Have you ever had an HIV test? Y N 
When have you last had an HIV test Date of last HIV test  
HIV status negative positive unknown 
 
VDRL/RPR test result:  Pos             Neg 
 
Date: 
 
Neuro-imaging/physiology:  CT                     MRI             EEG Dates: 
Result: 
 
 
Are you on any medication or vitamins? Name these here: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes No 
LOC: Yes No Duration of LOC: Age when occurred: 
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F. PAST FORENSIC HISTORY:  
Was this admission prompted by criminal justice system? 
How many times were you arrested and charged or convicted with the following: 
 
 Crime: Arrested 
and 
charged 
Nr of 
times 
Convicte
d 
 
 
Nr of 
times 
When was the last time you were 
arrested/charged with or without conviction? 
 
≤ 3 
months 
 
 ≤ 6 
months 
 
≤ 12 
months 
> 12 months 
ago 
(Indicate 
when) 
a Shoplifting       
b Vandalism       
c Parole/probation 
violations 
      
d Drug charges       
e Forgery       
f Weapons offense       
g Burglary, larceny, B&E       
h Robbery       
i Assault       
j Arson       
k Rape/ sexual assault 
(specify) 
      
l Homicide, 
manslaughter 
      
m Prostitution       
n Contempt of court       
o Disorderly conduct, 
vagrancy, public 
intoxication 
      
p Driving while 
intoxicated 
      
q Major driving violations 
(reckless driving, 
speeding, no licence) 
      
r Other: 
 
 
      
 
Have you EVER been in prison YES NO Specify type of 
criminal conviction IF YES, how many times?  
 
Length of most recent  incarceration (months)  
 
 
Length of 2nd incarceration (months)  
 
 
Length of 3rd incarceration (months)  
 
 
Longest time spent in prison (months)  
 
 
 
Yes 1 No 0 
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G. FAMILY (PSYCHIATRIC) HISTORY (include Genogram of three generations and age of biological parents) 
 
Age in years of biological father (current age)                                      
Age in years of biological mother (current age)        
 
Genogram (indicate racial descent of 1st and 2nd degree relatives, relatives’ suspected diagnosis and degree of 
confidence in this): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
34a 
 
I 
34b 
 
Relative Type of relative (i.e. brother, cousin aunt) Suspected psychiatric diagnosis 
1   
2   
3   
4   
5   
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H. PERSONAL HISTORY (BRIEF HISTORY ONLY): 
Pregnancy/Birth: 
Neonate+Childhood: 
School-academic: 
School-social: 
School-conduct: 
 
I. CURRENT SOCIAL FUNCTIONING: 
How have you been spending your time? Who do you spend your time with? 
 
Relationships: 
 
J. MENTAL STATE AT TIME OF INTERVIEW (BRIEF): 
Appearance: 
Attitude: 
Psychomotor retardation/agitation: 
Abnormal movements/ mannerisms: 
Speech: 
Affect: 
Cognition (attention and concentration): 
Mood: 
Objective: 
Subjective: 
Perceptual abnormalities: 
Thought process: 
Thought Content: 
Insight and Judgement: 
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K. Final clinical diagnoses given by treatment team in ward as reflected in most recent case note entry: 
 
 
 
 
L. Most likely current diagnoses and differential diagnsosis accoding to this assessment: 
 
 
 
 
 
M. Diagnoses that need to be ruled out: 
 
 
 
 
N. ADDITIONAL COLLATERAL INFORMATION: 
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SCID screening module (Optional) 
Now I want to ask you some more specific questions about problems you may have had. We’ll go into detail 
about them later. 
RESPOND TO POSITIVE RESPONSES BY: “We’ll talk about that later” 
1) Has there been any time in your life when you had five or more drinks (beer, wine, or liquor) on one 
occasion? 
 
 
2) Have you ever used street drugs? 
 
 
3) Have you ever gotten hooked on prescribed medication or taken more than you were supposed to? 
 
 
 
4) Have you ever had a panic attack, when you suddenly felt frightened or anxious or suddenly developed 
allot of physical symptoms? 
 
 
5) Were you ever afraid of going out of the house alone, being in crowds, standing in a line, travelling in buses 
or trains? Agoraphobia? 
 
 
6) Is there anything you have been afraid to do or uncomfortable doing in front of other people, like speaking, 
eating or writing? (Social phobia?) 
  
 
 
7) Are there any other things you have been especially afraid of like flying, seeing blood, getting a shot, 
heights, closed places, or certain kinds of animals or insects? (Specific phobia?) 
1 2 3 
NO YES:  Include module E 
1 2 3 
NO YES:  Include module E 
1 2 3 
NO YES:  Include module E 
1 2 3 
NO YES:  Include module F 
1 2 3 
NO YES:  Include module F 
1 2 3 
NO YES:  Include module F 
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8) Have you ever been bothered by thoughts that didn’t make any sense and kept coming back to you even 
when you tried not to have them? (OCD?) 
 
 
9) Was there ever anything that you had to do over and over again and couldn’t resist doing, like washing 
your hands again and again, counting up to a certain number, or checking something several times to make 
sure you had done it right? (OCD?) 
 
 
10) In the last six months have you been particularly nervous or anxious? (GAD?) 
 
 
11) Have you ever had a time when you weighed much less than other people thought you ought to weigh? 
(Anorexia nervosa?) 
 
 
12) Have you often had times when your eating was out of control? (Bulimia?) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 
NO YES:  Include module F 
1 2 3 
NO YES:  Include module F 
1 2 3 
NO YES:  Include module F 
1 2 3 
NO YES:  Include module F 
1 2 3 
NO YES:  Include module H 
1 2 3 
NO YES:  Include module H 
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9.3.2 SCID-I English and IsiXhosa versions available on request 
 
 
9.3.3 SCID-I Axis IV Psychosocial and Environmental Problems 
 
• Problems with primary support group - e.g., death of family member; health problems in 
family; disruption f family by separation, divorce, or estrangement; removal from the home; 
remarriage of parent; sexual or physical abuse; parental overprotection; neglect of child; 
inadequate discipline; discord with siblings; birth of a sibling. 
 
• Problems related to the social environment - e.g., death or loss of a friend; inadequate 
social support; living alone; difficulty with acculturation; discrimination; adjustment to life-cycle 
transition (such as retirement). 
 
• Educational problems - e.g., illiteracy; academic problems; discord with teachers or 
classmates; inadequate school environment. 
 
• Occupational problems - e.g., unemployment; threat of job loss; stressful work schedule; 
difficult work conditions; job dissatisfaction; job change; discord with boss or co-workers. 
 
• Housing problems - e.g., homelessness; inadequate housing; unsafe neighborhood; discord 
with neighbors or landlord. 
 
• Economic problems - e.g., extreme poverty; inadequate finances; insufficient welfare 
support. 
 
• Problems with access to health care - e.g., inadequate health care services; transportation 
to health care facilities unavailable; inadequate health insurance. 
 
• Problems related to interaction with the legal system/crime - e.g., arrest; incarceration; 
litigation; victim of crime. 
 
• Other psychosocial and environmental problems - e.g., exposure to disasters; war; other 
hostilities; discord with non-family caregivers such as counselor, social worker, or physician; 
unavailability of social service agencies. 
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9.3.4 SCID-I Axis V: Global Assessment of Functioning Scale (GAF score) 
 
Consider psychological, social, and occupational functioning on a hypothetical continuum 
of mental health-illness.  Do not include impairment in functioning due to physical (or 
environmental) limitations 
 
 
CODE  (Note: Use intermediate codes when appropriate, e.g., 45, 68, 72).  
 
 
 
 
 
 
__  __  __ 
  
 
 
 
 
P122 
 100 
  | 
  91 
 
Superior functioning in a wide range of activities, life's problems never seem to get out of 
hand, is sought out by others because of his/her many positive qualities. No symptoms. 
 
  
  90 
 | 
 | 
  81 
Absent or minimal symptoms (e.g., mild anxiety before an exam); good functioning in all 
areas, interested and involved in a wide range of activities, socially effective, generally 
satisfied with life, no more than everyday problems or concerns  (e.g., an occasional  
argument with family members). 
 
  
  80 
 | 
 | 
  71 
If symptoms are present, they are transient and expectable reactions to psychosocial 
stressors (e.g., difficulty concentrating after family argument); no more than slight 
impairment in social, occupational, or school functioning (e.g., temporarily falling behind in 
school work). 
 
  
  70 
 | 
 | 
  61 
Some mild symptoms (e.g., depressed mood and mild insomnia) OR some difficulty in  
social, occupational, or school functioning (e.g., occasional truancy, or theft within the 
household), but generally functioning pretty well, has some meaningful interpersonal  
relationships.  
 
  
  60 
 | 
  51 
 
Moderate symptoms (e.g., flat affect and circumstantial speech, occasional panic attacks) OR 
moderate difficulty in social, occupational, or school functioning (e.g., few friends, conflicts 
with peers or coworkers).  
 
  
  50 
 | 
  41 
Serious symptoms (e.g., suicidal ideation, severe obsessional rituals, frequent shoplifting) OR 
any serious impairment in social, occupational, or school functioning (e.g., no friends, 
unable to keep a job). 
 
  
  40 
 | 
 | 
 | 
  31 
Some impairment in reality testing or communication (e.g., speech is at times illogical,  
obscure, or irrelevant) OR major impairment in several areas, such as work or school,  
family relations, judgment, thinking, or mood (e.g., depressed man avoids friends, neglects 
family, and is unable to work; child frequently beats up younger children, is defiant at home, and 
is failing at school). 
 
  
  30 
 | 
 | 
  21 
Behavior is considerably influenced by delusions or hallucinations OR serious 
impairment in communication or judgment (e.g., sometimes incoherent, acts grossly 
inappropriately, suicidal preoccupation) OR inability to function in almost all areas (e.g., 
stays in bed all day; no job, home, or friends). 
 
  
  20 
 | 
 | 
  11 
Some danger of hurting self or others (e.g., suicide attempts without clear expectation of 
death, frequently violent, manic excitement) OR occasionally fails to maintain minimal 
personal hygiene (e.g., smears feces) OR gross impairment in communication (e.g., 
largely incoherent or mute).  
 
  
  10 
 | 
   1 
Persistent danger of severely hurting self or others (e.g., recurrent violence) OR persistent 
inability to maintain minimal personal hygiene OR serious suicidal act with clear 
expectation of death.  
 
  
   0 Inadequate information.   
 
 
 
 
 
 
 
 
 
 
137 
 
 
 
9.3.5 Extract from Addiction Severity Index-legal status section (see 2.1 Overview for adaptation) 
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9.3.6  WHO ASSIST version 3.  (IsiXhosa version) 
 
WHO ASSIST: 
Introduction (please read to patient) 
Ndiyabulela ngokuvuma kwakho ukuthatha inxaxheba koludliwano ndlebe olumalunga notywala,icuba nezinye 
iziyobsi.  Ndizakubuza imibuzo ngmava onawo okusebenzisa ezi zinto kubomi bakho nakwi nyanga ezintathu 
ezigqithileyo. 
Ezi zinto zingatshaywa, uziginye, uzifinye, uziphefumle, uzihlabe ngenaliti okanye uzithathe nje ngepilisi (Binia ikhadi 
lamayeza).  Ezinye zezinto zibhaliweyo zingafunyanwa kugqirha nje (ngamayeza anceda ukulala,amayeza entlungu ne 
amphetamines).  Kolu dliwano ndlebe asizikuwabhala phantsi amayeza athi uwanikwe kugqirha.  Kodwa, ukuba ukhe 
wathatha amayeza alolo hlobo ngesizathu esingesiso esi ugqirha akuyalele sona xa ekunika amayeza okanye 
uwathathe ngaphezu komyalelo kagqirha, nangomyinge ongasentla kwalowo kagqirha ndicela undixelele ngoku.  
Njengokuba, sise nomdla ngokusebenisa kwakho intlobo zeziyobisi, ndicela uthembe ukuba inkcazelo yokusebenzisa 
kwakho iziyobisi izakugcinwa iyimfihlo. 
Question 1 
Ebomini bakho zeziphi kwezi zilandelayo owakha wazisebenzisa? (EZINGEZO 
NYANGO LOKUGULA) 
 
Hayi Ewe 
Imveliso zecuba (isigarethi, imprimpri, inqawe, icuba lenqawe, etc.) 0 3 
Utywala (ibhiya, iwayini, ispiliti, umqobothi, etc.) 0 3 
Intsangu (marijuana, pot, grass, hash, etc.) 0 3 
ikhokheyini (coke, rock, crack, etc.) 0 3 
Amphetamine type substances (tik, speed, diet pills, ecstasy, etc.) 0 3 
Inhalants/Ezifunxwayi (iglu, ipetula, paint thinners, nitrous, etc.) 0 3 
Ipilisi zokunceda ukulala (Mandrax, buttons, Valium, Rohypnol, etc.) 0 3 
Hallucinogens (LSD, acid, mushrooms, PCP special K, etc.) 0 3 
Opiods (Umnga, heroin, morphine, methadone, codeine, etc.) 0 3 
Other – specify (Woonga, Efaverinz, etc.)  0 3 
IF ALL ANSWERS NEGATIVE: Zange xa 
wawusesikolweni? 
IF “NO” TO ALL ITEMS, STOP INTERVIEW 
IF YES TO ANY OF THESE ITEMS, ASK QUESTIONS 
2-7 FOR EACH SUBSTANCE USED. 
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Question 2 
Kwezunyanga zintathu zigqithileyo, 
uyisebenzise kangaphi lento 
ubundixelela ngayo? 
 
Zan
ge
 
K
an
ye
 
o
kan
ye
 
kab
in
i 
N
yan
ga-
n
e
n
yan
ga 
V
e
ki 
n
e
ve
ki 
M
ih
la 
n
ge
m
ih
la 
o
kan
ye
  
p
h
an
tse
 
im
ih
la 
yo
n
ke 
Imveliso zecuba (isigarethi, imprimpri, 
inqawe, icuba lenqawe, etc.) 
0 2 3 4 6 
Utywala (ibhiya, iwayini, ispiliti, 
umqobothi, etc.) 
0 2 3 4 6 
Intsangu (marijuana, pot, grass, hash, 
etc.) 
0 2 3 4 6 
ikhokheyini (coke, rock, crack, etc.) 0 2 3 4 6 
Amphetamine type substances (tik, 
speed, diet pills, ecstasy, etc.) 
0 2 3 4 6 
Inhalants/Ezifunxwayi (iglu, ipetula, 
paint thinners, nitrous, etc.) 
0 2 3 4 6 
Ipilisi zokunceda ukulala (Mandrax, 
buttons, Valium, Rohypnol, etc.) 
0 2 3 4 6 
Hallucinogens (LSD, acid, mushrooms, 
PCP special K, etc.) 
0 2 3 4 6 
Opiods (Umnga, heroin, morphine, 
methadone, codeine, etc.) 
0 2 3 4 6 
Other – specify (Woonga, Efaverinz, 
etc.)  
0 2 3 4 6 
Question 3 
Kule nyanga iphelileyo kuka ngaphi 
apho urhalele ngokumandla 
ukusebesnzisa iziyobisi? 
Zan
ge
 
K
an
ye
 
o
kan
ye
 
kab
in
i 
N
yan
ga-
n
e
n
yan
ga 
ve
ki 
n
e
ve
ki 
M
ih
la 
n
ge
m
ih
la 
o
kan
ye
  
p
h
an
tse
 
im
ih
la 
yo
n
ke 
Imveliso zecuba (isigarethi, 
imprimpri, inqawe, icuba lenqawe, 
etc.) 
0 2 3 4 6 
Utywala (ibhiya, iwayini, ispiliti, 
umqobothi, etc.) 
0 2 3 4 6 
Intsangu (marijuana, pot, grass, 
hash, etc.) 
0 2 3 4 6 
ikhokheyini (coke, rock, crack, etc.) 0 2 3 4 6 
Amphetamine type substances (tik, 
speed, diet pills, ecstasy, etc.) 
0 2 3 4 6 
Inhalants/Ezifunxwayi (iglu, ipetula, 
paint thinners, nitrous, etc.) 
0 2 3 4 6 
Ipilisi zokunceda ukulala (Mandrax, 
buttons, Valium, Rohypnol, etc.) 
0 2 3 4 6 
Hallucinogens (LSD, acid, 
mushrooms, PCP special K, etc.) 
0 2 3 4 6 
Opiods (Umnga, heroin, morphine, 
methadone, codeine, etc.) 
0 2 3 4 6 
Other – specify (Woonga, Efaverinz, 
etc.)  
0 2 3 4 6 
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Question 4 
Ekuhambeni kwale nyanga iphelileyo, 
kukangaphi apho ukusebenzisa 
kwakho(iziyobisi) kuye kwenza inxaki 
kwimilo,ekuhlaleni nakwi ngxaki zemali? 
Zan
ge
 
K
an
ye
 
o
kan
ye
 
kab
in
i 
N
yan
ga-
n
e
n
yan
ga 
V
e
ki 
n
e
ve
ki 
M
ih
la 
n
ge
m
ih
la 
o
kan
ye
  
p
h
an
tse
 
im
ih
la 
yo
n
ke 
Imveliso zecuba (isigarethi, imprimpri, inqawe, 
icuba lenqawe, etc.) 
0 2 3 4 6 
Utywala (ibhiya, iwayini, ispiliti, umqobothi, 
etc.) 
0 2 3 4 6 
Intsangu (marijuana, pot, grass, hash, etc.) 0 2 3 4 6 
ikhokheyini (coke, rock, crack, etc.) 0 2 3 4 6 
Amphetamine type substances (tik, speed, diet 
pills, ecstasy, etc.) 
0 2 3 4 6 
Inhalants/Ezifunxwayi (iglu, ipetula, paint 
thinners, nitrous, etc.) 
0 2 3 4 6 
Ipilisi zokunceda ukulala (Mandrax, buttons, 
Valium, Rohypnol, etc.) 
0 2 3 4 6 
Hallucinogens (LSD, acid, mushrooms, PCP 
special K, etc.) 
0 2 3 4 6 
Opiods (Umnga, heroin, morphine, methadone, 
codeine, etc.) 
0 2 3 4 6 
Other – specify (Woonga, Efaverinz, etc.)  0 2 3 4 6 
Question 5 
Ekuhambeni kwezi nyanga zintathu zigqithileyo 
kuka ngaphi apho uthe awakwazi ukwenza 
izinto ebekumele ukuba uyazenza ngesiqhelo 
kuba usebenzisa (iziyobisi)? 
Zan
ge
 
K
an
ye
 
o
kan
ye
 
kab
in
i 
N
yan
ga-
n
e
n
yan
ga 
V
e
ki 
n
e
ve
ki 
M
ih
la 
n
ge
m
ih
la 
o
kan
ye
  
p
h
an
tse
 
im
ih
la 
yo
n
ke 
Imveliso zecuba (isigarethi, imprimpri, inqawe, 
icuba lenqawe, etc.) 
0 2 3 4 6 
Utywala (ibhiya, iwayini, ispiliti, umqobothi, 
etc.) 
0 2 3 4 6 
Intsangu (marijuana, pot, grass, hash, etc.) 0 2 3 4 6 
ikhokheyini (coke, rock, crack, etc.) 0 2 3 4 6 
Amphetamine type substances (tik, speed, diet 
pills, ecstasy, etc.) 
0 2 3 4 6 
Inhalants/Ezifunxwayi (iglu, ipetula, paint 
thinners, nitrous, etc.) 
0 2 3 4 6 
Ipilisi zokunceda ukulala (Mandrax, buttons, 
Valium, Rohypnol, etc.) 
0 2 3 4 6 
Hallucinogens (LSD, acid, mushrooms, PCP 
special K, etc.) 
0 2 3 4 6 
Opiods (Umnga, heroin, morphine, methadone, 
codeine, etc.) 
0 2 3 4 6 
Other – specify (Woonga, Efaverinz, etc.)  0 2 3 4 6 
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Question 6 
Ingaba umhlobo okanye isizalwane sakho sike savakalisa 
ukuxhalaba ngoku sebenzisa kwakho (Iziyobisi)? 
H
ayi, Zan
ge
 
Ew
e
 
kw
e
zin
yan
ga 
zin
tath
u
 
zigq
ith
ile
yo
 
Ew
e
, h
ayi 
kw
e
zin
yan
ga 
zin
tath
u
 
zigq
ith
ile
yo
 
Imveliso zecuba (isigarethi, imprimpri, inqawe, icuba lenqawe, 
etc.) 
0 6 3 
Utywala (ibhiya, iwayini, ispiliti, umqobothi, etc.) 0 6 3 
Intsangu (marijuana, pot, grass, hash, etc.) 0 6 3 
ikhokheyini (coke, rock, crack, etc.) 0 6 3 
Amphetamine type substances (tik, speed, diet pills, ecstasy, 
etc.) 
0 6 3 
Inhalants/Ezifunxwayi (iglu, ipetula, paint thinners, nitrous, 
etc.) 
0 6 3 
Ipilisi zokunceda ukulala (Mandrax, buttons, Valium, Rohypnol, 
etc.) 
0 6 3 
Hallucinogens (LSD, acid, mushrooms, PCP special K, etc.) 0 6 3 
Opiods (Umnga, heroin, morphine, methadone, codeine, etc.) 0 6 3 
Other – specify (Woonga, Efaverinz, etc.)  0 6 3 
Question 7 
Ingaba ukhe wazama  kodwa woyisakala ukunqanda, ukwehlisa 
umyinge okanye ukuyeka ukusebenzisa (iziyobisi)  
 
H
ayi, Zan
ge
 
Ew
e
 
kw
e
zin
yan
ga 
zin
tath
u
 
zigq
ith
ile
yo
 
Ew
e
, h
ayi 
kw
e
zin
yan
ga 
zin
tath
u
 
zigq
ith
ile
yo
 
Imveliso zecuba (isigarethi, imprimpri, inqawe, icuba lenqawe, 
etc.) 
0 6 3 
Utywala (ibhiya, iwayini, ispiliti, umqobothi, etc.) 0 6 3 
Intsangu (marijuana, pot, grass, hash, etc.) 0 6 3 
ikhokheyini (coke, rock, crack, etc.) 0 6 3 
Amphetamine type substances (tik, speed, diet pills, ecstasy, 
etc.) 
0 6 3 
Inhalants/Ezifunxwayi (iglu, ipetula, paint thinners, nitrous, 
etc.) 
0 6 3 
Ipilisi zokunceda ukulala (Mandrax, buttons, Valium, Rohypnol, 
etc.) 
0 6 3 
Hallucinogens (LSD, acid, mushrooms, PCP special K, etc.) 0 6 3 
Opiods (Umnga, heroin, morphine, methadone, codeine, etc.) 0 6 3 
Other – specify (Woonga, Efaverinz, etc.)  0 6 3 
Question 8 
 Hayi, Zan
ge
 
Ew
e 
kw
ezin
yan
ga 
zin
tath
u
 
zigq
ith
ileyo
 
Ew
e, h
ayi 
kw
ezin
yan
ga 
zin
tath
u
 
zigq
ith
ileyo
 
Ukhe wasebenzisa iziyobisi ngokuzitofa (Hayi ezimalungana 
nogqirha)? 
0 6 3 
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9.3.7 Severity of Dependence Scale (IsiXhosa) 
 
Severity of Dependence Scale(SDS) 
Adapted from: 
Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., Strang, J. (1995). The Severity of Dependence Scale (SDS): psychometric 
properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90(5): 607-614. 
Lemibuzo ilandelayo ingokusebenzisa kwakho iziyobisi ngaphambi kokuba uqalise unyango.  Kwimibuzo 
yomihlanu nceda uphawule okanye ukhethe eyona mpendulo inento yokwenza nokusebenzisa kwakho iziyobisi 
phambi kokuba uqalise unyango 
[Note: Give Response Card to participant. When reading out the questions below, replace “(drug)” with the 
name of the principal opiate for which treatment is currently being received, e.g. heroin, opium, etc.] 
 Zange Ngamanye 
amaxesha 
Ngamaxesha 
athile 
Rhoqo 
1. Ingaba ucinga ukuba ukusebenzisa kwakho 
iziyobisi kwaku ngalawuleki? 
 
0 1 2 3 
2. Ingaba ukungafumani kwakho igaqa lesiyobisi 
kwakukwenza woyike okanye uxhalabe 
 
0 1 2 3 
3. Ubukhathazeka ngokusebenzisa kwakho 
iziyobisi? 
 
0 1 2 3 
4.  Ubunqwenela ukuba ungayeka? 
 
0 1 2 3 
 Akukho 
bunzima 
 
Kuthanda 
ukubanzima 
 
Inzima 
kakhuli 
Ayenzeki 
 
5. Ufumane obuphu ubunzima ekuyekeni iziyobisi 
nasekuhlaleni (xa ungazisabenzisanga)? 
 
0 1 2 3 
   SDS Total _________ 
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Ikhadi lempendulo 
SDS 
(Umbuzo wokuqala ukuya kowesine) 
Zange/ndaphantse andazisebenzisa  
Ngamanye amaxesha 
Ngamaxesha athile 
Rhoqo/phantse rhoqo 
(Umbuzo wesihlanu) 
Akukho bunzima 
Kuthanda ukubanzima 
Inzima 
Inzima kakhuli 
Ayenzeki 
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9.3.8 Abnormal Involuntary Movement Scale (AIMS) 
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9.3.9 Barnes Akathisia Rating Scale (BARS) 
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9.3.10 Simpson Angus Extra Pyramidal Symptom Scale 
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9.3.11 University of California, San Diego Brief Assessment of Capacity to Consent 
 
 
Original UBACC English version UBACC Xhosa version 
1. What is the purpose of the study that was just 
described to you? 
 
1. Yintoni injongo yoluphondo lwenzziwayo 
ndigqiba ukukucacisela ngalo? 
2. What makes you want to consider participating 
in this study? 
 
2. Yintoni ekwenze ukuba ufune ukuthabatha 
inxaxheba koluphando? 
3. Do you believe this is primarily research or 
primarily treatment? 
 
3. Ingaba ucinga ukuba olu luphando okanye 
lunyango? 
4. Do you have to be in this study if you do not 
want to participate? 
4. Ucinga ukuba kunyanzelekile na ukuba ube 
koluphando nokuba awufuni? 
 
5. If you withdraw from the study, will you still be 
able to receive regular treatment? 
 
5. Ucinga ukuba uye wayeka ukuthabatha 
inxaxheba koluphando ungakwazi ukufumana 
unyango lwakho njengesiqhelo? 
 
6. If you participate in this study, what are some of 
the things that you will be asked to do? 
6. Ukuba uthe wathatha inxaxheba koluphando 
zeziphi ezinye zezinto ozakucelwa uzenze? 
 
7. Please describe some of the risks or discomforts 
that people may experience if they participate in 
this study 
 
7. Ndicela uchaze ubungozi okanye ubunzima 
onokubufumana ukuba uthe wathatha inxaxheba 
koluphando? 
 
8. Please describe some of the possible benefits of 
this study 
 
8. Ndicela uchaze inzuzo/amanye amancedo 
anokufumaneka koluphando? 
 
9. Is it possible that being in this study will not 
have any benefit to you? 
 
9. Ingaba igenzeka into yokuba oluphando 
lungangabi luncedo kuwe? 
 
10. Who will pay for your medical care if you are 
injured as a direct result of participating in this 
study? 
Replaced with: Do you have to agree to store your 
cells? 
 
 
10. Ingaba kunyanzelekile ukuba imisebe yakho 
yegazi iyokugcinwa? 
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9.4. Original studies from which data originated for secondary analyses, their principal investigators, role of 
PhD candidate and original study aims: 
Study name UCT Ethics 
Rec Ref 
Principal 
investigator(s) and 
funding 
Role of PhD candidate Aims of original studies 
1. Presentation, Risk Factors 
and Psychobiology of 
Psychosis 
332/2008 
(for main 
study) 
(Linked to 
database 
035/2013) 
Dr Henk Temmingh 
University of Cape 
Town Research 
Committee Start-up 
grant 
Harry Crossley 
Foundation Clinical 
Fellowship 
(Dr Temmingh has 
received a speaker 
honorarium from 
Pharmadynamics in 
2013) 
Principal investigator 
 
Involved in design, 
recruitment and 
assessment, data 
management audit and 
data analysis, write-up 
Description of clinical 
profile and comorbidity 
(precludes a focus on 
substances). Facial 
morphometry, 
establishment of 
database for genetic 
analysis 
2. Cortical Inhibition and 
Attentional Modulation: A 
study of Psychosis 
192/2010 Dr Fleur Howells: 
National Research 
Foundation (NRF) 
funding 
University of Cape 
Town funding 
Co-investigator. 
Involved in design, 
recruitment and 
assessment, data 
management audit and 
data analysis, write-up 
Investigating 
associations between 
EEG, attentional measure 
s and functional 
neuroimaging (MRS) 
and across different 
psychotic disorders 
3. Social Inclusion in 
Psychosis 
511/2011 Dr Peter Milligan, 
Dr Goodman Sibeko 
University of Cape 
Town 
World Psychiatric 
Association 
Co-investigator. 
Involved in design, 
recruitment and 
assessment, data 
analysis, write-up  
A randomised controlled 
trial evaluating the 
efficacy of a Treatment 
Partner Intervention (text 
messaging) Focused on 
Adherence 
4. The genomics of 
Schizophrenia in the South 
African Xhosa Population 
049/2013 
 
Prof. DJ Stein, Prof. 
R Ramesar, Prof. 
Marie Claire King, 
Prof. Ezra Susser. 
 
National Institutes of 
Mental Health 
(NIMH) 
Consultant. 
 
Involved in design and 
training of research staff. 
Investigating the 
genomics of 
schizophrenia in the 
South African Xhosa 
population. 
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